United States Patent Application Publication 20250257408
Kind Code A1
Publication Date August 14, 2025
Inventor(s) BILLIA; Filio et al.

CLONAL HEMATOPOIESIS AS A BIOMARKER

Abstract

There is described herein methods predicting the risk of various disease condition by measuring clonal hematopoiesis in a patient, probes used to make such measurement and methods for treatment or preventive treatment of the disease condition.

Inventors: **BILLIA; Filio (Toronto, CA), DICK; John (Toronto, CA), VANNER; Robert (Toronto, CA), MEDEIROS; Jessie (Brampton, CA), SCOLARI; Fernando (Rio Grande do Sul, BR), ABELSON; Sagi (Toronto, CA)**

Applicant: **UNIVERSITY HEALTH NETWORK** (Toronto, CA)

Family ID: **1000008616765**

Appl. No.: **18/859154**

Filed (or PCT Filed): **April 24, 2023**

PCT No.: **PCT/CA2023/050553**

Related U.S. Application Data

us-provisional-application US 63333628 20220422

Publication Classification

Int. Cl.: **C12Q1/6886** (20180101); **C12Q1/6869** (20180101); **G16B20/20** (20190101); **G16H50/30** (20180101)

U.S. Cl.:

CPC **C12Q1/6886** (20130101); **C12Q1/6869** (20130101); **G16B20/20** (20190201); **G16H50/30** (20180101); C12Q2600/106 (20130101); C12Q2600/118 (20130101); C12Q2600/156 (20130101)

Background/Summary

RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application No. 63/333,628 filed on Apr. 22, 2022, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION
[0002] The invention relates to the measurement of clonal haematopoiesis for the purposes of assessing the risk associated with various disease states, particularly relating to solid organs and/or cancer.
BACKGROUND OF THE INVENTION
[0003] Clonal haematopoiesis (CH) is the acquisition of mutations in hematopoietic stem cells that results in selective clonal expansion leading to enhanced systemic inflammation..sup.5 While early studies had shown that at least 10% of individuals harbour CH mutations in their seventies,.sup.5 more sensitive techniques have demonstrated that CH mutations are ubiquitous in healthy middle-age adults..sup.6,7 Despite these mutations increasing the risk of haematological cancer development, progression to malignancy is low..sup.8
[0004] Interestingly, CH is also associated with elevated cardiovascular risk;.sup.5,9,10 more than most traditional risk factors..sup.11 The presence of CH mutations is linked to a 25% increase in the incidence of de novo heart failure (HF) and a 2-fold increase in mortality in patients with pre-existing HF..sup.9,12 In animal models of HF, mice harbouring CH mutations developed adverse left ventricular (LV) remodelling with fibrosis and a concomitant increase in IL-6 and IL-1ß..sup.13
[0005] However, the incidence of CH in more specific cardiac diseases, specific cancers and diseases in other organs, and its impact in clinical outcomes, remains unknown.
[0006] For example, cardiogenic shock (CS) is a life-threatening condition with markedly reduced cardiac output resulting in multi-organ failure..sup.1 Despite increasing recognition of CS and implementation of intensive therapies, morbidity and mortality remain exceedingly high..sup.2 The evolving epidemiological descriptions of CS patients illustrate that there is a large variability in the underlying aetiology, response to medical therapy, and outcomes..sup.1,3 The association of a systemic inflammatory response syndrome with worse outcomes in CS.sup.3 could be a key to understanding the heterogeneity in the natural history of CS and uncover new pathways to target for treatment..sup.4
[0007] Further, orthotopic heart transplant (OHT) is the treatment of choice for patients with advanced heart failure to improve quality of life and survival..sup.s1 In the United States, over 80,000 HT were performed in the past three decades and over 5,000 yearly worldwide..sup.s2, s3 However, despite the improvement in donor and recipient pre-transplant care, post-transplant survival is affected by a number of complications

including infections due to long-term immunosuppression therapy, cancer development and cardiac allograft vasculopathy (CAV)..sup.s4, s5 OHT recipients require extensive monitoring after transplantation with endomyocardial biopsies (EMB) for rejection vigilance, viral detection for opportunistic infection, echocardiograms and coronary angiography for allograft function and CAV assessment to instill early treatment and improve survival..sup.4 Despite this intensive care, new non-invasive surveillance methods that could improve morbidity and reduce mortality are still warranted..sup.s6 The increased inflammatory cytokine/chemokine production linked to CH could also affect outcomes in OHT recipients, but this association has never been evaluated..sup.s8, s15

[0008] There remains a need to study the link between CH and various disease states, including those listed above.

SUMMARY OF THE INVENTION

[0009] We hypothesized that the enhanced inflammatory environment associated with CH may play a significant role in various disease outcomes and its related complications. Therefore, we evaluated the prevalence of CH in patients with various cardiac diseases, solid organ diseases and specific cancers.

[0010] In an aspect, there is provided a method of predicting the risk of a disease condition of a solid organ in a patient, the method comprising: receiving a sample from the patient containing hematopoietic stem cells; sequencing the sample to detect a degree of clonal hematopoiesis; comparing the degree of clonal hematopoiesis in the patient to a control degree; and determining the patient is at an elevated risk of the disease condition if the degree of clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner.

[0011] In an aspect, there is provided a kit comprising a library of probes library comprising at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.

[0012] In an aspect, there is provided a method of predicting the benefit of immunotherapy in a patient with melanoma, the method comprising: receiving a sample from the patient containing hematopoietic stem cells; sequencing the sample to detect a degree of clonal hematopoiesis in TET2; comparing the degree of TET2 clonal hematopoiesis in the patient to a control degree; and determining the patient would benefit from immunotherapy if the degree of TET2 clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner. Preferably, the method further comprises treating the patient with immunotherapy.

[0013] In an aspect, there is provided a method of predicting metastatic risk in a patient with a non-hematological cancer, the method comprising: receiving a sample from the patient containing hematopoietic stem cells; sequencing the sample to detect a degree of clonal hematopoiesis in TET2; comparing the degree of TET2 clonal hematopoiesis in the patient to a control degree; and determining the patient is at a lower risk of metastasis if the degree of TET2 clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner. Preferably, the method further comprises treating the patient with a treatment and monitoring regimen reflective of a low risk of metastasis.

Description

BRIEF DESCRIPTION OF FIGURES

[0014] These and other features of the preferred embodiments of the invention will become more apparent in the following detailed description in which reference is made to the appended drawings wherein:

[0015] FIG. **1**. Study design. Cardiogenic shock patients were screened for eligibility and those with available biospecimen and consent were included. Ambulatory heart failure patients were screened on a digital database and those with complete data for age, sex, ejection fraction and aetiology of heart failure, available biospecimen and consent were included. Cardiogenic shock and ambulatory heart failure patients were matched on a 1:1 ratio for age, sex, ejection fraction, and aetiology. Ambulatory heart failure and cardiogenic shock patients were sequenced for clonal haematopoiesis related genes and its prevalence was estimated. A survival analysis was performed in each group. A survival analysis for specific genes mutations and a cytokine profile were assessed in cardiogenic shock patients.

[0016] FIG. **2**. Somatic variant characteristics in cardiogenic shock cohorts and ambulatory heart failure. Panel A shows the number of mutations for the 10 most frequently mutated genes according to each cohort. Panel B shows the number of mutations per patient in those where a clonal haematopoiesis mutation was identified. Panel C shows the variant allele frequency boxplot for patients with a mutation with a VAF≥2%. No differences were observed between cohorts (P=0.87). Panel D shows the number of patients with CH mutation according to age in both cohorts. Filled columns represent those with CH mutations, and unfilled those without.

[0017] FIG. **3**. Survival according to clonal haematopoiesis and specific gene mutations. Panels A, B and C shows the reduced survival in CS patients with CH mutations in 30-day, 90-day and 3-year survival respectively. Panels D, E and F shows the reduced survival in CS patients according to specific CH-related mutations (DNMT3A, ASLX1 and TET2) in 30-day, 90-day and 3-year survival respectively. All figures represents VAD/OHT censored survival analysis.

[0018] FIG. **4**. Inflammatory cytokines in CS patients with TET2 and ASXL1 mutations. Panel A shows the differences in SCD40L, IFNγ, IL-4, TNF-α and abundance in plasma of patients with or without TET2 mutations of variant allele frequency ≥2%. Panel B shows the differences in CCL7 in patients with or without ASXL1 mutations with a variant allele frequency ≥2% (P=0.03).

[0019] FIG. **5**. Somatic clonal hematopoiesis gene mutations prevalence and characteristics in orthotopic heart transplant recipients. Panel A shows the frequency of CH in OHT recipients. Panel B shows the number of mutations according to genes related to CH. Panel C shows the number of patients with one, two, three, five and six CH mutations. Panel D shows the number of patients with CH mutations according to age. (CH, clonal hematopoiesis; OHT, orthotopic heart transplant).

[0020] FIG. **6**. Survival analysis in orthotopic heart transplant recipients according to the presence of clonal hematopoiesis gene mutations. (CH, clonal hematopoiesis) FIG. **7**. Somatic mutations related to clonal hematopoiesis in patients with hypertrophic cardiomyopathy. Panel A shows the number of mutations in the most common affected genes in the cohort. Panel B shows the number of mutations per patients in those with clonal hematopoiesis. Panel C shows the number of patients with clonal hematopoiesis according to the decade of the assessment. (CH, clonal hematopoiesis; HCM, hypertrophic cardiomyopathy).

[0021] FIG. **8**. Survival in patients with hypertrophic cardiomyopathy stratified according to the presence of clonal hematopiesis. Panel A shows the survival according to the presence of clonal hematopoiesis among HCM patients. Panel B shows the survival according to the presence of clonal hematopiesis in the DNMT3A, TET2, and ASXL1 genes among HCM patients. Panel C shows the survival according to the presence of clonal hematopoiesis among HCM patients with sarcomeric mutations. Panel D shows the survival according to the presence of clonal hematopiesis in the DNMT3A, TET2, and ASXL1 genes among HCM patients with sarcomeric mutations. (CH, clonal hematopoiesis; HCM, hypertrophic cardiomyopathy).

[0022] FIG. **9**. Troponin I, cytokines and chemokines levels among HCM patients with sarcomeric mutations according to the presence of clonal hematopoiesis. (CH, clonal hematopoiesis; HCM, hypertrophic cardiomyopathy).

[0023] FIG. **10**. TET2-mutant clonal hematopoiesis is associated with clinical benefit from immunotherapy in melanoma. A) 569 patients with melanoma, bladder cancer, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC) treated with immune-checkpoint blockade were screened for clonal hematopoiesis using publicly-available exome sequencing, with at least one mutation of variant allele frequency (VAF)>0.02 detected in 74 patients (datasets EGAD00001006632, SRP064805, SRP067938, SRP072934, SRP090294, SRP095809, SRP115658, SRP128156). B) TET2-mutant clonal hematopoiesis is associated with significantly higher odds of clinical benefit 6 months after receiving immunotherapy in melanoma patients (Odds Ratio=5.98), but not bladder cancer, renal cell carcinoma, or non-small cell lung cancer patients (p value from Firth's multivariate logistic regression adjusted for patient age, sex, study, and immune checkpoint). C) In an animal model of immunotherapy, mice with

Tet2-mutant hematopoiesis—mimicking TET2-mutant clonal hematopoiesis—show enhanced response to PD-1 immune checkpoint blockade, while isotype control (ISO) treated tumours show identical growth kinetics (*p<0.05 by Mann-Whitney Test).

[0024] FIG. **11**. TET2-mutant clonal hematopoiesis is associated with lower risk of metastatic disease in patients with non-hematological cancers. A) 16,744 patients with metastatic or non-metastatic solid tumours from Nguyen et al. Cell, 2022 were tested for clonal hematopoiesis in Bolton et al. Nature Genetics, 2020 using the MSK-IMPACT targeted sequencing panel. CH mutations with variant allele frequency of at least 0.02 were detected in 19.5% of patients. B) The 5 most commonly detected clonal hematopoiesis mutations from A) are shown. C) Exposure to TET2-mutant CH is associated with lower risk of having metastatic cancer in patients from A) as assessed by multivariate logistic regression adjusted for age, sex, smoking status, and chemotherapy treatment. D) Exposure to TET2-CH is associated with significantly lower risk of having metastases in patients from A) with Non-Small Cell Lung and Breast Cancer, with a trend towards lower risk of metastases in colorectal and bladder cancer, as assessed by multivariate logistic regression adjusted for age, sex, smoking status, and chemotherapy treatment. Patients in A) with TET2-mutant CH have significantly few metastases detected on clinical imaging (E) and have fewer overall sites/organs involved with metastatic disease (F), p values from Wilcoxon Rank Sum Test.

[0025] FIG. **12**. Clonal hematopoiesis prevalence among the 782 transplant recipients.

[0026] FIG. **13**. Clonal hematopoiesis prevalence according to transplanted organ.

[0027] FIG. **14**. Clonal hematopoiesis mutated genes among the 782 transplant recipients.

[0028] FIG. **15**. Clonal hematopoiesis mutated genes among the 127 heart transplant recipients.

[0029] FIG. **16**. Clonal hematopoiesis mutated genes among the 90 lung transplant recipients.

[0030] FIG. **17**. Clonal hematopoiesis mutated genes among the 189 kidney transplant recipients.

[0031] FIG. **18**. Clonal hematopoiesis mutated genes among the 374 liver transplant recipients.

[0032] FIG. **19**. Mortality according to the transplanted organ.

[0033] FIG. **20**. Mortality according to clonal hematopoiesis.

[0034] FIG. **21**. Mortality according to clonal hematopoiesis by transplanted recipients.

DETAILED DESCRIPTION

[0035] In the following description, numerous specific details are set forth to provide a thorough understanding of the invention. However, it is understood that the invention may be practiced without these specific details.

[0036] As noted above, we investigated the role that the enhanced inflammatory environment associated with CH may play in various disease outcomes and its related complications.

[0037] In one example, we studied cardiogenic shock (CS) and its association with variable systemic inflammation and whether it may be responsible for the patient heterogeneity and the exceedingly high mortality rate. Cardiovascular events have been associated with clonal haematopoiesis (CH) where specific gene mutations in hematopoietic stem cells lead to clonal expansion and the development of inflammation. This study aims to assess the prevalence of CH and its association with survival in a population of CS patients in a quaternary centre.

[0038] We compared the frequency of CH mutations among 341 CS patients and 345 ambulatory heart failure (HF) matched for age, sex, ejection fraction, and HF aetiology. The association of CH with survival and levels of circulating inflammatory cytokines was analysed. We detected 266 CH mutations in 149 of 686 (22%) patients. CS patients had a higher prevalence of CH-related mutations than HF patients (OR 1.5; 95% Cl 1.0-2.1, P=0.02) and was associated with decreased survival (30-days: HR 2.7; 95% Cl 1.3-5.7, P=0.006; 90-days: HR 2.2; 95% Cl 1.3-3.9, P=0.003; and 3-years: HR 1.7; 95% Cl 1.1-2.8, P=0.01). TET2 or ASXL1 mutations were associated with lower survival in CS patients at all-time points (P≤0.03). CS patients with TET2 mutations had higher circulating levels of SCD40L, IFNγ, IL-4, and TNFα (P≤0.04), while those with ASXL1 mutations had decreased levels of CCL7 (P=0.03).

[0039] CS patients have high frequency of CH, notably mutations in TET2 and ASXL1. This was associated with reduced survival and dysregulation of circulating inflammatory cytokines in those CS patients with CH.

[0040] Novel risk stratification and non-invasive surveillance methods are also needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant, and this was thus the focus of another example. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing was used to detect CH-associated mutations. We evaluated the association between CH and acute cellular rejection, CMV infection, cardiac allograft vasculopathy (CAV), malignancies, and survival. CH mutations were detected in 26 (20.5%) patients, mostly in DNMT3A, ASXL1, and TET2. Patients with CH showed a higher frequency of CAV grade 2 or 3 (0% vs. 18%, P<0.001). Moreover, a higher mortality rate was observed in patients with CH [11 (42%) vs. 15 (15%), P=0.008] with an adjusted hazard ratio of 2.9 (95% CI, 1.4-6.3; P=0.003). CH was not associated with acute cellular rejection, CMV infection or malignancies. The prevalence of CH in OHT recipients is higher than previously reported for the general population of the same age group, with an associated higher prevalence of CAV and mortality.

[0041] Similar studies were conducted with respect to hypertrophic cardiomyopathy, lung transplant, immunotherapy benefit in myleloma and metatstic risk of a non-hematological cancer.

[0042] Accordingly, in an aspect, there is provided a method of predicting the risk of a disease condition of a solid organ in a patient, the method comprising: receiving a sample from the patient containing hematopoietic stem cells; sequencing the sample to detect a degree of clonal hematopoiesis; comparing the degree of clonal hematopoiesis in the patient to a control degree; and determining the patient is at an elevated risk of the disease condition if the degree of clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner.

[0043] As used herein, the term “control” refers to a specific value or dataset that can be used as a reference to classify a measured value e.g. the wild type or frequency of mutations in a cohort. A person skilled in the art will appreciate that the comparison between the measurement in the test sample and the reference values in the control will depend on the control used.

[0044] As used herein “hematopoietic stem cell” refers to cells capable of developing into any blood cell, including mature myeloid and/or lymphoid cells. These cells are typically bone marrow, liver, spleen or cord blood in origin. Myeloid and lymphoid lineages both are involved in dendritic cell formation. Myeloid cells include monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, and megakaryocytes to platelets. Lymphoid cells include T cells, B cells, natural killer cells, and innate lymphoid cells.

[0045] The term “sample” as used herein refers to any fluid, cell or tissue sample from a subject that can be assayed for the mutations in hematopoietic stem cells described herein.

[0046] In some embodiments, the degree of clonal hematopoiesis is measured using a variant allele frequency of mutations determined to be associated with clonal hematopoiesis. Preferably, the variant allele frequency (VAF) is ≥2%. Further preferably, the VAF is ≥5%.

[0047] In some embodiments, the following genes are sequenced in the sample: TET2, DNMT3A, and ASXL1, and optionally one or more of, but preferably all of, BCOR, BRAF, CALR, CBL, CEBPA, EZH2, FLT3A, GATA1, GATA2, GNAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TP53, U2AF1, WT1, and ZRSR2.

[0048] In some embodiments, the sequencing is performed using single-molecule molecular inversion probes (smMIPs). The smMIPs technique is an assay that combines single molecule tagging with multiplex targeted capture to enable practical and highly sensitive detection of low-frequency or subclonal variation.

[0049] In some embodiments, the mutations associated with clonal hematopoiesis are detectable by the probes listed in Table A.

[0050] In some embodiments, the mutations associated with clonal hematopoiesis are detected using a library comprising at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.

[0051] In some embodiments, the mutations associated with clonal hematopoiesis are detected using a library consisting of at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.
[0052] In some embodiments, the mutations associated with clonal hematopoiesis are detected using a library consisting of substantially all of the probes listed in Table A.
[0053] In some embodiments, the mutations associated with clonal hematopoiesis are detected using a library consisting of the probes listed in Table A.
[0054] In some embodiments, the solid organ is a heart.
[0055] In some embodiments, the disease condition is cardiogenic shock. In some embodiments, an elevated risk of cardiogenic shock is associated with an elevated risk of death. Preferably, the method further comprises treating or preventatively treating the patient for cardiogenic shock.
[0056] In some embodiments, the disease condition is an adverse outcome after orthotopic heart transplant (OHT). In some embodiments, the adverse outcome is an elevated risk of mortality and/or elevated risk of cardiac allograft vasculopathy. Preferably, the method further comprises treating or preventatively treating the patient for cardiac allograft vasculopathy.
[0057] In some embodiments, the disease condition is hypertrophic cardiomyopathy. Preferably, the method further comprises treating or preventatively treating the patient for hypertrophic cardiomyopathy.
[0058] In some embodiments, the solid organ is a lung. In some embodiments, the disease condition is an adverse outcome, including death, after lung transplant. Preferably, the method further comprises treating or preventatively treating the patient for the adverse outcome after lung transplant.
[0059] In an aspect, there is provided a kit comprising a library of probes library comprising at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.
[0060] In some embodiments, the kit comprises a library consisting of at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.
[0061] In some embodiments, the kit comprises a library consisting of substantially all of the probes listed in Table A.
[0062] In some embodiments, the kit comprises a library consisting of the probes listed in Table A.
[0063] In an aspect, there is provided a method of predicting the benefit of immunotherapy in a patient with melanoma, the method comprising: receiving a sample from the patient containing hematopoietic stem cells; sequencing the sample to detect a degree of clonal hematopoiesis in TET2; comparing the degree of TET2 clonal hematopoiesis in the patient to a control degree; and determining the patient would benefit from immunotherapy if the degree of TET2 clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner. Preferably, the method further comprises treating the patient with immunotherapy.
[0064] In an aspect, there is provided a method of predicting metastatic risk in a patient with a non-hematological cancer, the method comprising: receiving a sample from the patient containing hematopoietic stem cells; sequencing the sample to detect a degree of clonal hematopoiesis in TET2; comparing the degree of TET2 clonal hematopoiesis in the patient to a control degree; and determining the patient is at a lower risk of metastasis if the degree of TET2 clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner. Preferably, the method further comprises treating the patient with a treatment and monitoring regimen reflective of a low risk of metastasis.
[0065] The advantages of the present invention are further illustrated by the following examples. The examples and their particular details set forth herein are presented for illustration only and should not be construed as a limitation on the claims of the present invention.

Example 1

Materials and Methods

Patient Selection

[0066] We performed a retrospective study to evaluate the prevalence of CH in CS patients and compared it to matched stable ambulatory HF patients. Stable ambulatory HF patients were chosen as controls as there is a known relationship with CH. We screened 1,315 consecutive patient admission with CS admitted to the cardiac intensive care unit (CICU) at the Toronto General Hospital (Ontario, Canada) from January 2014 to December 2020, identifying 341 patients with suitable biospecimens and consent. CS was diagnosed based on international consensus..sup.14 Only the first CICU admission was considered for inclusion into the study. We also screened 9,485 ambulatory HF patients with no previous history of CS, orthotopic heart transplant (OHT), durable ventricular assist device (VAD), or HF admission in the 12 months prior to biospecimen collection and clinical evaluation (N=583). We included all patients aged ≥18 years, with biospecimens stored in the Peter Munk Cardiac Centre Cardiovascular Biobank. We excluded patients with incomplete digital records, those who withdrew consent during follow-up, or low biospecimen quality (FIG. **1**).

Definition of Clinical States of Enrolled Patients

[0067] Cardiogenic shock diagnosis was based on international consensus criteria.sup.14 which required a systolic blood pressure≤90 mmHg for more than 30 minutes, or the need for inotrope/vasopressor support, signs of end-organ failure (clammy skin, capillary filling time >3 seconds, urine output <0.5 mL/kg/h, lactate level >4 mmol/L), or a low cardiac output (<2.2 L/min/m.sup.2 if receiving inotropes/vasopressors or <1.8 L/min/m.sup.2 without inotropes/vasopressors). In contrast, we defined stable ambulatory HF as patients with HF, with no history of OHT or VAD, or HF admission in the 12 months up to the time-point of biospecimen collection.

Data Collection

[0068] Clinical and laboratory data for CS patients were collected within the first 24 hours of CICU admission. The Society for Cardiovascular Angiography and Intervention (SCAI) CS stage.sup.14 was calculated at 24 hours after CICU admission. Data collected after this time were related to in-hospital outcomes such as use of mechanical circulatory support (MCS), renal replacement therapy, mechanical ventilation and death. Data for ambulatory HF patients were collected as close to the biospecimen collection date as possible. All study data were collected from electronic records and prior to CH sequencing.

Follow-Up and Outcomes

[0069] All CS patients were followed until death or their last visit to our institution after hospital discharge. Follow-up time for the ambulatory HF group was defined from the time of biospecimen collection until the last visit to our institution or notice of death. As OHT and VAD substantially increase survival, a patient was right censored at the time of VAD, OHT or last follow-up, whichever was earlier. We reported event-free survival at 30-day, 90-day and 3-year. Similar to other studies,.sup.9 we defined CH-related mutations at a VAF cut-off ≥2%.

Biospecimens and Analysis

[0070] Biospecimens were collected from patients during their admission to the CICU unit of the Toronto General Hospital with deferred consent. In the case that a patient, or their substitute decision-maker, denied consent at a later time point, the biospecimens were discarded. Biospecimens from ambulatory HF patients were obtained during routine heart function clinic visits at our institution. All samples were stored at −80° C. at the Peter Munk Cardiac Centre biobank.
[0071] For patients with CS, biospecimens were collected within a median of 10 (interquartile range, IQR 67) days from CS admission. In the ambulatory HF patient group, 89% of biospecimens were collected on the same day as clinical evaluation. We felt the timing of biospecimen collection was appropriate as changes in clonal haematopoiesis do not occur over days, but rather over years.

Genetic Sequencing Procedures

[0072] Next-generation sequencing library construction was conducted with smMIPs..sup.15

Cytokine Analysis

[0073] To define whether cytokine levels can be potential markers of inflammation, the analysis was restricted to those samples obtained during the admission to the CICU.

Statistical Analysis

[0074] All analyses on the frequency and associations with CH were performed with a variant allele frequency (VAF) cut-off ≥2%. For specific gene analysis, we compared patients with no mutation with those with a mutation in one of the three more common mutations (DNMT3A, TET2, or ASXL1) with a VAF ≥2% but with no overlap mutations. We also transformed VAF and cytokines levels using the logarithm function to reduce the distribution skewness.

[0075] A sample size of 345 patients for each group would detect a ratio of 1.5 in CH frequency between CS and ambulatory HF groups with a power of 87.5% and alpha of 0.05. There were 345 CS patients and 583 stable HF patients selected after initial screening. The CS and stable HF groups were one-to-one matched by age, sex, aetiology of HF, and ejection fraction. A nearest neighbour method was applied without replacement. After matching, there were 345 patients in each group. FIG. **1** summarizes sample selection.

[0076] All variables were tested for normality with histogram analysis and Shapiro-Wilk test. Normal and non-normal continuous variables are presented as mean±standard deviation or median (interquartile range), and categorical variables with frequencies. Between-cohort differences in continuous variables were evaluated with a Student's t-test or Mann-Whitney accordingly. Between-cohort differences in categorical variables were evaluated with a chi-square test. Logistic regression was performed to quantify the association of the prevalence of CH between CS and ambulatory heart failure patients in terms of odds ratios. Next, we separately characterized the 30-day, 90-day and 3-year event-free survival for each cohort using the Kaplan-Meier survival method. Furthermore, within each cohort, we contrasted event-free survival in patients with and without CH in terms of hazard ratios (HR) using Cox proportional hazards regression and evaluated the survival differences using log-rank tests. The HRs in this descriptive analysis were not adjusted for covariates. Subsequently, we also quantified the association between CS and mortality both with age only and with other clinically relevant covariates (i.e., age, sex, aetiology, use of mechanical circulatory support, creatinine, sodium, and white blood count). The model was validated by the proportional hazard assumption test based on Schoenfeld residual. Finally, as a sensitivity analysis, we repeated the previous analyses on all-cause mortality without right censoring patients at the time of OHT and VAD implantation. We described and explored the event-free survival and the levels of 48 cytokines in patients with a single gene mutation in the three most commonly mutated genes to patients without any mutations. We used a statistical significance of 0.05 for all analyses and a two-sided p-value. All analyses were performed using SPSS, version 25.0 (SPSS Inc., NY, USA).

Results and Discussion

[0077] In this study, 341 patients were included in the CS group and 345 in the ambulatory HF group. Four (1%) patients were excluded from the CS group due to poor biospecimen quality (FIG. **1**). All characteristics included in the case-control study were similar between groups (Table 1). Our study population consisted mostly of males with a predominance of non-ischemic cardiomyopathy. Patients with CS, however, had a lower body mass index, more frequent history of smoking, lower incidence of pre-existing chronic HF, higher admission serum creatinine and higher BNP when compared with ambulatory HF patients.

[0078] In the CS group, the most common aetiology was acute decompensation of chronic HF in 225 (66%) patients, followed by new onset HF in 93 (27%), myocardial infarction in 10 (3%) and myocarditis in 11 (3%). The majority were classified at SCAI stage D (285 patients, 83%) and pulmonary artery catheter was used in 178 (52%) patients confirming disease severity. Fifty-two (15%) patients required temporary MCS with intra-aortic balloon pump being the most commonly used (n=26, 8%), followed by extra-corporeal life support (n=18, 5%), and Impella Device® (Abiomed Inc., Massachusetts, USA) (n=8, 2%). Mechanical ventilation was needed in 63 (18%) patients and renal replacement therapy in 35 (10%). Clinical characteristics are summarized for both CS patients (Table 2) and ambulatory HF (data not shown). CS patients were followed for a median of 676 (1289) days, while ambulatory HF patients were followed for 1246 (884) days.

[0079] In the CS group, 104 (30%) underwent OHT, 79 (23%) required durable VAD, 132 (39%) died during follow-up with 59 (17%) patients dying during the index hospitalization and 73 (21%) after hospital discharge. In the ambulatory HF group, 19 (6%) patients had OHT, seven (2%) were referred for durable VAD, and 35 (10%) patients died.

Prevalence and Distribution of CH Mutations in the Study Groups

[0080] Overall, 422 mutations were identified in 28 genes, of which 266 (63%) mutations had a VAF ≥2% and were included in the analysis (data not shown), affecting 149 (22%) of the 686 patients. The most common mutation type was missense, followed by frameshift, nonsense and splice site (data not shown). The most mutated gene was DNMT3A in 84 (32%), followed by TET2 in 48 (18%), and ASXL1 in 30 (11%) patients, with a similar distribution in mutations observed in both the CS and ambulatory HF groups (FIG. **2**A). Among all patients with CH, 83 (56%) had a single mutation, 35 (23%) had two and 31 (21%) had three or more (FIG. **2**B). The VAF distribution was similar in both populations (FIG. **2**C). As expected, an age-associated increase in CH prevalence (FIG. **2**D) was observed in both groups; however, the overall frequency of CH was significantly higher in CS patients, as compared with ambulatory HF patients (25.2% versus 18.3%; odds ratio, 1.5; 95% Cl 1.0-2.1, P=0.02). CS patients with CH were older than those without mutations, and had a higher frequency of dyslipidaemia, lower sodium, and white blood count (Table 2). The frequency of CH in CS patients with previous HF was similar than those without out [24 (26%) vs. 24 (23%), P=0.54). Ambulatory HF patients with CH were older and more likely to have ischemic cardiomyopathy (data not shown).

Association Between CH and Survival

[0081] The presence of CH in the CS group was associated with an increased risk of death in a multivariable adjusted analysis for age, sex, aetiology of CS, use of mechanical circulatory support, creatinine, sodium, and white blood count and censored for VAD/OHT: 17 patients (20%) with CH died in the first 30-days compared with only 17 (7%) without mutations (hazard ratio, (HR), 2.7; 95% Cl 1.3 to 5.7, P=0.006; FIG. **3**A). A similar ratio was seen at 90-days (HR, 2.2; 95% Cl 1.3 to 3.9, P=0.003; FIG. **3**B). At 3 years, 36 patients (42%) with CH had died compared with 47 (18%) without detectable CH at initial admission for CS (HR, 1.7, 95% Cl 1.1 to 2.8, P=0.01; FIG. **3**C). Similar results were observed with the unadjusted and age-adjusted analysis for both uncensored and VAD/OHT censored (data not shown). There were no differences in survival between CH and non-CH groups in the ambulatory HF patients uncensored or VAD/OHT censored (data not shown). In addition, when considering VAF as a continuous variable, there was no association with death. However, analysis of VAF categorized as ≥2 to <5% and ≥5% was associated with a higher risk of death in those with VAF ≥5%, at 90-days and 3-years. Increasing number of mutated genes was not associated with death (data not shown).

[0082] We then stratified the CS group according to the three most mutated genes (DNMT3A, TET2, and ASXL1, FIGS. **3**D, **3**E, **3**F) and found an association for TET2 and ASXL1 mutations with decreased 30-day, 90-day, and 3-year survival compared with patients who had no CH mutations. Results for survival censored for VAD/OHT had similar results. DNMT3A mutations had no effect on survival at 30-day, 90-day or 3-year follow-up.

Cytokine Expression in Cardiogenic Shock

[0083] To assess changes in the inflammatory milieu associated with CH, we compared 48 cytokines in the plasma of CS patients with mutations in the three most mutated genes, to those without CH. CS patients with TET2 mutations exhibited higher circulating levels of SCD40L, IFNγ, IL-4, and TNFα (FIGS. **4**A, **4**B, **4**C and **4**D), and those with ASXL1 mutations had lower levels of CCL7 (FIG. **4**E) compared with patients lacking CH mutations. There were no differences in the cytokine profiles of patients with DNMT3A mutations (data not shown).

DISCUSSION

[0084] CH mutations are associated with increased risk for adverse cardiovascular events in specific populations of patients with atherosclerosis and heart failure..sup.5,9,10 We found that patients with CS had a 1.5-fold higher prevalence of CH as compared to ambulatory HF patients, with an associated decrease in 30-day, 90-day, and 3-year survival. The observed prevalence of CH in ambulatory HF patients (18.3%) is consistent with other reported findings, emphasizing the comparability of the methodology applied..sup.9,16 Importantly, our data shows that CH may be considered as risk factor for CS admission regardless of prior HF. Of note, mutations specifically in TET2 and ASXL1 impacted the prognosis of CS and were associated with distinct circulating inflammatory cytokine profiles, compared with those patients without CH mutations. While the retrospective

nature of this study may have introduced a survival bias, as CS patients who did not survive the first hours of presentation were less likely to have biospecimens taken, our study likely underestimates the prevalence of CH in CS. To our knowledge, this is the first study to show the higher prevalence of CH and lower survival in patients admitted with CS.

[0085] DNMT3A was the most common mutated gene in both groups, followed by TET2 and ASXL1. These genes are epigenetic regulators with a role in altering DNA methylation to potentially promote stem cell self-renewal and clonal expansion..sup.17 While DNMT3A is responsible for de novo DNA methylation, TET2 promotes demethylation..sup.11 ASXL1 has a role in chromatin regulation, promoting myeloid leukemogenesis..sup.18 Although the mechanisms ascribed to these genes are still poorly understood, they likely boost systemic inflammation which may have an impact in CS..sup.10,13,17 TET2 mutations were associated with a significant decrease in both short- and long-term survival in CS patients. These findings mirror previous work showing higher pathogenicity of mutations in TET2, compared to DNMT3A in the broader setting of HF..sup.9,10,16,19 Additionally, ASXL1 mutations have been related to increased risk for myocardial infarction.sup.10 but its role in HF was unknown prior to our study. Here, we report a decrease of short- and long-term survival in ASXL1 carriers admitted with CS. DNMT3A mutations have been associated with HF hospitalization and death.sup.16, but this was not seen in our analysis. Mutations in DNMT3A may have lower pathogenicity in CS, explaining their higher frequency in this population.

[0086] CS is associated with acute systemic inflammation, which has been shown to increase mortality..sup.4,20 Augmentation of this inflammatory state could explain the increased risk of death seen in CS patients with CH mutations. In our study, patients with CS harbouring TET2 mutations had elevated circulating levels of SCD40L, IFNγ, IL-4, and TNF-α. SCD40L has a pro-inflammatory, pro-coagulant function associated with cardiovascular events related to atherosclerosis..sup.21,22 IL-4 leads to tissue macrophage accumulation,.sup.23 and increases IFNγ expression, which has a key role in the adaptive immune response.sup.24, and promotes myelopoiesis in response to inflammation.sup.24,25. TNF-α is primarily produced by macrophages and can induce apoptosis in hematopoietic cells..sup.26,27 Additionally, ASXL1 mutations in CS patients were associated with lower circulating levels of CCL7, a chemokine that is a potent chemo-attractant for myeloid cells..sup.28 The differential regulation of cytokines promoted by specific CH mutation could enhance the immune response leading to reduced survival in TET2 and ASXL1 mutation carriers. The lack of any dysregulation of circulating cytokines with DNMT3A mutations offers an explanation why survival was not affected in our CS patients.

[0087] Clinically, the increasing incidence of CS remains a major limitation in patient management..sup.2 The association of CH mutations with higher mortality could provide a new biomarker to help identify patients at elevated risk, establishing a new paradigm of risk assessment in CS. The fact that CH patients were older does not explain the dramatic increase in mortality in CH patients, as the age-adjusted analysis showed similar results. Also, similar age differences between study populations were described in previous studies showing the impact of CH in cardiovascular outcomes..sup.9,19 Mechanistically, the increased risk due to CH likely occurs through augmentation of the acute inflammatory state in CS. The altered cytokine profile may provide potential therapeutic targets in these patients. Prior studies have shown that decreased IL-6 receptor activity improved outcomes in patients with CH..sup.29 The development of smMIP-sq for CH assessment in our study should overcome the barrier to clinical implementation of other sequencing methods..sup.16,19 Furthermore, the 2% VAF cut-off remains controversial. VAF reflects the size of the expanded clone evaluated in the peripheral blood and it is reasonable to hypothesize that risk increases with an increase in VAF..sup.11,16,17 However, we did not find a difference in the VAF between CS patients and ambulatory HF, and its use as a continuous variable was not associated with increased mortality in CS patients. We did find that CH-associated risk increased with a categorized higher VAF cutoff..sup.16 This may be explained by the highly-skewed distribution of VAF.

[0088] CS patients had a 50% higher prevalence of CH mutations than stable ambulatory HF patients. These mutations were associated with a 2-fold reduction in survival of CS patients. Specifically, mutations in TET2 and ASXL1 genes were shown to be more lethal than DNMT3A in this context and were associated with an altered profile of circulating inflammatory cytokines that may suggest a mechanism for CH to affect patient outcomes.

Example 2

Materials and Methods

Study Population

[0089] We performed a retrospective study of 127 patients that underwent OHT in the Toronto General Hospital from 2005 to 2021. Only patients older than 18 with available biospecimens and complete clinical evaluation were included. No patients with active malignancies were included because it is considered a criteria for heart transplant candidacy.

Data Collection

[0090] The clinical chart and pre-transplant assessment of OHT recipients were reviewed from the patients' digital health records. We collected demographic data, medical history, laboratory assessment, date of OHT, transplant-related treatment at the time of the procedure and the immunosuppressive regimen at 1-yeart post-OHT, the occurrence and grade of acute cellular rejection episodes, CMV infection, CAV, any malignancy and death. All baseline characteristics regarding demographic and comorbidities were collected as close as possible to the biospecimens collection date because of its relationship with CH mutations.

Follow-Up and Outcomes

[0091] Patients were followed from the time of OHT procedure to the last visit at our institution or death. The patients were evaluated for the following outcomes: the first occurrence of acute cellular rejection, CMV infection, de novo post-transplant malignancy, CAV, and death.

[0092] Cellular rejection episode was diagnosed and classified according to the International Society for Heart and Lung Transplantation (ISHLT)..sup.s4 A positive cellular rejection episode was defined as the occurrence of 2R and 3R classification in EMB performed routinely or due to clinical suspicion of cellular rejection. As a routine, patients are routinely evaluated for rejection in weeks 1-4, 6, 8, 10 and months 3-6, 9, 12, 18, 24. Gene-expression profiling was also used for rejection surveillance in low-risk patients at our center, with a gene-expression derived high-risk score verified by confirmatory EMB. CMV assessment was performed when infection was suspected or when prophylaxis was discontinued. CMV infection was defined as positive PCR in peripheral blood regardless of clinical symptoms. Post-OHT malignancy vigilance is performed routinely by our centre and the diagnosis is based on tissue biopsy showing malignant neoplastic cells. OHT recipients have coronary angiography performed with intravascular ultrasound at 3 months, 12 months, 1-year and 5-years post OHT, though this may be deferred if intercurrent illness or significant kidney disease is present. The findings are graded according to the ISHLT criteria for CAV and considered positive in the presence of CAV2 or CAV3..sup.s4 In the survival analysis, we considered death from any cause in the end of follow-up.

Genetic Sequencing Procedures

[0093] Peripheral blood samples were collected with patient consent during clinical visits to Toronto General Hospital and were stored in the Peter Munk Cardiac Centre biobank. 100 ng of DNA was used to construct sequencing libraries using single molecule Molecular Inversion Probes (smMIP) as previously described..sup.s16 Paired-end 150 bp sequencing reads were generated using the Illumina Novaseq platform (Illumina Inc., California, USA).

Statistical Analysis

[0094] All variables were tested for normality using the Shapiro-Wilk test. Normal and non-normal continuous variables are presented as mean±standard deviation or median (interquartile range). Difference among groups were evaluated with a Student's t-test or Mann-Whitney accordingly. Group differences in categorical variables were evaluated with a chi-square test or Fisher's exact test as appropriate. The hazard ratios (HR) for the event-free survival for OHT patients with or without CH was calculated using the Cox proportional hazards regression. An adjusted Cox proportional hazards regression including age, sex, primary heart failure diagnosis (ischemic, non-ischemic and congenital) and chronic kidney disease was also calculated to estimate the impact of CH on survival. The model was ascertained by the proportional hazard assumption test based on

Schoenfeld residual and found to be valid. The survival function is represented graphically using Kaplan-Meier curves and compared according to the presence of CH mutations using log-rank test. We used a statistical significance of 0.05 for all analyses and a two-sided p-value. All analyses were performed using SPSS, version 25.0 (SPSS Inc., NY, USA).

Results and Discussion

Study Participants

[0095] Between 2005 and 2021, 589 patients underwent OHT at our institution. 127 patients (21.5%) were included in this study. 97 males and 30 females. Their mean age was 49±14 years. The most common comorbidities were prior smoking (n=34, 27%), hypertension (n=33, 26%), dyslipidemia (n=33, 26%) and type 2 diabetes (n=28, 22%). 90 patients (71%) were diagnosed with underlying non-ischemic HF prior to OHT while 28 patients (22%) had ischemic heart disease. Transplantation was conducted in 44 (35%) patients with a ventricular assist devices (VAD). All patients received induction therapy, with the vast majority (n-123, 97%) receiving rabbit anti-thymocyte globulin. The most common immunosuppressive therapy regimen at hospital discharge included tacrolimus (n=119, 94%), sodium mycophenolate (n=123, 97%) and corticosteroids (n=127, 100%). Table 3 summarizes the patient's baseline characteristics.

Evaluation of CH in OHT Recipients

[0096] The targeted sequencing of CH genes was successfully performed in all patients. In 87 (68%) cases, samples were collected before the procedure with a median time from sample to procedure of 200 (IQR 428) days, and in 40 (32%) cases the sample was collected after the transplant, with a median time from the procedure to the sample collection of 114 (IQR 624) days. We observed 46 CH mutations in 26 (20%) OHT recipients (FIG. **1**A) with a median variant allele frequency (VAF) of 8.6% (3.2-35.9). The most commonly affected genes were DNMT3A in 11 (9%), ASXL1 in 5 (4%), and TET2 in 4 (3%). TP53, PPM1D, and CEBPA affected two (2%) patients each, while JAK2, IDH2, SF3B1 and SMC1A were found in one (1%) patient each (FIG. **2**B). Most patients (N=16, 62%) with CH had only one mutation (FIG. **3**C). Clinical characteristics of patients with specific CH mutations were summarized (data not shown). The list of variants detected can be found in Table 5. Gene mutations and the VAF according to immunosuppressive regimen at hospital discharge were summarized (data not shown).

[0097] OHT patients with CH were older than those without mutation (54±13 vs 48±14 years, P=0.04) and were followed for a longer period after OHT (4.3±3.9 vs. 2.9±2.1, P=0.01). CH carriers also received an organ from EBV+ donor less frequently than those without CH [16 (62%) vs. 81 (80%), P=0.02]. At hospital discharge, CH patients were less likely to receive tacrolimus [22 (85%) vs. 97 (96%) P=0.03], and sodium mycophenolate [23 (89%) vs. 100 (99%), P=0.006]. There were no statistically significant differences in the prevalence of cardiovascular risk factors (diabetes, hypertension, BMI, smoking, dyslipidemia) or pre-OHT HF etiology between patients with and without CH (Table 3).

CH is Associated with Increase Mortality in the Setting of OHT

[0098] The mean follow-up post-OHT was 3.2±2.6 years. Primary graft dysfunction occurred in 19 (15%) with an in-hospital mortality post-OHT of 9%. During follow-up, 59 (46%) patients had CMV infection, 69 (54%) had at least one 2/3R acute cellular rejection episode, 11 (9%) had post-transplant malignancy, 4 (3%) CAV grade 2 or 3, and 26 (20%) died.

[0099] All four CAV diagnosis occurred OHT recipients with CH (18%; P<0.001), but no CAV was found among those without CH. The number of patients assessed for CAV with coronary angiogram was similar between patients with CH and those without CH CH [17 (65%). Vs. 68 (67%), P=0.85], and also time from OHT to first coronary angiogram 441 (1192) days vs. 399 (107) days, P=0.19. Patients with CH showed a higher mortality rate than those without CH [11 (42%) vs. 15 (15%), P=0.008], with an unadjusted hazard ratio (HR) of 3.1 (95% Cl 1.4-6.7), P=0.005, and an adjusted HR of 2.9 (95% Cl 1.4-6.3; P=0.003). The clinical characteristics and cause of death of patients with our without CH were summarized (data not shown). Because CH patients had a trend towards more Cyclosporine prescription at discharge and at the end of the first year after OHT, we performed an sensitivity analysis with age and type of immunosuppressive drugs in the of the 1.sup.st year. The adjusted model showed that CH was associated with increased mortality with an HR of 5.9 (95% Cl 1.7-19.9), P=0.004. FIG. **2** shows the Kaplan-Meier survival analysis with an increased mortality in those with CH (P log-rank=0.003). The evaluation of outcomes according to specific gene mutation showed that more acute cellular rejection 2/3R were observed in those with DNMT3A, more CAV grade 2/3 in patients with DNMT3A and with TET2, and higher mortality in those with TET2 gene mutation (data not shown). We did not observe a higher mortality in patients with a VAF≥10% (n=14) in comparison to those with VAF<10% (N=113) [5 (35.7%) vs. 21 (18.6%), P=0.31]. Considering our results, we undertook a post-hoc power calculation. With a sample size of 127 patients and a hazard ratio of 3.1 for OHT survival, given an alpha of 0.05, we would have a power of 99.2% of detecting such a difference. No differences were observed between OHT patients with or without CH regarding CMV infection, 2/3R acute cellular rejection or post-transplant malignancy. Both cases of post-OHT malignancy in patients with CH were diagnosed with squamous cell carcinoma of the skin, and one also developed lung carcinoma. No patients developed PTLD. Table 4 summarizes outcomes in OHT recipients according to CH.

DISCUSSION

[0100] CH has been linked to inflammatory conditions, increased mortality and incidence of cardiovascular diseases, but data in the setting of solid organ transplantation is scarce..sup.s8, s17 We showed that the CH prevalence in OHT recipients is higher than expected for the same age in the general population. CH mutations are associated CAV and a 3-fold increase in mortality after OHT. These findings suggests a new biomarker in post-transplantation risk assessment.

[0101] The detection of CH is an exceedingly common feature of aging, with a prevalence of 10% by the 7.sup.th decade of life and an overall prevalence of 4-5%..sup.s7 In this study, 20% of OHT recipients were found to have a CH mutation in a younger population, mainly in DNMT3A, ASXL1 and TET2 genes, with most patients harboring a single mutation. Previously, HF patients were shown to have an 18.5% frequency in CH mutations at a median age of 65 years..sup.s10, s14 Similarly, the median VAF in our cohort was 12%, which is much higher than the reported ≈4-6% in non-advanced HF cohorts..sup.s10, s14 Additionally, CH patients have been consistently reported to be older than those without these mutation, similar to our study. While concerns can been raised about CH being a risk marker of aging instead of a disease-driving factor, several studies have shown that CH is independently associated with increased cardiovascular risk after adjusting for age..sup.s10, s14 CH has also been shown to have a causal effect in mice harboring either Dnmt3a, Tet2, Jak2, Tp53, and Ppm1d mutations with adverse LV remodeling, lower LV ejection fraction and worsening degree of fibrosis post-myocardial infarction..sup.s15, s18-s21

[0102] CH mutations have been shown to be associated with atherosclerosis, myocardial infarction, stroke and HF..sup.s8-s10, s14 A similar background of inflammation driving clinical outcomes would be expected in OHT recipients. In our study, CH was associated CAV grade 3. Experimental models have shown that Tet2-deficient mice have larger atherosclerotic plaque size and increased levels of several inflammatory cytokines..sup.s8, s22 Higher levels of coronary artery disease have been observed in patients with CH..sup.s8 The pathways involved in atherosclerosis development overlap with the inflammatory background of CH, but the pathophysiology of CAV comprises a complex interaction of immune and non-immune factors which contribute to a pro-inflammatory state and ultimately result in endothelial injury, vascular cell proliferation, fibrosis, and remodeling..sup.s23-s25 The increased inflammatory cytokines expressed in patients with CH could have a role in CAV development, but further studies are needed to confirm this hypothesis, especially due to the low number of CAV diagnosis in the sample.

[0103] The complex relationship of immune phenomena and inflammation promoted by CH could be responsible for other outcomes in OHT recipients. The innate immune system can be activated by several different cytokines resulting in rejection episode.sup.s26, s27, and activation of IL-1R pathway has a central role in ischemic reperfusion injury..sup.s28 However, despite the overall higher proportion of CH patients experiencing acute cellular rejection, it failed to reach statistical significance. One possibility is that based on the 16% absolute increase observed, a sample size of over 400 patients would be required to reach statistical significance. CH has also been associated with the occurrence of infections and malignancies..sup.s11, s12 We observed only a small number of such events which may explain the lack of association of CH with these outcomes. Nevertheless, CH was associated with a 3-fold increase in mortality in OHT recipients even after adjustment for confounding factors. Cardiovascular

events in CH patients have been shown to be related with ischemic events and progression to heart failure, but these are not common in OHT recipients..sup.s8, s10, s14 The cause of death in this study was related to allograft dysfunction, acute rejection episode, CAV, and septic shock. The mechanisms responsible for the observed high mortality rate remains unclear, yet previous work have shown that non-survivors after OHT were more likely to present with sustained inflammation..sup.s29 Nonetheless, patients with CH were older, and, despite not being statistically significant, also had higher frequency of hypertension, dyslipidemia and smoking that could have an impact in our results.

[0104] In summary, we demonstrated that CH is associated with, and a potential risk factor, for CAV and mortality in OHT recipients. The complex interaction of the inflammatory cytokines promoted by CH and the immune system could drive several other potential outcomes such as rejection, infections and malignancies. A prior case series of graft versus host disease in transplanted liver patients showed that 71% had CH, highlighting the possible association with these somatic mutations to adverse outcomes..sup.s30

Example 3

Methods and Materials

[0105] We investigated a cohort of patients with hypertrophic cardiomyopathy (HCM) submitted to targeted sequencing for detecting CH. We included 799 patients who were ≥18 years of age, with a clinical diagnosis of HCM by current guidelines.sup.22, cardiac magnetic resonance imaging (MRI) and available biospecimens from the PMCC Biobank. We excluded patients with incomplete records, those that withdraw consent, or low biospecimen quality.

[0106] Among the 799 included patients, CH was found in 183 (22.9%). HCM patients with genotype-positive and CH were found to be more symptomatic and with a higher burden of fibrosis. CH was associated with major cardiovascular event (MACE) in HCM patients [adjusted HR of 3.46 (95% Cl 1.25-9.52; p=0.016)], with the highest risk among genotype-positive and DNMT3A, TET2 and ASXL1 mutated genes [adjusted HR of 7.23 (95% Cl 1.79-29.13) p=0.005]. Several cytokine and chemokines (IL-1ra, IL-6, IL-17F, TGFa, CCL21, CCL1, CCL8, and CCL17), and also troponin I were upregulated in those genotype-positive with CH. Fibrosis, a hallmark of HCM, was found to be increased in those with CH, as well as ABPR at exercise. CH was also associated with a higher mortality and major cardiovascular events (MACE). These results indicate that CH is frequent among HCM patients and associated with a worse clinical phenotype and outcomes.

Definitions

[0107] HCM was defined as the presence of maximal LV wall thickness (MLVWT) ≥15 mm. Also included were patients with MLVWT ≥13 mm and a P/LP genetic variant or a family history of HCM in the absence of other causes for hypertrophy. MLVWT was defined as the higher LV wall measure on echocardiogram or cardiac MRI. The assessment of P/LP variants was conducted using a previously published strategy by our group.sup.23. Evaluation for non-sustained ventricular tachycardia (NSVT) or abnormal blood pressure response (ABPR) at exercise were performed according to the attending clinician discretion. All patients with HCM underwent cardiac MRI with late gadolinium enhancement (LGE) for quantification of fibrosis. The LGE was assessed visually and quantified manually as previously validated.sup.8. LGE extent was defined as the LGE mass percentage of the total LV mass. We were able to quantify LGE in (84.1%) of patients with MRI. In the remaining 127 (15.9%) patients, we only included the qualitative measure of LGE as present or not.

Clonal hematopoiesis and cytokine assessment

[0108] The full method on CH and cytokines evaluation was performed substantially as described in earlier examples. Briefly, we used a single molecule molecular inversion probe (smMIP) method including 35 myeloid genes related to CH and smMIP-tools to call mutations and reported those with variant allele frequency (VAF), a measure of clone size, ≥2% for all analysis. The cytokine analysis was performed using a human cytokine/chemokine 71-plex assay with the Luminex™ 200 system by Eve Technologies Corp. (Alberta, Canada) and included brain natriuretic peptide (BNP) and cardiac troponin I (cTnI).

Results and Discussion

Clonal Hematopoiesis Prevalence and Characteristics

[0109] Overall characteristic of cohort is summarized in Table 7. The median time from biospecimen collection to the echocardiogram was 0 (0-16) days and median time from biospecimen to MRI assessment was 2.2 (0.2-5.6) years.

[0110] All patients had an assessment of CH performed and all samples passed quality control specifications. CH mutations were observed in 183 (22.9%) patients with a median VAF of 6.7 (2.8-40.8) %, being 136 (17.0%) in the three most common genes: DNMT3A in 70 (8.8%), TET2 in 51 (6.3%), and ASXL1 in 24 (3.0%), comprising 73.8% of all CH mutations. All other genes included in the smMIP panel were present in less than 1% of patients. Most patients (158, 19.8%) harbored a single mutation, while two mutations were found in 18 (2.3%) patients, 4 (0.5%) three mutations, and 3 (0.3%) four or more mutations. Among the 183 patients with CH, 135 (73.7%) were over 50 years old. However, among the 54 patients <30 years, CH was present in 14 (25.9%). In relation to the age of HCM diagnosis, 27 (14.8%) patients with CH were diagnosis before 30 years of age, while 62 (33.8%) within 31-50 years, and the majority, 94 (51.3%), were diagnosed after 50 years old. FIG. **7** summarizes CH mutations characteristics. Overall clinical characteristics of CH patients were similar to those without CH (Table 7).

[0111] We then analyzed the association of CH with the HCM phenotype. No differences were found in those with or without CH on echocardiographic parameter such as MLVWT (18.3±4.2 mm vs. 18.8±5.1 mm, p=0.256), left atrium diameter (36.7±14.5 mm vs. 38.1±12.7 mm, p=0.208) and LVOT gradient (24.1±36.2 mmHg vs. 22.1±34.6 mmHg, p=0.491). Cardiac MRI parameters, including the presence of fibrosis evaluated by LGE, as well as other HCM features such as syncope, ABPR at exercise, among others were also similar between groups. However, apical aneurysm [33 (5.4%) vs. 14 (7.7) %, p=0.004] and death or need for orthotopic heart transplant was higher among patients with CH [4 (0.6%) vs. 6 (3.3%), p=0.005]. MACE was also more frequent among patients with CH [12 (2.0%) vs. 9 (5.2%), p=0.026], with an unadjusted HR of 2.72 (95% Cl 1.14-6.49; p=0.023), and adjusted HR of 3.46 (95% CI 1.25-9.52; p=0.016). CH patients showed a worse survival in comparison to those without CH as shown in the Kaplan-Meier curve (Log-Rank P=0.018) (FIG. **8**A).

Clonal Hematopoiesis Related to DNMT3A, TET2 and ASXL1

[0112] We evaluated whether somatic mutations in 3 genes (DNMT3A, TET2 and ASXL1) alone are sufficient to drive poor HCM patient outcome. We found that patients harboring DNMT3A, TET2 and ASXL1 mutations were older than their counterparts [55.3 (14.5%) vs. 58.1 (14.5%), p=0.042] and were more likely to have a family history of SCD [28 (4.2%) vs. 9 (6.7%), p=0.038]. As we noted in the wider CH analysis, these patients were more likely to have hypertension, a P/LP germline HCM related mutation, a pacemaker and treated with a non-dihydropyridine calcium channel blocker (Table 6).

[0113] While patients with DNMT3A, TET2 and ASXL1 CH mutations, exhibited a similar HCM phenotype to those without CH, patients with CH showed a higher mortality or need for orthotopic heart transplant [4 (0.6%) vs. 6 (4.4%), p<0.0001] and MACE [13 (2.0%) vs. 8 (6.2%), p=0.008]. The unadjusted HR for MACE was 3.19 (95% Cl 1.32-7.73; p=0.010) and adjusted HR 3.97 (95% Cl 1.39-11.28; p=0.010). FIG. **8**B shows the Kaplan-Meir curve with worse survival for patients with CH (Log-Rank p=0.006).

Clonal Hematopoiesis in HCM Patients with a Sarcomeric Mutation

[0114] HCM patients harboring a sarcomeric gene mutation are associated with early age at diagnosis, higher MLVWT and worse outcomes.sup.25. Because this subtype of HCM patients have a distinct clinical profile, we sought to investigate if there could be a distinct interaction with CH. The overall characteristics shown among those with or without CH were recorded (data not shown). A trend of a higher burden of symptoms (NYHA class II to IV) [15 (40.5%) versus 47 (28.0%), p=0.132] among those with CH, but it was not statistically significant. However, CH was associated with a higher burden of fibrosis as reflected by LGE in >15% of the LV mass [11 (29.7%) versus 26 (15.3%), p=0.044], with an odds ratio of 2.32 (95% Cl 1.00-5.38, p=0.048), there was a trend towards a higher amount of fibrosis in the LV of those with CH [15.6% (10.4-24.6)] in comparison to those without CH [12.2% (7.7-17.6)], p=0.068. CH patients also showed a higher frequency of ABPR at exercise [25 (29.8%) vs. 10 (62.5%),

p=0.012]. Finally, CH was associated with worse outcomes with higher mortality or orthotopic heart transplant [3 (8.1%) versus 2 (1.2%), (p=0.013)]. This was also observed for MACE in patients with CH [5 (13.5%) versus 5 (3.0%), p=0.008], with an unadjusted HR of 5.28 (95% Cl 1.51-18.4, p=0.009), and adjusted HR of 6.89 (95% CI 1.78-26.6, p=0.005). FIG. **8**C shows the Kaplan-Meier survival curve showing a worse survival for those with CH (log-rank p=0.003).

[0115] We then stratified the HCM phenotype and clinical outcomes in those with sarcomeric mutations and specifically the presence of DNMT3A, TET2, and ASXL1 mutations. Baseline characteristics was similar between groups. The amount of fibrosis assessed by LGE was higher in those with CH [21.2% (13.7-41.8) versus 12.2% (7.7-17.5), p=0.014], whereas LGE≥15% was not statistically different in HCM patients with and without CH [7 (35.0%) vs. 30 (18.3%), p=0.09]. However, CH patients showed a higher frequency of abnormal blood pressure response (ABPR) with exercise than those without CH [8 (66.7%) vs. 27 (30.7%), p=0.014). Finally, mortality or orthotopic heart transplant was more common in the CH group than in those without CH [3 (13.0%) vs. 2 (1.1%), p<0.0001], as well as MACE [4 (17.4%) vs. 6 (3.2%), p=0.004]. MACE was associated with CH with an unadjusted HR of 5.04 (95% Cl 1.39-18.28) p=0.014 and adjusted HR of 7.23 (95% Cl 1.79-29.13) p=0.005. FIG. **8**D shows the Kaplan-Meier survival curve showing a worse survival for those with CH (log-rank p=0.007).

Biomarkers and Cytokines/Chemokines

[0116] A panel of 71 cytokines and chemokines, BNP and cardiac troponin I were evaluated in patients with a sarcomeric mutation and levels were compared among those with (N=37) or without CH (N=169). It was observed that troponin I (p=0.008), IL-1ra (p=0.037), IL-6 (p=0.028), IL-17F (p=0.006), TGFa (p=0.005), CCL21 (p=0.036), CCL1 (p=0.002), CCL8 (p=0.036), and CCL17 (p=0.047) were all upregulated in patients with CH. FIG. **9** shows levels measured among those with and without CH. We then sought to investigate if specific CH mutations were associated with specific cytokines/chemokines. In HCM patients with sarcomeric mutations, those with CH due to DNMT3A (N=16) mutations showed higher levels of IL-9 (p=0.031) and CXCL12 (p=0.046). TET2 CH carriers (N=6) showed higher levels of troponin I (p=0.013), IL-5 (p=0.012), IL-10 (p=0.010), CXCL10 (p=0.001), CXCL9 (p=0.012), CCL4 (p=0.037), VEFG-A (p=0.041), CCL21 (p=0.013), CXCL13 (BCAp=0.012) and CCL1 (p=0.007). Finally, CH due to ASXL1 (N=2) did not show any differences in comparison to those without CH.

Discussion

[0117] In this study, we showed that CH prevalence among HCM patients is higher than described in the general population. Fibrosis, a known SCD risk factor, was more prevalent among CH patients with HCM sarcomeric gene mutations. We also observed higher burden of symptoms and higher frequency of ABPR during exercise among CH patients. Finally, CH was associated with higher mortality or orthotopic heart transplant and MACE. Several cytokines, chemokines and troponin were differently expressed in HCM patients with CH, highlighting a plausible causal relationship with the phenotype and outcomes. This is the first cohort in which there is an association between CH prevalence, HCM phenotype and clinical outcomes.

[0118] To our knowledge, this is the first study to evaluate the prevalence of CH in patients with HCM. In this study, we found that 22.9% of HCM patients harbored CH.

[0119] When restricting analysis to the three specific genes DNMT3A, TET2 and ASXL1, we observed that 17% of HCM patients harbored CH mutations.

[0120] Fibrosis was more common in those patients with HCM who have a sarcomeric mutation and specific DNMT3A, TET2 and ASXL1 mutations. This is an important finding as fibrosis is linked to SCD in patients with HCM.sup.40. In addition, ABPR at exercise, a known marker of SCD risk and worse outcomes.sup.41-43, was also more frequent among those with CH and HCM with sarcomeric mutations. This result potentially illustrates that CH could affect the HCM phenotype and promote adverse outcomes in patients with HCM.

[0121] We showed that, in subsets of HCM patients and evaluating for overall CH or specific CH mutations, the mortality or need for orthotopic heart transplant is increased among CH patients even when adjusting for confounding factors. Moreover, condensing important major cardiovascular events in HCM, such as stroke, sudden cardiac death, appropriate ICD shock, death or orthotopic heart transplant, CH increases its risk in all subsets of patients, reaching the highest risk among those with sarcomeric mutations and with specific CH genes. Our results show that CH is a new risk factor among HCM patients. In fact, HCM patients with sarcomeric mutations with CH on the most common genes showed the worse survival (17%), contrasting to recent cohorts showing that HCM patients have a low mortality..sup.9 Our results do not show a clear evidence of which mechanisms CH increase mortality in HCM, but its strong association with ageing.sup.13 leads us to hypothesize that the epigenic ageing and the inflammatory milieu may have a causal relationship with the reduced survival.

[0122] Among HCM with sarcomeric mutations, CH was associated with several inflammatory cytokines and chemokines such as IL-1ra, IL-6, IL-17F, TGFa, CCL21, CCL1, CCL8, and CCL17, but also with troponin I, a marker of myocyte injury that is associates with clinical outcomes in HCM..sup.47 However, specific CH mutations may have distinct prognosis and inflammatory profiles..sup.14,34 We observed that DNMT3A driven CH was associated with IL-9 and CXCL12. TET2 driven CH was associated with the higher number of differently expressed cytokines/chemokines including troponin I among all tested genes. DNMT3A was associated with LV remodeling and worse outcomes, but the high frequency CH mediated by this gene in the population could be explained by its low lethality and lower burden of inflammation, introducing a survival bias..sup.11,19,28,29,34 Cardiac aging processes mediated by TET2 have shown to produce an enhanced inflammatory background that could be related to hypertrophy and fibrosis, but the worse prognosis associated with TET2 could also explain its lower frequency in studies..sup.11,17,29 ASXL1 carriers did not show different levels of expressed cytokines, chemokines, BNP or Troponin I. We believe that the low number of patients with this specific mutation could explain the results.

Example 4

[0123] We also investigated TET2 mutant clonal hematopoiesis and its association with the benefit of immunotherapy, as well as metastasis of non-hematological cancers. Referring to FIG. **10**, TET2-mutant clonal hematopoiesis is associated with clinical benefit from immunotherapy in melanoma. FIG. **10**A shows 569 patients with melanoma, bladder cancer, renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC) treated with immune-checkpoint blockade were screened for clonal hematopoiesis using publicly-available exome sequencing, with at least one mutation of variant allele frequency (VAF)>0.02 detected in 74 patients (datasets EGAD00001006632, SRP064805, SRP067938, SRP072934, SRP090294, SRP095809, SRP115658, SRP128156). FIG. **10**B shows TET2-mutant clonal hematopoiesis is associated with significantly higher odds of clinical benefit 6 months after receiving immunotherapy in melanoma patients (Odds Ratio=5.98), but not bladder cancer, renal cell carcinoma, or non-small cell lung cancer patients (p value from Firth's multivariate logistic regression adjusted for patient age, sex, study, and immune checkpoint). FIG. **10**C shows in an animal model of immunotherapy, mice with Tet2-mutant hematopoiesis—mimicking TET2-mutant clonal hematopoiesis—show enhanced response to PD-1 immune checkpoint blockade, while isotype control (ISO) treated tumours show identical growth kinetics (*p<0.05 by Mann-Whitney Test).

[0124] Referring to FIG. **11**, TET2-mutant clonal hematopoiesis is associated with lower risk of metastatic disease in patients with non-hematological cancers. FIG. **11**A shows 16,744 patients with metastatic or non-metastatic solid tumours from Nguyen et al. Cell, 2022 were tested for clonal hematopoiesis in Bolton et al. Nature Genetics, 2020 using the MSK-IMPACT targeted sequencing panel. CH mutations with variant allele frequency of at least 0.02 were detected in 19.5% of patients. FIG. **11**B shows the 5 most commonly detected clonal hematopoiesis mutations from FIG. **11**A are shown. FIG. **11**C shows exposure to TET2-mutant CH is associated with lower risk of having metastatic cancer in patients from FIG. **11**A as assessed by multivariate logistic regression adjusted for age, sex, smoking status, and chemotherapy treatment. FIG. **10**D shows exposure to TET2-CH is associated with significantly lower risk of having metastases in patients from FIG. **11**A with Non-Small Cell Lung and Breast Cancer, with a trend towards lower risk of metastases in colorectal and bladder cancer, as assessed by multivariate logistic regression adjusted for age, sex, smoking status, and chemotherapy treatment. Patients in FIG. **11**A with TET2-mutant CH have significantly few metastases detected on clinical imaging (FIG. **11**E) and have fewer overall sites/organs involved with metastatic disease (FIG. **11**F), p values from Wilcoxon Rank Sum Test.

Example 5

[0125] Applicant further sought to investigate the prevalence of CH among solid organ transplant (SOT) recipients (heart, lung, liver and kidney), study the association with specific CH-related genes and the impact on outcomes.

Methods and Materials

Study Population

[0126] We conducted a retrospective study of 1,500 patients who underwent SOT at the Toronto General Hospital between 2005 and 2021. The inclusion criteria were patients aged 18 years or older with available biospecimens and complete clinical evaluation. Patients with active malignancies were excluded, as it is a criterion for solid organ transplant candidacy.

Data Collection

[0127] The electronic health records of the SOT recipients were reviewed to collect demographic data, medical history, laboratory assessments, date of SOT, transplant-related treatment at the time of the procedure, and the immunosuppressive regimen at one year post-SOT. Baseline characteristics, including demographic data and comorbidities, were collected as close as possible to the biospecimens collection date due to their relationship with CH mutations.

Follow-Up and Outcomes

[0128] Patients were followed from the time of SOT procedure until the last visit at our institution or death. The following outcomes were evaluated: the first occurrence of acute cellular rejection, CMV infection, de novo post-transplant malignancy, CAV, and death.

Genetic Sequencing

[0129] Peripheral blood samples from patients who had provided consent during their visits to Toronto General Hospital. These samples were stored in the biobank of the Peter Munk Cardiac Centre. To construct the sequencing libraries, 100 ng of DNA was utilized, and single molecule Molecular Inversion Probes (smMIP) were employed. The smMIPs were utilized to capture 35 genes known to be recurrently mutated in myeloid neoplasms. Sequencing was performed using the Illumina Novaseq platform, and an in-house computational pipeline was used to reduce artifacts and false-positive mutation calls. Alleles were filtered based on a P-value cut-off of 0.05 and were manually inspected based on several criteria, including base-pair change, annotation in COSMIC, minor allele frequency, and number of reads supporting the alternative allele. The resulting variants were analyzed and manually inspected to avoid selecting false positives.

Statistical Analysis

[0130] The normality of all variables was assessed using the Shapiro-Wilk test, and both normal and non-normal continuous variables are reported as mean±standard deviation or median (interquartile range). Student's t-test or Mann-Whitney test were used to evaluate differences among groups depending on the normality of the data. Categorical variables were assessed using chi-square test or Fisher's exact test. All analyses were performed using SPSS, version 25.0 (SPSS Inc., NY, USA), with a statistical significance level of 0.05 and a two-sided p-value.

Results and Discussion

[0131] Out of the 1,500 patients enrolled, 782 have been sequenced as of the current date. Among these patients, 127 (16.2%) underwent heart transplant, 90 (11.5%) underwent lung transplant, 189 (24.2%) underwent kidney transplant, 374 (47.8%) underwent liver transplant, and 2 (0.3%) underwent lung-liver transplant. The average age of the entire cohort was 54.2±12.7 years, with a majority of male patients (52.9%). The age distribution varied significantly across organ groups ($p<0.0001$), with lung-liver transplant patients being the youngest (47±12.7), followed by heart (49.2±14.0), kidney (53.7±13.3), lung (54.4±15.1) and liver (56.1±10.8) transplant patients. Sex also differed among the organ groups ($p=0.05$), with all lung-liver transplant recipients being male, and a majority of heart (76.4%), kidney (76.2%), liver (66.5%), and lung (58.9%) transplant recipients being male. For a summary of the overall cohort characteristics, refer to Table 8.

[0132] CH was observed in 123 (15.7%) patients. CH prevalence was similar across the organ groups (FIG. **12**), except for kidney (8%) that was lower than heart (20%), lung (19%), and (liver 18%), $p=0.007$. Lung-liver showed a 50% of CH, but the low number of patients may explain this result.

[0133] We than analyzed the specific mutated genes among patients with CH. In the literature, DNMT3A is the most common mutated gene in the general population, followed by TET2. [13] In our cohort, DNMT3A was the most commonly mutated gene (n=45, 5.7%), followed by TET2 (n=40, 5.1%) and ASXL1 (n=20, 2.5%). Notably, DNMT3A was the most commonly mutated gene among heart transplant recipients (FIG. **15**) and among kidney recipients (FIG. **17**), while TET2 was the most common mutated gene among lung (FIG. **16**) and liver (FIG. **18**) recipients. These findings suggest that TET2 may play a role in lung and liver end-stage disease, but further clinical validation is required.

[0134] The overall mortality rate in our cohort was 18.3%. Mortality differed across the different SOT ($p<0.0001$), with the highest mortality observed in lung-liver recipients (50%), followed by lung (43.3%), heart (20.5%), liver (14.2%), and kidney (12.7%) recipients (FIG. **19**). We observed a trend in mortality according to the presence of CH (17.4% vs. 23.4%) (FIG. **20**). Among solid organ transplant recipients, those who received a heart transplant showed a higher mortality rate when developing CH (14% vs. 42%, $p=0.002$) with a trending shown for lung. CH did not affect the mortality of recipients of kidney or liver (FIG. **21**).

[0135] The study partial results shows that CH was observed in 15.7% of patients, with similar prevalence across most organ groups except for kidney, which had a lower prevalence. DNMT3A was the most commonly mutated gene among heart and kidney transplant recipients, while TET2 was the most common in lung and liver recipients. Heart transplant recipients had a higher mortality rate when developing CH.

[0136] Although preferred embodiments of the invention have been described herein, it will be understood by those skilled in the art that variations may be made thereto without departing from the spirit of the invention or the scope of the appended claims. All documents disclosed herein, including those in the following reference list, are incorporated by reference.

TABLE-US-00001 TABLE 1 CHARACTERISTICS OF THE PATIENTS AT BASELINE.sup.A Cardiogenic Shock Ambulatory HF P (N = 341) (N = 345) value Matched variables Age (years) 55 ± 15 57 ± 15 0.25 - median (range) 58 (19) 58 (19) Male sex 249 (73%) 247 (72%) 0.64 Heart failure aetiology Ischemic cardiomyopathy 107 (31%) 106 (31%) 0.85 Non-ischemic cardiomyopathy 221 (65%) 225 (65%) 0.91 Congenital disease 13 (4%) 14 (4%) 0.86 Ejection fraction (%) 26 ± 12 27 ± 10 0.09 Other baseline characteristics Body mass index (kg/m.sup.2).sup.b 26 ± 6 29 ± 6 <0.001 Hypertension 125 (37%) 109 (32%) 0.16 Dyslipidaemia 115 (34%) 122 (35%) 0.65 Diabetes 99 (29%) 78 (23%) 0.05 Prior/current smoker 101 (30%) 82 (24%) <0.001 Prior history of cancer 33 (10%) 41 (12%) 0.35 Prior coronary revascularization 69 (20%) 84 (24%) 0.19 Previous cerebrovascular 39 (11%) 33 (10%) 0.42 disease/transient ischemic attack Atrial Fibrillation/Flutter 122 (36%) 101 (29%) 0.06 Chronic Heart Failure 237 (70%) 345 (100%) <0.001 Implantable cardioverter-defibrillator 85 (25%) 106 (31%) 0.09 Cardiac resynchronization therapy 69 (20%) 70 (20%) 0.98 White blood count (×10.sup.9/L) 10.7 ± 6.6 7.3 ± 2.4 <0.001 Creatinine (μmol/L) 179 ± 128 110 ± 73 <0.001 Sodium (mmol/L) 135 ± 6 138 ± 3 <0.001 B-type natriuretic peptide (pg/mL) 1,428 (1730) 168 (337) <0.001 .sup.aPlus-minus are means ± SD. .sup.bThe body-mass index is the weight in kilograms divided by the square of the height in meters.

TABLE-US-00002 TABLE 2 Characteristics of Cardiogenic Shock Patients.sup.a No clonal Clonal All cardiogenic shock haematopoiesis haematopoiesis P (N = 341) (N = 256) (N = 85) value Age (year) 55 ± 15 54 ± 15 60 ± 14 0.002 Male sex 249 (73%) 188 (73%) 61 (72%) 0.76 Body mass index (kg/m.sup.2).sup.b 26 ± 6 26 ± 6 26 ± 6 0.50 Hypertension 125 (37%) 87 (34%) 38 (44%) 0.09 Dyslipidaemia 115 (34%) 78 (30%) 37 (44%) 0.03 Diabetes 99 (29%) 72 (28%) 27 (31%) 0.57 Prior/current smoker 101 (30%) 75 (29%) 25 (29%) 0.89 Prior history of cancer 33 (10%) 25 (10%) 9 (11%) 0.86 Prior coronary 69 (20%) 52 (20%) 17 (20%) 0.90 revascularization Previous cerebrovascular 39 (11%) 27 (11%) 12 (14%) 0.39 disease/transient ischemic attack Cardiogenic shock aetiology Acute decompensation of 225 (66%) 168 (66%) 57 (67%) 0.94 chronic heart failure New onset of heart 93 (27%) 72 (28%) 21 (25%) 0.27 failure Myocardial infarction 10 (3%) 6 (2%) 4 (5%) 0.87 Myocarditis 11 (3%) 8 (3%) 3 (4%) 0.58 SCAI classification.sup.c B 27 (8%) 21 (8%) 6 (7%) 0.73 C 27 (8%) 20 (8%) 7 (8%) 0.90 D 285 (83%) 213 (83%) 72 (85%) 0.74 E 2

(1%) 2 (1%) 0 0.41 Number of inotropes or 1.7 ± 1.0 1.6 ± 1.0 1.8 ± 1.0 0.24 vasopressors Pulmonary artery catheter 178 (52%) 134 (52%) 44 (52%) 0.92 Temporary mechanical circulatory support Intra-aortic balloon pump 26 (8%) 20 (8%) 6 (7%) 0.50 Impella device ® 8 (2%) 8 (3%) 0 0.09 Extra-corporeal life 18 (5%) 16 (6%) 3 (4%) 0.59 support Mechanical ventilation 63 (18%) 45 (18%) 18 (21%) 0.45 Renal replacement therapy 35 (10%) 24 (9%) 11 (13%) 0.34 White blood count (×10.sup.9/L) 7.3 ± 2.4 11.1 ± 7.2 9.4 ± 4.3 0.01 Creatinine (□mol/L) 110 ± 73 176 ± 129 188 ± 124 0.44 Sodium (mmol/L) 138 ± 3 135 ± 6 133 ± 5 0.02 Peak lactate (mmol/L) 3.4 ± 3.2 3.4 ± 3.1 3.4 ± 3.1 0.86 B-type natriuretic peptide 1428 (1730) 1446 (1712) 1350 (1737) 0.42 (pg/mL) .sup.aPlus-minus are mean ± SD. .sup.bThe body-mass index is the weight in kilograms divided by the square of the height in metres. .sup.cPatients were classified according to the Society for Cardiovascular Angiography & Interventions. Briefly, Class B are patients at beginning of shock; Class C is classic cardiogenic shock; Class D is deteriorating and failure to respond to initial interventions; and Class E is extreme shock on patients supported by multiple interventions who may be experiencing cardiac arrest and/or extracorporeal life support.

TABLE-US-00003 TABLE 3 Clinical characteristics of OHT recipients and according to CH status. All No CH CH Characteristics (N = 127) (N = 101) (N = 26) P value Age - year 49 ± 14 48 ± 14 54 ± 13 0.04 Median (range) 53 (23) 52 (24) 58 (21) 0.03 Male sex - no. (%) 97 (77%) 79 (78%) 18 (69%) 0.33 Body mass index - kg/m.sup.2† 25 ± 6 25 ± 6 25 ± 5 0.97 Hypertension - no. (%) 33 (26%) 25 (25%) 8 (31%) 0.53 Dyslipidemia - no. (%) 33 (26%) 24 (24%) 9 (35%) 0.26 Diabetes - no. (%) 28 (22%) 23 (23%) 5 (19%) 0.69 Prior smoker - no. (%) 34 (27%) 25 (25%) 9 (35%) 0.31 Prior neoplasia- no. (%) 8 (6%) 8 (8%) None 0.20 Heart failure etiology- no. (%) 0.41 Ischemic cardiomyopathy 28 (22%) 20 (20%) 8 (31%) Non-ischemic 90 (71%) 73 (72%) 17 (65%) cardiomyopathy- no. (%) Congenital disease- no. 9 (7%) 8 (8%) 1 (4%) (%) Previous VAD - no. (%) 44 (35%) 37 (37%) 7 (27%) 0.35 White blood count (×10.sup.9/L) 8.8 ± 4.4 7.9 ± 4.5 6.9 ± 3.5 0.11 Sodium (mmol/L) 134 ± 5 136 ± 5 135 ± 6 0.53 Creatinine (mmol/L) 117 (92) 122 (86) 116 (127) 0.65 Induction therapy Thymoglobulin 123 (97%) 97 (96%) 26 (100%) 0.30 Basiliximab 4 (3%) 4 (4%) None Primary graft dysfunction 19 (15%) 17 (17%) 2 (8%) 0.24 In-hospital death post OHT 12 (9%) 10 (10%) 2 (8%) 0.73 MCS post-OHT 18 (14%) 17 (17%) 1 (4%) 0.09 Follow-up from OHT, years 3.2 ± 2.6 2.9 ± 2.1 4.3 ± 3.9 0.01 Donor CMV+ 57 (46%) 45 (46%) 12 (46%) 0.98 Recipient CMV+ 80 (65%) 63 (64%) 17 (65%) 0.91 Donor EBV+ 97 (14%) 81 (80%) 16 (62%) 0.02 Recipient EBV+ 115 (93%) 89 (91%) 26 (100%) 0.10 Immunosuppressive therapy at discharge post-OHT Tacrolimus 119 (94%) 97 (96%) 22 (85%) 0.03 Sodium mycophenolate 123 (97%) 100 (99%) 23 (89%) 0.006 Steroids 127 (100%) 101 (100%) 26 (100%) — MTOR inhibitor 1 (1%) None 1 (4%) 0.04 Cyclosporine 6 (5%) 3 (3%) 3 (12%) 0.06 Azathioprine 1 (1%) None 1 (4%) 0.04 Immunosuppressive therapy at 1 year after OHT Tacrolimus 80 (86%) 64 (87%) 16 (84%) 0.79 Sodium mycophenolate 71 (77%) 58 (80%) 13 (68%) 0.30 Steroids 87 (94%) 68 (82%) 19 (100%) 0.19 MTOR inhibitor 17 (19%) 11 (15%) 6 (32%) 0.09 Cyclosporine 8 (9%) 5 (7%) 3 (16%) 0.21 Azathioprine 2 (2%) 1 (1%) 1 (5%) 0.30 CH, clonal hematopoiesis; CMV, cytomegalovirus; EBV, Epstein-barr virus; HF, heart failure MCS, mechanical circulatory support; OHT, orthotopic heart transplant; VAD, ventricular assist device; VAF, variant allele frequency;

TABLE-US-00004 TABLE 4 Clinical outcomes in patients with OHT according to CH mutations All No CH CH P- (N = 127) (N = 101) (N = 26) value CMV infection 59 (46%) 48 (47.5%) 11 (42.3%) 0.63 Acute cellular rejection 69 (54%) 51 (53%) 18 (69%) 0.14 2/3R Post-transplant 11 (9%) 9 (9%) 2 (8%) 0.84 malignancy CAV grade 2 or 3 4 (3%) None 4 (18%) <0.001 Mortality 26 (20%) 15 (15%) 11 (42%) 0.008 CAV, cardiac allograft vasculopathy; CH, clonal hematopoiesis; CMV, cytomegalovirus

TABLE-US-00005 TABLE 5 List of clonal hematopoiesis mutations detected among orthotopic heart transplant recipients. Start End Variant Sample ID Gene Chromosome position position Variant type type text missing or illegible when filed CHCVD_0004 CEBPA chr19 33792312 33792312 Missense_Variant SNV text missing or illegible when filed CHCVD_0006A ASXL1 chr20 31023894 31023894 Missense_Variant SNV text missing or illegible when filed CHCVD_0010B DNMT3A chr2 25463562 25463562 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0010B DNMT3A chr2 25467086 25467086 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0010B FLT3 chr13 28608064 28608064 Missense_Variant SNV text missing or illegible when filed CHCVD_0011 DNMT3A chr2 25463187 25463187 Missense_Variant SNV text missing or illegible when filed CHCVD_0014 ASXL1 chr20 31024221 31024221 Missense_Variant SNV text missing or illegible when filed CHCVD_0017 ASXL1 chr20 31022344 31022344 Missense_Variant SNV text missing or illegible when filed CHCVD_0017 BCOR chrX 39933074 39933074 Missense_Variant SNV text missing or illegible when filed HCVD_0017 DNMT3A chr2 25470612 25470612 Missense_Variant SNV text missing or illegible when filed CVD_0017 SF3B1 chr2 198266552 198266552 Missense_Variant SNV text missing or illegible when filed HCVD_0017 TP53 chr17 7577127 7577127 Stop_Gained SNV text missing or illegible when filed HCVD_0029 DNMT3A chr2 25469086 25469086 Missense_Variant SNV text missing or illegible when filed CHCVD_0038 DNMT3A chr2 25468174 25468174 Missense_Variant SNV text missing or illegible when filed CHCVD_0038 TP53 chr17 7578371 7578371 Missense_Variant SNV ARCHCVD_0038 TP53 chr17 7578380 7578380 Missense_Variant SNV ARCHCVD_0041 TP53 chr17 7578380 7578380 Missense_Variant SNV ARCHCVD_0043 IDH2 chr15 90631946 90631946 Missense_Variant SNV ARCHCVD_0046 DNMT3A chr2 25470590 25470590 Missense_Variant SNV ARCHCVD_0055 TET2 chr4 106158134 106158134 Missense_Variant SNV ARCHCVD_0060 ASXL1 chr20 31023667 31023667 Missense_Variant SNV ARCHCVD_0060 TET2 chr4 106158560 106158560 Missense_Variant SNV ARCHCVD_0096 TET2 chr4 106157326 106157326 Stop_Gained SNV ARCHCVD_0100 DNMT3A chr2 25463568 25463568 Missense_Variant SNV ARCHCVD_0100 PTPN11 chr12 112910785 112910785 Missense_Variant SNV ARCHCVD_0114 DNMT3A chr2 25467491 25467491 Missense_Variant SNV text missing or illegible when filed CHCVD_0117 DNMT3A chr2 25467124 25467124 Frame_Shift_Ins indel text missing or illegible when filed CHCVD_0117 PPM1D chr17 58740549 58740549 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0117 PPM1D chr17 58740604 58740607 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0117 PPM1D chr17 58740714 58740714 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0117 PPM1D chr17 58740732 58740732 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0117 TP53 chr17 7577526 7577526 Missense_Variant SNV text missing or illegible when filed CHCVD_0128 DNMT3A chr2 25469633 25469633 Missense_Variant SNV text missing or illegible when filed CHCVD_0128 TP53 chr17 7577556 7577556 Missense_Variant SNV text missing or illegible when filed CHCVD_0147 ASXL1 chr20 31023190 31023190 Missense_Variant SNV text missing or illegible when filed CHCVD_0149 DNMT3A chr2 25463196 25463197 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0165 TP53 chr17 7577120 7577120 Missense_Variant SNV text missing or illegible when filed CHCVD_0166 DNMT3A chr2 25463236 25463238 Frame_Shift_Del indel text missing or illegible when filed HCVD_0166 DNMT3A chr2 25463586 25463586 Missense_Variant SNV text missing or illegible when filed HCVD_0166 DNMT3A chr2 25464455 25464455 Missense_Variant SNV text missing or illegible when filed HCVD_0170 DNMT3A chr2 25463583 25463583 Missense_Variant SNV text missing or illegible when filed HCVD_0200 PHF6 chrX 133549136 133549136 Stop_Gained SNV text missing or illegible when filed CHCVD_0210 SMC1A chrX 53431967 53431967 Stop_Gained SNV text missing or illegible when filed CHCVD_0227 DNMT3A chr2 25462078 25462078 Missense_Variant SNV ARCHCVD_0227 PPM1D chr17 58740522 58740522 Frame_Shift_Del indel ARCHCVD_0241 RUNX1 chr21 36252975 36252975 Missense_Variant SNV ARCHCVD_0296 DNMT3A chr2 25458637 25458637 Stop_Gained SNV ARCHCVD_0331 DNMT3A chr2 25470583 25470583 Stop_Gained SNV ARCHCVD_0398 ASXL1 chr20 31022341 31022341 Missense_Variant SNV ARCHCVD_0456 GATA2 chr3 128200154 128200154 Missense_Variant SNV ARCHCVD_0492 TET2 chr4 106157803 106157810 Frame_Shift_Del indel ARCHCVD_0563 BCOR chrX 39933121 39933121 Missense_Variant SNV ARCHCVD_0563 EZH2 chr7 148506185 148506185 Missense_Variant SNV ARCHCVD_0568 EZH2 chr7 148504787 148504787 Missense_Variant SNV ARCHCVD_0568 STAG2 chrX 123220456 123220456 Missense_Variant SNV text missing or illegible when filed CHCVD_0585 TP53 chr17 7578278 7578278 Missense_Variant SNV text missing or illegible when filed CHCVD_0603 JAK2 chr9 5073739 5073739 Missense_Variant SNV

text missing or illegible when filed CHCVD_0614 TET2 chr4 106197039 106197039 Missense_Variant SNV text missing or illegible when filed CHCVD_0629 CEBPA chr19 33792987 33792987 Missense_Variant SNV text missing or illegible when filed CHCVD_0636 DNMT3A chr2 25457243 25457243 Missense_Variant SNV text missing or illegible when filed CHCVD_0636 DNMT3A chr2 25469096 25469096 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0636 DNMT3A chr2 25469162 25469162 Stop_Gained SNV text missing or illegible when filed CHCVD_0644 TET2 chr4 106155429 106155429 Missense_Variant SNV text missing or illegible when filed CHCVD_0657 BCOR chrX 39933039 39933039 Frame_Shift_Del indel text missing or illegible when filed CHCVD_0673 PPM1D chr17 58740698 58740698 Stop_Gained SNV text missing or illegible when filed CHCVD_0680 ASXL1 chr20 31021109 31021109 Missense_Variant SNV Ref. Alt. Protein Alt. Ref. Sample ID Allele Allele change reads reads VAF text missing or illegible when filed CHCVD_0004 T A p.Thr337Ser 442 656 0.67378049 text missing or illegible when filed CHCVD_0006A G A p.Asp1127Asn 2559 13221 0.19355571 text missing or illegible when filed CHCVD_0010B C − p.Gly707fs 791 32884 0.02405425 text missing or illegible when filed CHCVD_0010B G − p.Arg597fs 277 92757 0.0029863 text missing or illegible when filed CHCVD_0010B T A p.Lys634Asn 19623 42835 0.45810669 text missing or illegible when filed CHCVD_0011 A G p.Ile769Thr 496 16037 0.03092848 text missing or illegible when filed CHCVD_0014 T G p.Ser1236Ala 6179 37380 0.1653023 text missing or illegible when filed CHCVD_0017 G A p.Gly610Asp 1265 7311 0.17302695 text missing or illegible when filed CHCVD_0017 A G p.Trp509Arg 745 46356 0.01607127 text missing or illegible when filed HCVD_0017 G A p.Arg288Trp 1350 4998 0.27010804 text missing or illegible when filed CVD_0017 C T p.Ala762Thr 734 24252 0.03026555 text missing or illegible when filed HCVD_0017 C A p.Glu271* 619 6642 0.09319482 text missing or illegible when filed HCVD_0029 G A p.Arg458Trp 416 4097 0.10153771 text missing or illegible when filed CHCVD_0038 T C p.Asn501Ser 9671 29430 0.32861026 text missing or illegible when filed CHCVD_0038 C G p.Gly187Arg 133 17741 0.00749676 ARCHCVD_0038 C G p.Asp184His 133 17740 0.00749718 ARCHCVD_0041 C G p.Asp184His 142 20782 0.00683284 ARCHCVD_0043 T C p.Asn136Ser 2076 5343 0.38854576 ARCHCVD_0046 A T p.Leu295Gln 570 8500 0.06705882 ARCHCVD_0055 C T p.Pro1012Leu 3565 9098 0.39184436 ARCHCVD_0060 G A p.Arg1051His 841 9827 0.08558054 ARCHCVD_0060 A G p.Asn1154Ser 2104 7665 0.27449446 ARCHCVD_0096 C T p.Gln743* 200 28409 0.00704002 ARCHCVD_0100 A G p.Ile705Thr 375 12290 0.03051261 ARCHCVD_0100 G A p.Arg265Gln 238 21688 0.01097381 ARCHCVD_0114 C T p.Asp529Asn 170 10755 0.0158066 text missing or illegible when filed CHCVD_0117 T + p.Tyr584fs 1599 36285 0.0440678 text missing or illegible when filed CHCVD_0117 G − p.Ile486fs 77 24796 0.00310534 text missing or illegible when filed CHCVD_0117 AACA − p.Asn505fs 70 29465 0.0023757 text missing or illegible when filed CHCVD_0117 A − p.Glu540fs 362 22820 0.01586328 text missing or illegible when filed CHCVD_0117 T − p.Leu546fs 262 22819 0.01148166 text missing or illegible when filed CHCVD_0117 A T p.Leu252His 278 15061 0.01845827 text missing or illegible when filed CHCVD_0128 G A p.Arg379Cys 4474 62094 0.07205205 text missing or illegible when filed CHCVD_0128 C T p.Cys242Tyr 422 40218 0.01049281 text missing or illegible when filed CHCVD_0147 C A p.Ser892Tyr 228 36353 0.00627183 text missing or illegible when filed CHCVD_0149 TT − p.Lys766fs 1027 37205 0.02760382 text missing or illegible when filed CHCVD_0165 C G p.Arg273Pro 4705 12830 0.36671863 text missing or illegible when filed CHCVD_0166 A − p.Trp753fs 1226 55482 0.02209726 text missing or illegible when filed HCVD_0166 C T p.Gly699Asp 658 13363 0.04924044 text missing or illegible when filed HCVD_0166 G C p.Asp686Glu 145 12401 0.01169261 text missing or illegible when filed HCVD_0170 G A p.Pro700Leu 172 15467 0.01112045 text missing or illegible when filed HCVD_0200 C T p.Arg274* 895 62494 0.01432137 text missing or illegible when filed CHCVD_0210 G A p.Arg725* 697 13878 0.05022338 text missing or illegible when filed CHCVD_0227 G A p.Pro777Ser 547 19125 0.02860131 ARCHCVD_0227 A − p.Asn477fs 728 13283 0.0548069 ARCHCVD_0241 C T p.Leu129Leu 203 40261 0.0050421 ARCHCVD_0296 G A p.Gln846* 196 7986 0.02454295 ARCHCVD_0331 C T p.Trp297* 152 14952 0.01016586 ARCHCVD_0398 C T p.Thr609Ile 5571 12858 0.43327112 ARCHCVD_0456 C G p.Arg384Thr 127 47555 0.00267059 ARCHCVD_0492 AGAA − p.Asn903fs 240 70735 0.00339295 ACCA ARCHCVD_0563 C T p.Gly493Asp 58 29158 0.00198916 ARCHCVD_0563 C G p.Glu725Gln 59 24362 0.0024218 ARCHCVD_0568 G C p.Ala736Gly 134 25452 0.00526481 ARCHCVD_0568 G C p.Trp1038Leu 99 40520 0.00244324 text missing or illegible when filed CHCVD_0585 G C p.Pro191Ala 118 31392 0.00375892 text missing or illegible when filed CHCVD_0603 C A p.His606Gln 9294 25742 0.36104421 text missing or illegible when filed CHCVD_0614 C G p.Ser1791Cys 146 29756 0.00490657 text missing or illegible when filed CHCVD_0629 G T p.Pro112Thr 128 130 0.98461538 text missing or illegible when filed CHCVD_0636 G A p.Arg882Cys 6936 287680 0.02411012 text missing or illegible when filed CHCVD_0636 G − p.Lys456fs 659 100672 0.00654601 text missing or illegible when filed CHCVD_0636 G C p.Tyr432* 897 91092 0.00984719 text missing or illegible when filed CHCVD_0644 G T p.Lys110Asn 476 19776 0.02406958 text missing or illegible when filed CHCVD_0657 G − p.Asn520fs 461 41910 0.01099976 text missing or illegible when filed CHCVD_0673 A T p.Lys535* 3230 36839 0.08767882 text missing or illegible when filed CHCVD_0680 T A p.Ser370Thr 12555 20108 0.62437836 text missing or illegible when filed indicates data missing or illegible when filed

TABLE-US-00006 TABLE 6 Clinical phenotype and outcomes according to CH among HCM patients with sarcomeric mutations All-CH DNMT3A, TET2, ASXL1 No CH CH No CH CH (N = 169) (N = 37) p (N = 182) (N = 23) p Echocardiogram MLVWT, mean (SD), mm 17.3 (4.6) 17.6 (5.1) 0.765 17.4 (4.7) 17.5 (4.9) 0.874 LA diameter, mm 3.9 (1.2) 3.8 (1.1) 0.651 3.9 (1.2) 3.7 (1.4) 0.642 LAVi, ml/m.sup.2 38.5 (30.8) 41.3 (20.7) 0.599 39.5 (30.2) 35.6 (20.3) 0.547 LV EF, % 58.2 (15.3) 62.4 (6.2) 0.106 58.5 (14.8) 63.0 (7.3) 0.156 LVOT maximal gradient, mm Hg 17.2 (26.6) 22.5 (40.3) 0.316 17.6 (27.4) 22.6 (43.5) 0.442 SAM, No. (%) 76 (45.0) 21 (56.8) 0.193 84 (45.9) 13 (56.5) 0.336 Moderate-severe MR, No. (%) 7 (4.1) 1 (2.7) 0.681 8 (4.4) 0 0.306 Cardiac MRI LV mass, g 137.3 (52.9) 143.1 (61.4) 0.601 137.8 (52.9) 142.3 (65.5) 0.728 LV mass index, g/m.sup.2 72.1 (25.5) 74.7 (27.2) 0.622 72.5 (25.3) 73.1 (30.2) 0.920 MLVWT, mm 18.9 (6.4) 19.2 (5.6) 0.814 19.0 (6.4) 19.0 (5.8) 0.980 LV EF, % 60.8 (8.3) 62.1 (6.2) 0.390 61.0 (8.2) 61.1 (5.8) 0.979 LGE, No (%) 134 (79.3) 27 (73.0) 0.400 144 (78.7) 17 (73.9) 0.601 LGE >15%, No (%) 26 (17.7) 11 (33.3) 0.044 30 (18.8) 7 (35.0) 0.090 LV mass % of LGE.sup.1, % 12.2 (7.7-17.6) 15.6 (10.4-24.6) 0.068 12.2 (7.7-17.5) 21.2 (13.7-41.8) 0.014 Apical Aneurysm, No (%) 1 (0.6) 1 (2.7) 0.145 2 (1.1) 0 0.613 Syncope, No (%) 6 (3.6) 3 (8.1) 0.219 7 (3.8) 2 (8.7) 0.281 ABPR at exercise, No. (%) (85/15) 25 (29.8) 10 (62.5) 0.012 27 (30.7) 8 (66.7) 0.014 NVST, No. (%) (145/21) 52 (37.7) 11 (39.3) 0.873 56 (37.6) 7 (41.2) 0.772 Stroke, No. (%) 2 (1.2) 2 (5.4) 0.092 3 (1.6) 1 (4.3) 0.375 Appropriate ICD shock, No. (%) 2 (1.2) 0 0.506 2 (1.1) 0 0.614 Cardiac arrest, No. (%) 0 0 n/a 0 0 n/a Death or orthotopic heart transplant, No. (%) 2 (1.2) 3 (8.1) 0.013 2 (1.1) 3 (13.0) <0.0001 MACE, No. (%) 5 (3.0) 5 (13.5) 0.008 6 (3.4) 4 (17.4) .004 .sup.1Quantified LGE >5%. ABPR, abnormal blood pressure response; EF, ejection fraction; LA, left atrium diameter; LAVi, left atrium volume index; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; LV, left ventricle; LVOT, left ventricular outflow tract; MACE, major cardiovascular events; MLVWT, maximal left ventricular wall thickness; MR, mitral regurgitation; MRI, magnetic resonance imaging; NSVT, non-sustained ventricular tachycardia; SAM, systolic anterior motion;

TABLE-US-00007 TABLE 7 Overall characteristics of the HCM cohort and between those with or without CH. All No CH CH (N = 799) (N = 616) (N = 183) P Age, mean (SD), years 55.7 (14.6) 55.3 (14.5) 57.2 (14.8) 0.126 Age at diagnosis, mean (SD), years 47.8 (15.8) 47.3 (15.6) 49.6 (16.3) 0.089 Male sex, No. (%) 547 (68.5) 424 (68.8) 123 (67.2) 0.679 Body mass index.sup.1, mean (SD), kg/m.sup.2 29.0 (6.9) 29.0 (7.1) 29.2 (6.2) 0.647 Hypertension, No. (%) 315 (39.4) 233 (37.8) 82 (44.8) 0.093 Diabetes, No. (%) 104 (13.0) 78 (12.6) 26 (14.2) 0.863 Prior/current smoker, No. (%) 155 (19.3) 119 (19.3) 36 (19.6) 0.637 Coronary artery disease, No. (%) 73 (9.1) 61 (9.9) 12 (6.5) 0.166 Atrial fibrillation, No. (%) 143 (17.8) 107 (17.3) 36 (19.6) 0.493 Genetic testing, No. (%) 712 (89.1) 554 (89.9) 158 (86.3) 0.170 Pathogenic/Likely pathogenic variant, No. (%) 206 (25.8) 169 (30.5) 37 (23.4) 0.083 MYH7, No. (%) 53 (25.7) 43 (25.6) 10 (27.0) 0.664 MYBPC3, No. (%) 127 (61.6) 106 (63.1) 21 (56.8) Other, No. (%) 26 (12.6) 20 (11.8) 6 (16.2) Family history of HCM, No. (%) 251 (31.4) 194 (31.5) 57 (31.1) 0.087 Family history of SCD, No. (%) 37 (4.6) 26 (4.2) 1 (5%) 0.30 Implantable cardioverter defibrillator, No. (%) 111 (13.9) 89 (14.4) 22 (12.0) 0.405 Pacemaker, No. (%) 13 (1.6) 6 (1.0) 7 (3.8) 0.007 NYHA II-IV, No. (%) 235 (29.4) 182 (29.5) 53 (28.9) 0.803 Beta-blocker, No. (%) 421 (52.7) 321 (52.1) 100 (54.6) 0.547 Non-dihydropyridine calcium channel blocker, No. 116 (14.5) 77 (12.5) 39 (21.3) 0.003 (%) Disopyridine, No (%) 67 (8.4) 51 (8.3) 16 (8.7) 0.842 Diuretic, No (%) 81

(10.1) 59 (9.5) 22 (12.0) 0.303 Septal reduction therapy, No. (%) 76 (9.5) 53 (8.6) 23 (12.5) 0.130 Abbreviations: CH, clonal hematopoiesis; HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death .sup.1Body mass index calculated as weigh (kg)/height.sup.2(m)
TABLE-US-00008 TABLE 8 Clinical characteristics of OHT recipients and according to CH status. All No CH CH Characteristics (N = 782) (N = 659) (N = 123) P value Age - year 54.2 ± 12.7 54.1 ± 12.8 54.4 ± 12.3 0.795 Median (range) 57 (48-63) 58 (46-63) Male sex 52.9% 68% 67.3% 0.882 Organ Heart 127 (16.2%) 101 (15.3%) 26 (21.1%) 0.007 Lung 90 (11.5%) 73 (11.1%) 17 (13.8%) Kidney 189 (24.2%) 174 (26.4%) 15 (12.2%) Liver 374 (47.8%) 310 (47.0%) 64 (52%) Lung-Liver 2 (0.3%) 1 (0.2%) 1 (0.8%)
TABLE-US-00009 TABLE A SmMIP Probe List ext_ ext_ ext_ lig_ lig_ logistic_ probe_ probe_ probe_ _ SEQ probe probe_ >mip_key score chr start stop copy ext_probe_sequence ID stop copy 1: 43814899-43815068/26, 18/− 0.78875 1 43815043 43815068 1 TGGTCCACCGCCAGTCTCCTGCCTGG 1 43814916 1 1: 115256459-115256628/21, 23/+ 0.981109 1 115256459 115256479 1 GATGGCAAATACACAGAGGAA 2 115256628 1 1: 115258635-115258804/21, 23/− 0.951804 1 115258784 115258804 1 CAACAGGTTCTTGCTGGTGTG 3 115258657 1 2: 25457124-25457293/22, 22/+ 0.833844 2 25457124 25457145 2 TACCTCAGTTTGCCCCCATGTC 4 25457293 1 2: 25457152-25457321/20, 24/− 0.839643 2 25457302 25457321 2 TCACCCTGCCCTCTCTGCCT 5 25457175 1 2: 25458549-25458718/20, 24/− 0.96996 2 25458699 25458718 2 TCCTCTTTTCTCCTCTTCAT 6 25458572 1 2: 25459749-25459918/21, 23/− 0.860238 2 25459898 25459918 1 GTTATCCAGGTTTCTGTTGTT 7 25459771 1 2: 25461967-25462136/22, 22/− 0.90969 2 25462115 25462136 1 GCTGTTTCATGCTCCTCCTTGG 8 25461988 1 2: 25463123-25463292/20, 24/+ 0.881523 2 25463123 25463142 1 AGGTAGAAGCCATTAGTGAG 9 25463292 1 2: 25463185-25463354/20, 24/− 0.871458 2 25463335 25463354 2 GCCCCAGCTGATGGCTTTCT 10 25463208 1 2: 25463484-25463653/20, 24/+ 0.917457 2 25463484 25463503 1 GTGGAGGGGACAGGATGGTA 11 25463653 1 2: 25464510-25464629/20, 24/+ 0.808999 2 25464510 25464529 1 TCCTCACACACCTCCGAGGC 12 25464629 1 2: 25464407-25464566/24, 20/− 0.825581 2 25464543 25464566 1 GCTGAAGGACTTGGGCATTCAGGT 13 25464426 1 2: 25466743-25466912/20, 24/− 0.909729 2 25466893 25466912 1 GCTGGGTGGGAGCTTGGGAC 14 25466766 1 2: 25467012-25467163/20, 24/+ 0.81207 2 25467012 25467031 1 CCCAGCACTCACAAATTCCT 15 25467163 1 2: 25466991-25467110/22, 22/− 0.807386 2 25467089 25467110 1 AAGGGTACCTACGGGCTGCTGC 16 25467012 1 : 25467117-25467237/22, 22/− 0.81286 2 25467216 25467237 1 GTCTCCTCTGCTCACTGGGTCT 17 25467138 1 2: 25467383-25467552/23, 21/− 0.896693 2 25467530 25467552 1 GTGGTTTCTGACCCTTCCCGCTG 18 25467403 1 2: 25468100-25468249/20, 24/+ 0.927609 2 25468100 25468119 1 TCCTGGGTGGGTGTGCTCCT 19 25468249 1 2: 25468075-25468224/23, 21/− 0.855948 2 25468202 25468224 1 CATCCCCTCCCTCTGCTTTCCAG 20 25468095 1 2: 25468817-25468986/24, 20/+ 0.721162 2 25468817 25468840 1 CTTCCTAAGTGCCTCTGCTACTCT 21 25468986 1 2: 25468993-25469162/20, 24/+ 0.826636 2 25468993 25469012 2 TCCTGGTGCCACCCTCTCCA 22 25469162 1 2: 25469087-25469256/24, 20/+ 0.953003 2 25469087 25469110 1 GGGCTTTTTGGCTGGTGGAGGTGG 23 25469256 1 2: 25469510-25469676/20, 24/+ 0.700311 2 25469510 25469529 1 TAGGGCCAGAAGGCTGGAAG 24 25469676 1 2: 25469385-25469551/22, 22/− 0.787747 2 25469530 25469551 1 TGATTGAATGGGCCCTGGGGGG 25 25469406 1 2: 25469926-25470095/23, 21/+ 0.871049 2 25469926 25469948 1 GACCTCGTAGATGGCTTTGCGGT 26 25470095 1 2: 25469859-25470028/22, 22/− 0.898607 2 25470007 25470028 1 GGTGTGTGTTGAGAAGCTGATG 27 25469880 1 2: 25470436-25470599/22, 22/+ 0.833016 2 25470436 25470457 1 CTACTGCCAAACCCCACAACTT 28 25470599 1 2: 25470523-25470685/23, 21/− 0.911389 2 25470663 25470685 1 ATGGGGGGATCAGGGTGGCAGGG 29 25470543 1 2: 25470913-25471078/26, 18/+ 0.711861 2 25470913 25470938 1 TCTGGCTCGTCATCGCCTGCTTTGGT 30 25471078 1 2: 198266544-198266713/20, 24/+ 0.804959 2 198266544 198266563 1 GTAGTTGGCATATTCTGCAT 31 198266713 1 2: 198266417-198266586/23, 21/− 0.890112 2 198266564 198266586 1 TGGGTATCTTATTCCTCTTATGG 32 198266437 1 2: 198266730-198266899/20, 24/− 0.956695 2 198266880 198266899 1 TAGGTAATGTTGGGGCATAG 33 198266753 1 2: 198267419-198267588/22, 22/+ 0.934101 2 198267419 198267440 1 GGGCAATAAAGAAGGAATGCCC 34 198267588 1 2: 198267315-198267484/21, 23/− 0.947509 2 198267464 198267484 1 CGTAACACAACAGCTAGAGCT 35 198267337 1 2: 209113063-209113232/24, 20/+ 0.895571 2 209113063 209113086 1 CAAAATCACATTATTGCCAACATG 36 209113232 1 3: 128200021-128200186/21, 23/− 0.950888 3 128200166 128200186 1 TCTGAAAACTGGTGGTTGCCT 37 128200043 1 3: 128200661-128200783/24, 20/+ 0.899098 3 128200661 128200684 1 CATTGTGCAGCTTGTAGTAGAGGC 38 128200783 1 3: 128202705-128202871/20, 24/− 0.848532 3 128202852 128202871 2 TGTCTCTCCCTGTTCCCCTG 39 128202728 1 4: 55589697-55589866/23, 21/+ 0.941587 4 55589697 55589719 1 GTTGCTGAGGTTTTCCAGCACTC 40 55589866 1 4: 55599221-55599390/20, 24/− 0.944773 4 55599371 55599390 1 GCAGGACTGTCAAGCAGAGA 41 55599244 1 4: 106155115-106155234/21, 23/+ 0.928618 4 106155115 106155135 1 ACCAACCATGTTGAGGGCAAC 42 106155234 1 4: 106155243-106155367/20, 24/+ 0.976973 4 106155243 106155262 1 AAATGGAGACACCAAGTGGC 43 106155367 1 4: 106155161-106155308/20, 24/− 0.963051 4 106155289 106155308 1 TGGCTTCCCTTCATACAGGG 44 106155184 1 4: 106155408-106155577/22, 22/+ 0.954287 4 106155408 106155429 1 CTCTGGGCTCCTTCAGATCAAG 45 106155577 1 4: 106155297-106155466/23, 21/− 0.967386 4 106155444 106155466 1 GTCTTTCTCCATTAGCCTTTTGG 46 106155317 1 4: 106155628-106155777/18, 26/+ 0.954069 4 106155628 106155645 1 CCAGAGCTTCAGATTCTG 47 106155777 1 4: 106155497-106155666/20, 24/− 0.964361 4 106155647 106155666 1 ACTTTTCCCCTCCTGCTCAT 48 106155520 1 4: 106155827-106155996/20, 24/+ 0.947632 4 106155827 106155846 2 AGAAAACCACATCTCACATA 49 106155996 1 4: 106155708-106155877/20, 24/− 0.944218 4 106155858 106155877 1 ACTCATTAGTAGCCTGACTG 50 106155731 1 4: 106156035-106156184/25, 19/+ 0.927737 4 106156035 106156059 1 TACCTGTTCCTTTCAGAAACCAGAA 51 106156184 2 4: 106155947-106156116/22, 22/− 0.98082 4 106156095 106156116 1 GTTATTTTCTGCAGGAGATGGG 52 106155968 1 4: 106156251-106156420/22, 22/+ 0.902481 4 106156251 106156272 1 CTCAGTGTTCACTAAGGATTCC 53 106156420 1 4: 106156143-106156312/25, 19/− 0.903718 4 106156288 106156312 1 GCAATTGTGATGGTGGTGGTGGTGT 54 106156161 1 4: 106156470-106156639/22, 22/+ 0.946747 4 106156470 106156491 1 ACCACCTTCCCAGAGTCCTAAT 55 106156639 1 4: 106156348-106156517/20, 24/− 0.958324 4 106156498 106156517 1 GAAGGGCTGCATACATGTGT 56 106156371 1 4: 106156694-106156863/20, 24/+ 0.907492 4 106156694 106156713 1 TGATGAGAAACAAAGAGCAA 57 106156863 1 : 106156579-106156748/20, 24/− 0.965115 4 106156729 106156748 1 CGTGTTTGCTCCTTGTCTCG 58 106156602 1 4: 106156916-106157085/23, 21/+ 0.951204 4 106156916 106156938 1 CTGGAAATTCCAACATGCCTGGG 59 106157085 1 4: 106156809-106156978/21, 23/− 0.972677 4 106156958 106156978 1 GCTGTGTTGTTTTCTGGGTGT 60 106156831 1 4: 106157149-106157318/21, 23/+ 0.947906 4 106157149 106157169 1 CAACAAAGAGCAGATTCCCAA 61 106157318 1 4: 106157036-106157205/20, 24/− 0.962137 4 106157186 106157205 1 GTGCTGTTTCAACACTGGGG 62 106157059 1 4: 106157399-106157568/18, 26/+ 0.930675 4 106157399 106157416 1 ATGATCAGCAAAGAGAAG 63 106157568 1 4: 106157269-106157438/18, 26/− 0.968587 4 106157421 106157438 1 TTAGTCTGGCCAAAGAAT 64 106157294 1 4: 106157597-106157766/21, 23/+ 0.921979 4 106157597 106157617 1 CTTGTTCAAACAATACACACC 65 106157766 1 4: 106157482-106157651/20, 24/− 0.953483 4 106157632 106157651 1 GGATGTGTAGTCTGTTCTTT 66 106157505 1 4: 106157839-106158008/21, 23/+ 0.951954 4 106157839 106157859 1 CTTGCTCAGCAAAGGTACTTG 67 106158008 1 4: 106157718-106157892/22, 22/− 0.959552 4 106157871 106157892 1

AGGCACAGGAAAAACATTTGCA 68 106157739 1 4: 106158007-106158176/18, 26/+ 0.886265 4 106158007 106158024 1
ACTGAGTCTTGCCATAGT 69 106158176 1 4: 106157931-106158100/23, 21/− 0.983485 4 106158078 106158100 1
TGTTTTCTGGTGGTGCTGTGTGC 70 106157951 1 4: 106158223-106158378/21, 23/+ 0.956903 4 106158223 106158243 1
GACCATAAGGCTCTTACTCTC 71 106158378 1 4: 106158127-106158296/22, 22/− 0.950701 4 106158275 106158296 1
GTCAAAACTGTGACTGGCCCTG 72 106158148 1 4: 106158415-106158589/20, 24/+ 0.882262 4 106158415 106158434 1
GAGTCACCTTCCAAATTACT 73 106158589 1 4: 106158315-106158478/20, 24/− 0.979383 4 106158459 106158478 1
GAGTCTTGACAGGTGTATCC 74 106158338 1 4: 106162450-106162619/20, 24/+ 0.88601 4 106162450 106162469 1
TAGTATAATTGAGGTCTAAA 75 106162619 1 4: 106163956-106164125/22, 22/+ 0.980266 4 106163956 106163977 4
TTGTATGTGTGTGTGTTTCTGT 76 106164125 1 4: 106164761-106164930/21, 23/+ 0.926757 4 106164761 106164781 1
TGTGTTTGGTGCGGGAGCGAG 77 106164930 1 4: 106164674-106164843/20, 24/− 0.873669 4 106164824 106164843 1
CGGGATTCCTTCCCACACCA 78 106164697 1 4: 106164852-106165021/21, 23/− 0.899251 4 106165001 106165021 1
CACGCTGAACTCTCTTCCTTT 79 106164874 1 4: 106180720-106180889/24, 20/+ 0.846203 4 106180720 106180743 1
TGCACAGCCTATATAATGCTATCC 80 106180889 1 4: 106180786-106180955/20, 24/− 0.931831 4 106180936 106180955 1
AGCGATTATACATCAGGAAG 81 106180809 1 4: 106182895-106183049/19, 25/+ 0.697024 4 106182895 106182913 1
AGAATTATTCACTTTATAC 82 106183049 1 4: 106190771-106190940/20, 24/+ 0.930131 4 106190771 106190790 1
AATATGAACACAGAGCACCA 83 106190940 1 4: 106190690-106190859/21, 23/− 0.810744 4 106190839 106190859 1
AGCACAGAAGTCCAAACATGC 84 106190712 1 4: 106193771-106193940/22, 22/+ 0.917879 4 106193771 106193792 1
GGATGAGCAGCTTCACGTTCTG 85 106193940 1 4: 106193686-106193855/20, 24/− 0.956667 4 106193836 106193855 3
TTTTTTCTCCTCCTGAGCTT 86 106193709 1 4: 106193946-106194115/20, 24/+ 0.908902 4 106193946 106193965 1
GAAGCCAAGAAAGCTGCAGC 87 106194115 1 4: 106193871-106194040/22, 22/− 0.986116 4 106194019 106194040 1
TGTTTTGTACGTGATGGGGCTG 88 106193892 1 4: 106196177-106196316/24, 20/+ 0.915559 4 106196177 106196200 1
TTTCTGTTCTCTCTTACCCTGTCC 89 106196316 1 4: 106196361-106196530/21, 23/+ 0.913618 4 106196361 106196381 1
CCACCAATCCATACATGAGAC 90 106196530 1 4: 106196262-106196431/20, 24/− 0.95844 4 106196412 106196431 1
GATATCTGAAGTGTGTGAAG 91 106196285 1 4: 106196561-106196730/20, 24/+ 0.846784 4 106196561 106196580 1
CAATGCAATGGAAACCTATC 92 106196730 1 4: 106196462-106196631/21, 23/− 0.977129 4 106196611 106196631 1
GGCTGAGACTGGGGAGAATAG 93 106196484 1 4: 106196781-106196950/20, 24/+ 0.893805 4 106196781 106196800 1
GTTTCAGCAGTTGTACCATT 94 106196950 1 4: 106196677-106196846/21, 23/− 0.987067 4 106196826 106196846 1
GAGTGGGATAAGGAGGCAATT 95 106196699 1 4: 106196887-106197056/21, 23/+ 0.931081 4 106196887 106196907 1
ACCACCCAATCTGAGCAATCC 96 106197056 1 4: 106196980-106197149/20, 24/+ 0.893803 4 106196980 106196999 1
CATGTTCAACAGCTCTCTTC 97 106197149 1 4: 106197193-106197362/24, 20/+ 0.908112 4 106197193 106197216 1
CAACGATGAGGTCTGGTCAGACAG 98 106197362 1 : 106197071-106197240/18, 26/− 0.907301 4 106197223 106197240 1
TCAGGATCCAGAAAGCTC 99 106197096 1 4: 106197400-106197569/20, 24/+ 0.975927 4 106197400 106197419 1
ACATGGCTTGGCTCTTTGGG 100 106197569 1 4: 106197289-106197458/24, 20/− 0.959564 4 106197435 106197458 1
CTTCCTCTTTCTCACGGGCTTTTT 101 106197308 1 4: 106197523-106197692/20, 24/− 0.923275 4 106197673 106197692 1
ACAAAAGGGGGTGATATCAT 102 106197546 1 5: 170837475-170837644/22, 22/− 0.943775 5 170837623 170837644 17
GGACAGCCAGATATCAACTGTT 103 170837496 1 7: 140453073-140453242/20, 24/+ 0.916227 7 140453073 140453092 1
ACCATCCACAAAATGGATCC 104 140453242 1 7: 148504716-148504885/20, 24/+ 0.944239 7 148504716 148504735 1
AGGGGGGAGGAGGTAGCAGA 105 148504885 1 7: 148506108-148506277/22, 22/− 0.949232 7 148506256 148506277 1
GCTCACTGACACCAGTGTGTCT 106 148506129 1 7: 148506397-148506516/24, 20/+ 0.969517 7 148506397 148506420 1
CCTACCTTTTGCATAGCAGTTTGG 107 148506516 1 7: 148507392-148507561/23, 21/− 0.965315 7 148507539 148507561 1
GTCAGGCTTGATCACCTTTATCC 108 148507412 1 7: 148508689-148508858/20, 24/− 0.923191 7 148508839 148508858 2
TTTTCACCCTCCTTTTTTGA 109 148508712 1 7: 148511097-148511266/23, 21/+ 0.841123 7 148511097 148511119 1
TTACTGTCCCAATGGTCAGCGGC 110 148511266 1 7: 148510995-148511164/20, 24/− 0.869647 7 148511145 148511164 1
CTGGCTGTCCGAGAGTGTGA 111 148511018 1 7: 148511955-148512124/20, 24/− 0.889269 7 148512105 148512124 1
CTCTAACCATGTTTACAACT 112 148511978 1 7: 148512532-148512701/22, 22/− 0.917806 7 148512680 148512701 1
GCTCTCTGTTGGATTTGTAGCT 113 148512553 1 7: 148516641-148516810/20, 24/− 0.763635 7 148516791 148516810 1
TATTAGATTCTTTGTTTCAT 114 148516664 1 7: 148523639-148523808/20, 24/+ 0.843345 7 148523639 148523658 1
CAGATTTAGCATTTGGTCCA 115 148523808 1 7: 148523519-148523688/20, 24/− 0.900594 7 148523669 148523688 1
ACTTCCTCCTGAATGTACCC 116 148523542 1 7: 148526795-148526954/21, 23/− 0.896884 7 148526934 148526954 1
TTTTTTTCTTTTAGGTGGAAG 117 148526817 1 8: 117864762-117864931/20, 24/− 0.909931 8 117864912 117864931 1
TTACACCGCTTGTACCAGAA 118 117864785 1 8: 117864807-117864976/23, 21/− 0.857987 8 117864954 117864976 17
GAAATTTTTCTTTTTTTTTTTTT 119 117864827 1 8: 117866456-117866633/21, 23/+ 0.779265 8 117866456 117866476 1
GAAGTAAAAATTCTGCAAACT 120 117866633 1 8: 117866573-117866742/24, 20/− 0.877384 8 117866719 117866742 1
CAGGAAAATGATCTTATTTTTTAT 121 117866592 1 8: 117868372-117868549/24, 20/− 0.808009 8 117868526 117868549 31
TTTTTTTTTTTTTTTTTTTACAGTG 122 117868391 1 9: 5069922-5070091/20, 24/− 0.88135 9 5070072 5070091 1
AAGGACAAAAAAGACAGTAA 123 5069945 1 9: 5073712-5073881/20, 24/+ 0.965559 9 5073712 5073731 1
AGCAAGTATGATGAGCAAGC 124 5073881 1 10: 112350147-112350316/21, 23/+ 0.883234 10 112350147 112350167 1
TTTTCATTTCTGACAACTTAC 125 112350316 1 10: 112350217-112350386/21, 23/− 0.943637 10 112350366 112350386 1
TAAGCTATTCTTATTCCCTCT 126 112350239 1 10: 112350706-112350875/22, 22/+ 0.922256 10 112350706 112350727 1
CCTGAGTACCAATAAAGATTTG 127 112350875 1 10: 112350813-112350982/20, 24/− 0.959726 10 112350963 112350982 1
GTGTATAGTGCCTGGGCACT 128 112350836 1 10: 112352791-112352960/22, 22/+ 0.980092 10 112352791 112352812 1
CTGTGTTGTGATCTCTCTGTTG 129 112352960 1 10: 112352887-112353056/21, 23/− 0.892519 10 112353036 112353056 1
CGCCCAGCCAGATTATATGTT 130 112352909 1 10: 112356126-112356295/20, 24/+ 0.893075 10 112356126 112356145 1
ACAGACCTATTACATATGTT 131 112356295 1 11: 32413487-32413656/20, 24/+ 0.897861 11 32413487 32413506 1
GAAAAATAAATGTGAAGAAA 132 32413656 1 11: 32414159-32414328/20, 24/− 0.930567 11 32414309 32414328 1
TCAAATAGAATATGTGTCTT 133 32414182 1 11: 32417866-32418035/20, 24/+ 0.938676 11 32417866 32417885 1
GGTAAGCACACATGAAGGGG 134 32418035 1 11: 32417752-32417921/20, 24/− 0.91638 11 32417902 32417921 1
TCTTGTACGGTCGGCATCTG 135 32417775 1 11: 32421472-32421637/20, 24/+ 0.93191 11 32421472 32421491 1
TGGGGCCTGTCTGTGTGCTC 136 32421637 1 11: 119148811-119148980/23, 21/+ 0.851218 11 119148811 119148833 1
CTGTTAACATTTATAATTGCAGT 137 119148980 1 11: 119148895-119149064/20, 24/− 0.92696 11 119149045 119149064 1
TACCGAATTTTCCAAGGTTA 138 119148918 1 11: 119149175-119149344/20, 24/+ 0.895932 11 119149175 119149194 2
AGTATTTTCAGATGCATCTG 139 119149344 1 2: 25378504-25378673/20, 24/− 0.911124 12 25378654 25378673 1
GTACCTATGGTCCTAGTAGG 140 25378527 1 12: 25380216-25380385/20, 24/− 0.967652 12 25380366 25380385 1
TGCACTGTAATAATCCAGAC 141 25380239 1 12: 25398165-25398334/20, 24/− 0.933725 12 25398315 25398334 1
ATAAGGCCTGCTGAAAATGA 142 25398188 1 12: 112888093-112888262/23, 21/− 0.916866 12 112888240 112888262 3

CCATTCTTCTCTTTTAATTGCCC 143 112888113 1 12: 112910715-112910880/22, 22/+ 0.894139 12 112910715 112910736 1
CACGTAATAATATTGACTTTTC 144 112910880 1 12: 112915411-112915580/20, 24/− 0.966125 12 112915561 112915580 1
GGCTAGAAATGTATGGTCAG 145 112915434 1 12: 112926198-112926363/20, 24/− 0.918085 12 112926344 112926363 2
CATAAACTAAAAACAGAAAC 146 112926221 1 12: 112926812-112926981/20, 24/+ 0.957582 12 112926812 112926831 1
GATGTTTCCTTCGTAGGTGT 147 112926981 1 13: 28592560-28592729/20, 24/+ 0.919768 13 28592560 28592579 1
CACAAAATAGCCGTATAAAA 148 28592729 1 13: 28602295-28602464/16, 29/+ 0.881258 13 28602295 28602310 2
TTTTCGTGGAAGTGGG 149 28602464 1 13: 28607990-28608155/20, 24/− 0.927129 13 28608136 28608155 1
GCACGTACTCACCATTTGTC 150 28608013 1 13: 28608205-28608374/20, 24/+ 0.894916 13 28608205 28608224 1
CATTCCATTCTTACCAAACT 151 28608374 1 13: 28608170-28608339/20, 24/− 0.920908 13 28608320 28608339 1
GAAAGCCAGCTACAGATGGT 152 28608193 1 13: 28608401-28608570/20, 24/+ 0.891863 13 28608401 28608420 1
AGAGGAAAGAATAATGAATT 153 28608570 1 13: 28609586-28609755/21, 23/+ 0.98033 13 28609586 28609606 1
GTGGGGAATTCCTGATGGTGG 154 28609755 1 13: 28609701-28609870/20, 24/+ 0.946119 13 28609701 28609720 1
ACCCTTTTATGGCTTCACTC 155 28609870 1 13: 28610048-28610217/20, 24/+ 0.916878 13 28610048 28610067 1
AAGAGGCATCAATGTCCTTA 156 28610217 1 15: 90631745-90631914/20, 24/+ 0.801172 15 90631745 90631764 1
AAGAGGATGGCTAGGCGAGG 157 90631914 1 15: 90631845-90632014/20, 24/+ 0.93551 15 90631845 90631864 1
TGGTGATGGGCTTGGTCCAG 158 90632014 1 17: 7572870-7573039/21, 23/+ 0.981202 17 7572870 7572890 1
AGGGGAGGGAGAGATGGGGGT 159 7573039 1 17: 7573943-7574112/22, 22/− 0.910933 17 7574091 7574112 1
CAAACAATTGTAACTTGAACCA 160 7573964 1 17: 7576792-7576961/24, 20/− 0.847926 17 7576938 7576961 1
TTCACTTTTATCACCTTTCCTTGC 161 7576811 1 17: 7577075-7577244/24, 20/+ 0.980151 17 7577075 7577098 1
TTCTCTTCCTCTGTGCGCCGGTCT 162 7577244 1 17: 7576963-7577132/21, 23/− 0.924868 17 7577112 7577132 1
GCTTTGAGGTGCGTGTTTGTG 163 7576985 1 17: 7577438-7577602/20, 24/+ 0.897643 17 7577438 7577457 1
AGAGGCAAGCAGAGGCTGGG 164 7577602 1 17: 7577529-7577693/22, 22/− 0.959787 17 7577672 7577693 14
AAAAAAAAAAAAAAAGGCCTCC 165 7577550 1 17: 7578169-7578338/23, 21/+ 0.893158 17 7578169 7578191 1
AACCAGACCTCAGGCGGCTCATA 166 7578338 1 17: 7578093-7578262/23, 21/− 0.937736 17 7578240 7578262 1
GAGTGGAAGGAAATTTGCGTGTG 167 7578113 1 17: 7578393-7578562/18, 26/+ 0.843508 17 7578393 7578410 1
ATGGTGGGGGCAGCGCCT 168 7578562 1 17: 7578334-7578453/18, 26/− 0.833295 17 7578436 7578453 1 CATGGCCATCTACAAGCA
169 7578359 1 17: 7578469-7578628/26, 18/− 0.890436 17 7578603 7578628 1 CTGCCGTCTTCCAGTTGCTTTATCTG 170 7578486 1 17:
7579238-7579407/20, 24/+ 0.809488 17 7579238 7579257 1 CAAACAAAAGAAATGCAGGG 171 7579407 1 17: 7579298-7579467/21,
23/+ 0.74921 17 7579298 7579318 1 TCAGGGCAACTGACCGTGCAA 172 7579467 1 17: 7579416-7579577/20, 24/+ 0.784204 17 7579416
7579435 2 AGGAGGGGGCTGGTGCAGGG 173 7579577 1 17: 7579495-7579664/21, 23/− 0.900055 17 7579644 7579664 2
TGGGGACCTGGAGGGCTGGGG 174 7579517 1 17: 7579802-7579971/24, 20/− 0.864469 17 7579948 7579971 1
TCATGCTGGATCCCCACTTTTCCT 175 7579821 1 17: 58740425-58740594/22, 22/+ 0.952631 17 58740425 58740446 1
GCCTTCTCAGAGAATTTTTTAG 176 58740594 1 17: 58740303-58740472/20, 24/− 0.827005 17 58740453 58740472 1
CTCTCGAGCTATCTCAGCTG 177 58740326 1 17: 58740633-58740802/21, 23/+ 0.979392 17 58740633 58740653 1
TGAAGATGTCAACTCCTGGCC 178 58740802 1 17: 58740506-58740675/21, 23/− 0.853213 17 58740655 58740675 1
TCAATTTCTTGGGCTTTCATT 179 58740528 1 17: 58740833-58741002/20, 24/+ 0.902941 17 58740833 58740852 1
ATGCGACGCAGACTTAGGGG 180 58741002 1 7: 58740728-58740897/21, 23/− 0.938281 17 58740877 58740897 1
GTTTTCCTGTGTTGATGAAGT 181 58740750 1 17: 74732929-74733008/24, 20/+ 0.924881 17 74732929 74732952 1
GGTCCCCGGCGGCTGTGGTGTGAG 182 74733008 1 18: 42531843-42532012/21, 23/+ 0.911291 18 42531843 42531863 1
CTCCCTAAAGGAAATCACGCT 183 42532012 1 19: 13054585-13054754/20, 24/+ 0.937952 19 13054585 13054604 1
AAGAAGACAAGAAACGCAAA 184 13054754 1 19: 13054480-13054649/24, 20/− 0.794174 19 13054626 13054649 1
ATCTTTGTCCTCATCATCCTCCTT 185 13054499 1 19: 33792231-33792385/16, 27/− 0.810719 19 33792370 33792385 12
GAAGGTGCTGGAGCTG 186 33792257 1 19: 33792335-33792504/20, 24/− 0.830437 19 33792485 33792504 1
AAGGCCAAGAAGTCGGTGGA 187 33792358 1 19: 33792732-33792851/16, 26/+ 0.652911 19 33792732 33792747 19
GCGGGTGCGGGTGCGG 188 33792851 1 19: 33792942-33793051/16, 24/− 0.849634 19 33793036 33793051 2 GGCCAAGGCGGCCGTG
189 33792965 1 19: 33793045-33793154/16, 29/+ 0.8992 19 33793045 33793060 10 CTTGGCCTTCTCCTGC 190 33793154 1 19:
33793184-33793288/16, 26/+ 0.876116 19 33793184 33793199 12 GGTGGGGGGGGAGGCT 191 33793288 1 20: 31021052-31021221/21,
23/+ 0.922229 20 31021052 31021072 1 GGCCTGAAACTGATGGCTGTG 192 31021221 1 20: 31021242-31021411/22, 22/+ 0.940116 20
31021242 31021263 1 CAGATCTCCGAACCAGAGCCAG 193 31021411 1 20: 31021151-31021320/24, 20/− 0.925719 20 31021297
31021320 1 TTTGCATCCTTAGCAACCCCTGCT 194 31021170 1 20: 31021437-31021606/20, 24/+ 0.888392 20 31021437 31021456 1
CCGAATTCCCAGTTGAGTCT 195 31021606 1 20: 31021362-31021531/23, 21/− 0.82328 20 31021509 31021531 1
CAGGCTAGGAATTCTGTCTGGAG 196 31021382 1 20: 31021534-31021703/20, 24/+ 0.939897 20 31021534 31021553 1
TCAGGAAACTGTGGATCAGG 197 31021703 1 20: 31022183-31022352/22, 22/+ 0.894333 20 31022183 31022204 1
TAGGTCAGATCACCCAGTCAGT 198 31022352 1 20: 31022389-31022533/16, 25/+ 0.740488 20 31022389 31022404 2
GAGGGGCGAGAGGTCA 199 31022533 1 20: 31022292-31022441/20, 24/− 0.670733 20 31022422 31022441 1
TCCGATGGCAGTGGTGGCCG 200 31022315 1 20: 31022643-31022812/21, 23/+ 0.806603 20 31022643 31022663 1
GGAACTGCCATGTCCAGAGCT 201 31022812 1 20: 31022555-31022724/20, 24/− 0.907715 20 31022705 31022724 1
CTGTAGCCCTCTGTAGTAGG 202 31022578 1 20: 31022881-31023050/22, 22/+ 0.931489 20 31022881 31022902 1
GTGAGTCTGGCACCACTTCCTG 203 31023050 1 20: 31022782-31022951/23, 21/− 0.91537 20 31022929 31022951 1
ACCATTGTCTGCAGGAACGGTGG 204 31022802 1 20: 31023086-31023255/21, 23/+ 0.933626 20 31023086 31023106 1
GCAGAACAGAGCATTTGATGA 205 31023255 1 20: 31022984-31023153/23, 21/− 0.932364 20 31023131 31023153 1
TATCACTTTCCCTCATAGGAGGG 206 31023004 1 20: 31023328-31023497/20, 24/+ 0.949461 20 31023328 31023347 1
CTGCATTGCCTGGGGATTTG 207 31023497 1 20: 31023202-31023371/21, 23/− 0.881999 20 31023351 31023371 1
AGGATCTAGACCCTCCTCAGC 208 31023224 1 20: 31023421-31023590/20, 24/− 0.918557 20 31023571 31023590 1
CTTTGTCACTGCAGCTTCTC 209 31023444 1 20: 31023517-31023686/20, 24/− 0.878099 20 31023667 31023686 1
ATCTGTCCTTGTAACCAGAC 210 31023540 1 20: 31023708-31023877/22, 22/+ 0.887733 20 31023708 31023729 1
TGGGTGTCTCGAGTATGTGCGG 211 31023877 1 20: 31023619-31023788/20, 24/− 0.904275 20 31023769 31023788 1
GGCTCTTGGCTGGTACTCAG 212 31023642 1 20: 31023826-31023995/20, 24/− 0.897669 20 31023976 31023995 1
GCCACTGTTTTTTCCAAGAC 213 31023849 1 20: 31024004-31024173/20, 24/+ 0.889572 20 31024004 31024023 1
TGGAAGCAGCCCCAGTTCTT 214 31024173 1 20: 31024067-31024236/21, 23/+ 0.894101 20 31024067 31024087 1
AGGCACTGGTCTTGCCAGGAT 215 31024236 1 20: 31023931-31024100/20, 24/− 0.934792 20 31024081 31024100 1
CTGGGTGGCCTCAATCCTGG 216 31023954 1 20: 31024183-31024352/20, 24/+ 0.897143 20 31024183 31024202 1
CTAGGAAACTGGAAGAAATG 217 31024352 1 20: 31024301-31024470/24, 20/+ 0.881533 20 31024301 31024324 1
CCCAGGAGATCTTACTACCTCGAG 218 31024470 1 20: 31024409-31024578/20, 24/+ 0.868986 20 31024409 31024428 2
AGGCCAAGGGAAGAAGCTTT 219 31024578 1 20: 31024513-31024682/20, 24/+ 0.949413 20 31024513 31024532 1

TTCCCAGTGGGAAGTTGGGA 220 31024682 1 20: 31024623-31024792/20, 24/+ 0.95695 20 31024623 31024642 1
GAGAAGACTTTTGTGGGGGG 221 31024792 1 0: 31024736-31024905/23, 21/+ 0.924311 20 31024736 31024758 1
CTTGCCCTTCTGGAAATTACCCC 222 31024905 1 20: 31024855-31025024/21, 23/+ 0.905752 20 31024855 31024875 1
TCCAACTGAGTTCCACCAGCT 223 31025024 1 20: 31024965-31025134/20, 24/+ 0.950131 20 31024965 31024984 1
CACAGTGCATCACTTTCCTT 224 31025134 1 20: 57484366-57484525/18, 26/− 0.944333 20 57484508 57484525 1
CAAGAAACCATGATCTCT 225 57484391 1 21: 36164530-36164685/20, 24/+ 0.734511 21 36164530 36164549 1
GGTTCGGGAGGCTGGGGTTG 226 36164685 1 21: 36164619-36164747/21, 23/+ 0.781897 21 36164619 36164639 2
ACCATGGAGAACTGGTAGGAG 227 36164747 1 21: 36164705-36164815/20, 24/+ 0.711885 21 36164705 36164724 1
TTGCGACGAGCCGGGGTAGG 228 36164815 1 21: 36164717-36164857/23, 21/+ 0.828908 21 36164717 36164739 1
GGGGTAGGGCGGCGGCAGGTAGG 229 36164857 1 21: 36164802-36164956/19, 25/+ 0.794232 21 36164802 36164820 1
GTCGGGGAGTAGGTGAAGG 230 36164956 1 21: 36171528-36171697/21, 23/− 0.841039 21 36171677 36171697 1
TCCATTGCCTCTCCTTCTGTG 231 36171550 1 21: 36171646-36171815/22, 22/− 0.879815 21 36171794 36171815 1
CATTTTTTAAATCCCACCCCAC 232 36171667 1 21: 36206622-36206777/23, 21/+ 0.865415 21 36206622 36206644 1
GGGAAGGTGTGTGCACATGGGGG 233 36206777 1 21: 36206730-36206885/21, 23/+ 0.735902 21 36206730 36206750 1
GGGTTAAAGGCAGTGGAGTGG 234 36206885 1 21: 36206799-36206954/23, 21/− 0.791705 21 36206932 36206954 15
TCTTCCCTCCCTCCTTCCCTCCC 235 36206819 1 21: 36231732-36231901/22, 22/− 0.873923 21 36231880 36231901 1
TTTTGTTCTCTATCGTGTCCCC 236 36231753 1 21: 36252801-36252970/23, 21/+ 0.943161 21 36252801 36252823 1
TGGGTTTGTTGCCATGAAACGTG 237 36252970 1 21: 36252916-36253085/21, 23/− 0.94378 21 36253065 36253085 1
ATCACTACACAAATGCCCTAA 238 36252938 1 21: 36259108-36259222/16, 29/+ 0.817091 21 36259108 36259123 15
CTGTCCTCCCACCACC 239 36259222 2 21: 36259159-36259263/22, 22/+ 0.706198 21 36259159 36259180 3
GTCTTGTTGCAGCGCCAGTGCG 240 36259263 1 21: 44514729-44514898/22, 22/− 0.933507 21 44514877 44514898 2
TTTCGCCGTGAGGAAGATGCGG 241 44514750 1 21: 44524416-44524585/20, 24/+ 0.94191 21 44524416 44524435 1
CAAACAAACCTGGCTAAACG 242 44524585 1 X: 15833872-15834041/20, 24/+ 0.979296 X 15833872 15833891 2
AATGGAGCAGTGCAGGAGGG 243 15834041 1 X: 15833745-15833914/20, 24/− 0.924197 X 15833895 15833914 2
GCTTGCGTCAGGGTCATAGT 244 15833768 1 X: 15836657-15836826/21, 23/− 0.93315 X 15836806 15836826 1
AACAGAAACAGAACAACAAAC 245 15836679 1 X: 15838303-15838483/23, 21/+ 0.712992 X 15838303 15838325 1
GCATATCATTTGATTTTTGGTTT 246 15838483 1 X: 39911340-39911509/20, 24/+ 0.940705 X 39911340 39911359 1
GTACATGGTGGGTCCAGCTT 247 39911509 1 X: 39911542-39911711/21, 23/+ 0.932675 X 39911542 39911562 1
TTCTGCCTCTGCAATGGTGAC 248 39911711 1 X: 39911448-39911617/20, 24/− 0.941736 X 39911598 39911617 1
GAAATTGAAAATGTCCTCCC 249 39911471 1 X: 39914595-39914764/20, 24/+ 0.919934 X 39914595 39914614 1
AGACCATTTCTTGAACTTTG 250 39914764 1 X: 39914691-39914860/24, 20/− 0.966337 X 39914837 39914860 1
TGCCCAGCTTTGCCTGTTGCTTTT 251 39914710 1 X: 39932843-39933012/24, 20/+ 0.82704 X 39932843 39932866 1
TCCTGCTGGTTTTGGTGCCATCTG 252 39933012 1 X: 39933079-39933248/20, 24/+ 0.945629 X 39933079 39933098 1
GAGGGAGCAGTGCTGATGAT 253 39933248 1 X: 39932964-39933133/20, 24/− 0.933519 X 39933114 39933133 1
CTCCAGGAAATGGTTGTGCT 254 39932987 1 X: 48649464-48649633/16, 29/+ 0.856993 X 48649464 48649479 14
TTTCTGTGTCTGAGGA 255 48649633 1 X: 48649695-48649864/21, 23/+ 0.897556 X 48649695 48649715 1
TGGCCTACTACAGGGACGCTG 256 48649864 1 X: 48649576-48649745/20, 24/− 0.823488 X 48649726 48649745 1
TGGAGTTACCTGGGGAGTGT 257 48649599 1 X: 53431899-53432068/20, 24/+ 0.892295 X 53431899 53431918 1
TGTGTGGATGGCCTTTGGAG 258 53432068 1 X: 53432011-53432180/22, 22/+ 0.897516 X 53432011 53432032 1
ATCTGCAGTCCATGGGCCTGAG 259 53432180 1 X: 53432104-53432273/23, 21/+ 0.897847 X 53432104 53432126 1
GCTAGGTGGTAAGGTGGTGGCTG 260 53432273 1 X: 53432228-53432397/24, 20/+ 0.904552 X 53432228 53432251 1
TTTCTCATCCCAGCGCCGTGCCTT 261 53432397 1 X: 53432336-53432505/20, 24/+ 0.904126 X 53432336 53432355 1
GGGGGAAGAGAGAAGAGGGG 262 53432505 1 : 53432548-53432717/23, 21/+ 0.873273 X 53432548 53432570 1
ATCAATCACTAGCTTGGCCCCCT 263 53432717 1 X: 53432438-53432607/22, 22/− 0.912547 X 53432586 53432607 1
CAGGTGAAGCCTACAGATGAGA 264 53432459 1 X: 53432775-53432944/23, 21/+ 0.945673 X 53432775 53432797 1
GCCTGTCTTCTCCGAGTCCACAA 265 53432944 1 X: 53432662-53432831/22, 22/− 0.898153 X 53432810 53432831 1
ACCAAGGTTTTGGGCAAGAACA 266 53432683 1 X: 123181234-123181403/20, 24/+ 0.95047 X 123181234 123181253 1
TGGCACTAAATCTTAGCATT 267 123181403 1 X: 123181157-123181326/20, 24/− 0.9185 X 123181307 123181326 1
GCCTCTCATTGGCTCGTTTT 268 123181180 1 X: 123182833-123183002/20, 24/+ 0.820783 X 123182833 123182852 1
GAAATGATGTGTTTTTTTAC 269 123183002 1 X: 123184006-123184184/21, 23/+ 0.907704 X 123184006 123184026 1
TTATGCATCGTTTTTCCTTCC 270 123184184 1 X: 123184910-123185079/20, 24/+ 0.833242 X 123184910 123184929 1
GAAGTTGAAAATACATAGAG 271 123185079 1 X: 123185026-123185195/22, 22/+ 0.858971 X 123185026 123185047 1
AAGAGCTTAATTCCAAACTGGA 272 123185195 1 X: 123185116-123185285/20, 24/+ 0.932372 X 123185116 123185135 5
CTTTTCTCTTGCTTTCCTTT 273 123185285 1 X: 123189951-123190120/21, 23/− 0.874373 X 123190100 123190120 1
GCCTTAGAAAATGAGTAACAG 274 123189973 1 X: 123220363-123220532/20, 24/+ 0.871879 X 123220363 123220382 1
GTATCAAAGCTAACAGTTTC 275 123220532 1 X: 123220475-123220644/20, 24/− 0.7772 X 123220625 123220644 1
AAAGAGAATAAATTATATCC 276 123220498 1 X: 133511649-133511818/20, 24/+ 0.966325 X 133511649 133511668 1
TGTCAAGCTCAGTTGAACAG 277 133511818 1 X: 133511601-133511770/20, 24/− 0.96135 X 133511751 133511770 1
CGCTGCCACCTTCTGGTTTT 278 133511624 1 X: 133527602-133527771/20, 24/+ 0.867927 X 133527602 133527621 1
CTACCACTGTGCATTGCATG 279 133527771 1 X: 133527477-133527646/20, 24/− 0.939432 X 133527627 133527646 1
GGTTTCTCTCGTATTTGAGC 280 133527500 1 X: 133527898-133528017/22, 22/+ 0.864925 X 133527898 133527919 1
TTAGTTTGCTTACTAATTTTTG 281 133528017 1 X: 133547773-133547942/20, 24/+ 0.896119 X 133547773 133547792 1
GAAATGTTAAGTAAGCTTGA 282 133547942 1 X: 133547875-133548044/23, 21/− 0.984411 X 133548022 133548044 17
AAACAAACAACAAAAAAACAAAA 283 133547895 1 X: 133549006-133549180/27, 27/− 0.875443 X 133549154 133549180 1
TGTTGCATAACAAATATAAAAACTACA 284 133549032 X: 133551196-133551365/22, 22/− 0.876924 X 133551344 133551365 1
GTTTAGGGAAATAGACAACTGT 285 133551217 1 mip_scan_ SEQ start_ lig_probe_sequence ID position mip_name
TCAGACTTCGGCCCACCC 286 43814917 MPL_001_Myeloid_Panel GTGTGGAGGGTAAGGGGGCAGGG 287 115256480
NRAS_001_Myeloid_Panel GTAGCCCGCTGACCTGATCCTGT 288 115258658 NRAS_002_Myeloid_Panel
ACTGGGAAACCAAATACCCTGG 289 25457146 DNMT3A_001_Myeloid_Panel GCTGAAGGAGTATTTTGCGTGTGT 290 25457176
DNMT3A_002_Myeloid_Panel CCCGGGTTGTGCTGGCATCTGGCT 291 25458573 DNMT3A_003_Myeloid_Panel
GCAGGGAGAAGGAAGGGCAGGAT 292 25459772 DNMT3A_004_Myeloid_Panel GCTCCTGGGCCTGGGGGGCTGT 293 25461989
DNMT3A_005_Myeloid_Panel GCGCATCATGCAGGAGGCGGTAGA 294 25463143 DNMT3A_006_Myeloid_Panel
GCGTTAGTGACAAGAGGGACATCT 295 25463209 DNMT3A_007_Myeloid_Panel GCTGTCCAGGGACAGAGGCAGACA 296 25463504
DNMT3A_008_Myeloid_Panel TTGGAGCCATCTCCCTGGCACCCT 297 25464530 DNMT3A_009_Myeloid_Panel
GTCCATGCTGTGGGGCGCAG 298 25464427 DNMT3A_010_Myeloid_Panel GTGAGGGGTGCAGGCCCAAGAGGT 299 25466767

DNMT3A_011_Myeloid_Panel CTTCCTTAATGGCTGCCTGGGCAG 300 25467032 DNMT3A_012_Myeloid_Panel
GCCTGGGGCGCGGTCTCGAGCT 301 25467013 DNMT3A_013_Myeloid_Panel CCCCTGGAACTGCTACATGTGC 302 25467139
DNMT3A_014_Myeloid_Panel GCTGTTGTGGCCTCCAGTGGT 303 25467404 DNMT3A_015_Myeloid_Panel
GGTGAGTACCACCGAAGGGCCTCT 304 25468120 DNMT3A_016_Myeloid_Panel TGCCGTTGAGGCCGGCCCTTC 305 25468096
DNMT3A_017_Myeloid_Panel CCGCGCCTGCTCCTCGGATG 306 25468841 DNMT3A_018_Myeloid_Panel
CACATGTCCGTGTACACTTCTTTG 307 25469013 DNMT3A_019_Myeloid_Panel TTCCCCCACCCTCCTTACAG 308 25469111
DNMT3A_020_Myeloid_Panel GTGACACGCCAGGGTTGGGGTTGT 309 25469530 DNMT3A_021_Myeloid_Panel
GGCTGCCAAGGCCTCCACAGAG 310 25469407 DNMT3A_022_Myeloid_Panel CACCCACCCCATGCCTTGCAA 311 25469949
DNMT3A_023_Myeloid_Panel GCACTAGGAGGCCTGGAAGTTG 312 25469881 DNMT3A_024_Myeloid_Panel
TTCCCCCACACCAGCTCCCCAA 313 25470458 DNMT3A_025_Myeloid_Panel GTGTCTTGGTGGATGACGGGC 314 25470544
DNMT3A_026_Myeloid_Panel CGGGCCCCTGGTTTTCTT 315 25470939 DNMT3A_027_Myeloid_Panel AGGTAATTGGTGGATTTACCTTTC
316 198266564 SF3B1_001_Myeloid_Panel CTGGATATGTTTCATGGTTCT 317 198266438 SF3B1_002_Myeloid_Panel
GTGTTAAAGCCTTTATGGAAGGGT 318 198266754 SF3B1_003_Myeloid_Panel GAAAGGACAGTCATGAGTTGGT 319 198267441
SF3B1_004_Myeloid_Panel CTTATGGGCTGTGCCATCTTGCC 320 198267338 SF3B1_005_Myeloid_Panel GGTGCCATTTGGTGATTTCC
321 209113087 IDH1_001_Myeloid_Panel TGCAGGAGAAGTCATCCCCCTTC 322 128200044 GATA2_001_Myeloid_Panel
GGTGCCGGCTCTTCTGGCGG 323 128200685 GATA2_002_Myeloid_Panel CACTCATCAAGCCCAAGCGAAGAC 324 128202729
GATA2_003_Myeloid_Panel GTCCAGGAACTGAGCAGAGGT 325 55589720 KIT_001_Myeloid_Panel GTGAATACACTATTAGGTTGGAGG
326 55599245 KIT_002_Myeloid_Panel GCCCACTGCCTGAGAGAGCTCAT 327 106155136 TET2_001_Myeloid_Panel
GTAGAGGGTATTCCAAGTGTTTGC 328 106155263 TET2_002_Myeloid_Panel GTTCTGTCTGGCAAATGGGAGGTG 329 106155185
TET2_003_Myeloid_Panel TCTGTAGCCCAAGAAAATGCAG 330 106155430 TET2_004_Myeloid_Panel CGACTATTCTGGCTTCCCTTC 331
106155318 TET2_005_Myeloid_Panel TGGAACACACACATGGTGAACTCCTG 332 106155646 TET2_006_Myeloid_Panel
CATTTGGTTGACTGCTTTCACCTG 333 106155521 TET2_007_Myeloid_Panel GTGAGTGAGGCCTGTGATGCTGAT 334 106155847
TET2_008_Myeloid_Panel GCACCATTAGGCATTAGCACTGCC 335 106155732 TET2_009_Myeloid_Panel CCAGCAGCAATTTGCAAGC 336
106156060 TET2_010_Myeloid_Panel GCAGCTGGCTTTGGAGGCAGCT 337 106155969 TET2_011_Myeloid_Panel
CACCACCACTACCCCAACCAAA 338 106156273 TET2_012_Myeloid_Panel TGAACAGAATTCTTCACCA 339 106156162
TET2_013_Myeloid_Panel CCAATGTCAGAACACCTCAAGC 340 106156492 TET2_014_Myeloid_Panel
GCTTTTTCCTTCTGAAGGAAGCTG 341 106156372 TET2_015_Myeloid_Panel CGTAATGAGGCATCACTGCCATCA 342 106156714
TET2_016_Myeloid_Panel CCACAATGGAACAGTCATTGTCCC 343 106156603 TET2_017_Myeloid_Panel CCCTCACACCAGGTGCACTTC
344 106156939 TET2_018_Myeloid_Panel GGGATTCCGCTTGGTGAAAACGA 345 106156832 TET2_019_Myeloid_Panel
TCCCAGAGTTCACATCTCCCTCA 346 106157170 TET2_020_Myeloid_Panel GGAACTGGAGATGTTGGTCCACTG 347 106157060
TET2_021_Myeloid_Panel GAAATTCCCCTTATAGTCAGACCATG 348 106157417 TET2_022_Myeloid_Panel
GGTTGTGTTTGTGCTGCCTGTTTATG 349 106157295 TET2_023_Myeloid_Panel GCTTTCAAGAACAGGAGCAGAAG 350 106157618
TET2_024_Myeloid_Panel GACATTATGAGTCTCGAACTCGCT 351 106157506 TET2_025_Myeloid_Panel
CAGCAAACACAGCAACCCCAAAC 352 106157860 TET2_026_Myeloid_Panel GTGAAGAAGATCTTGCTTTGGG 353 106157740
TET2_027_Myeloid_Panel AATGTGCAGCAAAAGAGCATCATTGA 354 106158025 TET2_028_Myeloid_Panel
GCAGCATGCTTTTGAGTGTCC 355 106157952 TET2_029_Myeloid_Panel CTTCTTCAGAAAAGACACCAACC 356 106158244
TET2_030_Myeloid_Panel CACAGCTTGCAGGTGGATTCTC 357 106158149 TET2_031_Myeloid_Panel CTTCAGATATGGGATTTTCCTTCT
358 106158435 TET2_032_Myeloid_Panel GCTGGGGTGTGGCTATCAAGTTCT 359 106158339 TET2_033_Myeloid_Panel
GCAAAGGCACAGGGCAGATTAACG 360 106162470 TET2_034_Myeloid_Panel GCCTTTGGTCTTAAATCTTGGG 361 106163978
TET2_035_Myeloid_Panel CCAATCGCCGGTGTGCCTTGAAT 362 106164782 TET2_036_Myeloid_Panel
CCCCCCACCCCAACCAAAACAAAA 363 106164698 TET2_037_Myeloid_Panel GCTCCGAGTAGAGTTTGTCAGCC 364 106164875
TET2_038_Myeloid_Panel TTTGCCAGAAGCAAGATCCC 365 106180744 TET2_039_Myeloid_Panel TTCTGGATCCAGCCCCTGACAGGC
366 106180810 TET2_040_Myeloid_Panel GGCAGCAATTGTAACAACTTACTTG 367 106182914 TET2_041_Myeloid_Panel
GAGGACAGCTTAGCAGCTGTTGAG 368 106190791 TET2_042_Myeloid_Panel GAAAACTCACTAGTATTTAGACC 369 106190713
TET2_043_Myeloid_Panel GTCAAGACTTGCCGACAAAGGA 370 106193793 TET2_044_Myeloid_Panel
GTAAGACATTACAGCCTCAACTAC 371 106193710 TET2_045_Myeloid_Panel GCATTTGTAGATAAATGTGTTGTG 372 106193966
TET2_046_Myeloid_Panel GCCGAAAAGAACTCAGTACCTG 373 106193893 TET2_047_Myeloid_Panel CCCCAGCAGCAGCAGCCACA 374
106196201 TET2_048_Myeloid_Panel CCATGAACCCTTACCCTGGGCTT 375 106196382 TET2_049_Myeloid_Panel
GCTGGGGCTGTGGTGGCTGCTTCT 376 106196286 TET2_050_Myeloid_Panel GCCAAGGTTTGGAAATAGCCAGAG 377 106196581
TET2_051_Myeloid_Panel CCTGCAGCTTGAGATGAGGTGGA 378 106196485 TET2_052_Myeloid_Panel
GGTGAACATCATTCACCTTCTCAC 379 106196801 TET2_053_Myeloid_Panel GTGTATGGATGGGTGGTAGACTG 380 106196700
TET2_054_Myeloid_Panel GCTTTCCCACACAGCTAATGGGT 381 106196908 TET2_055_Myeloid_Panel
GTGATGCTAATGGTCAGGAAAAGC 382 106197000 TET2_056_Myeloid_Panel TCACCCCACCAGGATCTCCC 383 106197217
TET2_057_Myeloid_Panel GCAGTTCTATCATGGTTAAGAGCTGG 384 106197097 TET2_058_Myeloid_Panel
CAGAGCCCACTTACCTGCGTTTCA 385 106197420 TET2_059_Myeloid_Panel GCAGCTCACGCTTTGCACAC 386 106197309
TET2_060_Myeloid_Panel GAAGTTTCATGTGGCTCAGCAGGC 387 106197547 TET2_061_Myeloid_Panel
CCACAACACTTCATAGACATCA 388 170837497 NPM1_001_Myeloid_Panel CAGTAGATCTCATTTTCCTATCAG 389 140453093
BRAF_001_Myeloid_Panel CACAACAAAGCCTGCTGAAGATAG 390 148504736 EZH2_001_Myeloid_Panel
GGGCTTTTTCTACTGGATTGTG 391 148506130 EZH2_002_Myeloid_Panel GTAAGCACAGCCCAGTGAAT 392 148506421
EZH2_003_Myeloid_Panel GCTGGGAGGCAGTGAGTTCCT 393 148507413 EZH2_004_Myeloid_Panel GGCACTGATAACCTGTATTCAGGT
394 148508713 EZH2_005_Myeloid_Panel GGAGGTTCTTCACTCATCACC 395 148511120 EZH2_006_Myeloid_Panel
GTAGTTAGCTATTTAGTGATGCAA 396 148511019 EZH2_007_Myeloid_Panel GCATGAGAACTAAATAGGTCTTTG 397 148511979
EZH2_008_Myeloid_Panel GCTTTGTTTTCATTTGTTTTAG 398 148512554 EZH2_009_Myeloid_Panel GCAGAGGGTACTTGAGAGGACTTT
399 148516665 EZH2_010_Myeloid_Panel GTTTCTAAAAGGTTTCCATGTGTT 400 148523659 EZH2_011_Myeloid_Panel
CGTTTTCATTTTCTATCTTTGTTG 401 148523543 EZH2_012_Myeloid_Panel GAGCCATATGCTTCTTCTCTTGG 402 148526818
EZH2_013_Myeloid_Panel TTGTTCTGTTGGAATAGTTCCTTG 403 117864786 RAD21_001_Myeloid_Panel
GAGGACCAGCAACAGCAGCAT 404 117864828 RAD21_002_Myeloid_Panel GAATAATCACTAAGTTGGGCTCT 405 117866477
RAD21_003_Myeloid_Panel GGATCTGGCACCGCCCACCA 406 117866593 RAD21_004_Myeloid_Panel CCTTTAGATTTATACAGCAT 407
117868392 RAD21_005_Myeloid_Panel AGACTAGAAGGTTTGATTTATCTG 408 5069946 JAK2_001_Myeloid_Panel
CAGGATCACAGCTAGGTGTCAGTG 409 5073732 JAK2_002_Myeloid_Panel CTTTCTACACATGCGTGGAAGTC 410 112350168
SMC3_001_Myeloid_Panel GCTGGTTTATTCCTTTTCGACGG 411 112350240 SMC3_002_Myeloid_Panel GTTAGATGTCAGGGATACAGCC
412 112350728 SMC3_003_Myeloid_Panel AGTAACCTCTCCAGGAAGATTCAT 413 112350837 SMC3_004_Myeloid_Panel
CAGCTGGCCCGTGCTTTCACTA 414 112352813 SMC3_005_Myeloid_Panel GAGTCTTTCCAAACACATGTTTG 415 112352910
SMC3_006_Myeloid_Panel GCAAAGCTCAATGAAAACCTGCGC 416 112356146 SMC3_007_Myeloid_Panel
GCCTCGGCCCTAACAATGTGGGCA 417 32413507 WT1_001_Myeloid_Panel GCTGTGTTCCCTTGGGCTAGGGTT 418 32414183

WT1_002_Myeloid_Panel GTCTTGAGGGAGAGTGAGCACTGG 419 32417886 WT1_003_Myeloid_Panel GCAAACATGGTTCAAGAGCTCCTT 420 32417776 WT1_004_Myeloid_Panel AGGCTCAGTGTGGCTCACAGTCGC 421 32421492 WT1_005_Myeloid_Panel GAGCCCTGTGGACACCTCATG 422 119148834 CBL_001_Myeloid_Panel GTTGGAATGTGGAGCCCATCTCAC 423 119148919 CBL_002_Myeloid_Panel GAGGCAAGGAGCAGAGGGAGCTCC 424 119149195 CBL_003_Myeloid_Panel CACAGATCTGTTTTCTGCAAAATC 425 25378528 KRAS_001_Myeloid_Panel GACTGGGGAGGGCTTTCTTTGTGT 426 25380240 KRAS_002_Myeloid_Panel GCATATTACTGGTGCAGGACCATT 427 25398189 KRAS_003_Myeloid_Panel GTCCATTGGAAAGGGAGGCAA 428 112888114 PTPN11_001_Myeloid_Panel TCCGCTCAGTAATAGTCACTCT 429 112910737 PTPN11_002_Myeloid_Panel GGTCACATAAGTCCTGGACTGCTT 430 112915435 PTPN11_003_Myeloid_Panel GGACAACAGAATCATTCATGGGGG 431 112926222 PTPN11_004_Myeloid_Panel GCGCAGGATTGAAGAAGAGCAGGT 432 112926832 PTPN11_005_Myeloid_Panel GGCCAGGTCTCTGTGAACACACTG 433 28592580 FLT3_001_Myeloid_Panel AAGGAGCATTAAAAATGTAAAACTCAAGT 434 28602311 FLT3_002_Myeloid_Panel GTGGAAGGACAGCAACAAAGATGC 435 28608014 FLT3_003_Myeloid_Panel GCTTCAGAGATGAAATGATGAGTC 436 28608225 FLT3_004_Myeloid_Panel TCTGCAGCATTTCTTTTCCATTGG 437 28608194 FLT3_005_Myeloid_Panel GCAACAAAAGAGTGTCACTCAGCG 438 28608421 FLT3_006_Myeloid_Panel CTGCTCGACACCCACTGTCCAAA 439 28609607 FLT3_007_Myeloid_Panel GCTGTCATCAGATTGGAAGTTAGG 440 28609721 FLT3_008_Myeloid_Panel CGTGTGAAATAAGCTCACTGGCTG 441 28610068 FLT3_009_Myeloid_Panel GCAGATGATGGGCTCCCGGAAGAC 442 90631765 IDH2_001_Myeloid_Panel GAGATAATAGTGGTCCCACTGCAG 443 90631865 IDH2_002_Myeloid_Panel GACAGAAGCAGGGAGGAGAGATG 444 7572891 TP53_001_Myeloid_Panel GCTGGGAAGGAGCCAGGGGGGA 445 7573965 TP53_002_Myeloid_Panel GTCTAACACTCAAAATGCCG 446 7576812 TP53_003_Myeloid_Panel ACCAGGCTCCATCTACTCCC 447 7577099 TP53_004_Myeloid_Panel CCAAGGGTGCAGTTATGCCTCAG 448 7576986 TP53_005_Myeloid_Panel GTAGTGGATGGTGGTACAGTCAGA 449 7577458 TP53_006_Myeloid_Panel GCGGCATGAACCGGAGGCCCAT 450 7577551 TP53_007_Myeloid_Panel CCTGGGGACCCTGGGCAACCA 451 7578192 TP53_008_Myeloid_Panel GTGAGCAGTAGGGGGGCTTTC 452 7578114 TP53_009_Myeloid_Panel GTTGAGGGCAGGGGAGTACTGTAGGA 453 7578411 TP53_010_Myeloid_Panel GGGCTGGAGAGACGACAGGGCTGGTT 454 7578360 TP53_011_Myeloid_Panel TTCCACACCCCCGCCCGG 455 7578487 TP53_012_Myeloid_Panel TTTCTGGGAAGGGACAGAAGATGA 456 7579258 TP53_013_Myeloid_Panel GTAGGAGCTGCTGGTGCAGGGGC 457 7579319 TP53_014_Myeloid_Panel GCATCAAATCATCCATTGCTTGGG 458 7579436 TP53_015_Myeloid_Panel ACCCAGGTCCAGATGAAGCTCCC 459 7579518 TP53_016_Myeloid_Panel AAGGGCAGGCCCACCACCCC 460 7579822 TP53_017_Myeloid_Panel GCCTTCCAATTGGCCTTGTGCC 461 58740447 PPM1D_001_Myeloid_Panel AAAAAATTTATCCCAGAACTCAAC 462 58740327 PPM1D_002_Myeloid_Panel AGCCTGCAAGTCTCCCCACAACC 463 58740654 PPM1D_003_Myeloid_Panel CAATTTTCTTCAAGTGGTTCTGG 464 58740529 PPM1D_004_Myeloid_Panel GATGTTGAACTTTTTTTAAGGGGA 465 58740853 PPM1D_005_Myeloid_Panel CGTCTATGCTTCTTCATCAGGGG 466 58740751 PPM1D_006_Myeloid_Panel AGCTCGCGGCCGTCCAGCAC 467 74732953 SRSF2_001_Myeloid_Panel TTTCTGCTCCCTGGACAACCCGG 468 42531864 SETBP1_001_Myeloid_Panel GGCCTGCCTCCAGGGCTGGACTGA 469 13054605 CALR_001_Myeloid_Panel CTTGCCCCCTGCCAGCCCTG 470 13054500 CALR_002_Myeloid_Panel GCAACTGCGCGTGAGGCGCGCGGCTGT 471 33792258 CEBPA_001_Myeloid_Panel TGACCGCCTGCGCAAGCGGGTGGA 472 33792359 CEBPA_002_Myeloid_Panel GCGGGGCTCCTGCTTGATCACCAGCG 473 33792748 CEPBA_003_Myeloid_Panel TCATGCCCGGGGGAGCGCACGGGC 474 33792966 CEBPA_004_Myeloid_Panel GCTGATGTCGATGGACGTCTCGTGCTCGC 475 33793061 CEBPA_005_Myeloid_Panel GCAGGTGGCTGCTCATCGGGGGCCGC 476 33793200 CEBPA_006_Myeloid_Panel GCCACCCGACAGCGAGATGGGCA 477 31021073 ASXL1_001_Myeloid_Panel TCCCCATCTGCCAGGCACATCC 478 31021264 ASXL1_002_Myeloid_Panel CCTGGGACACACAAGCCACT 479 31021171 ASXL1_003_Myeloid_Panel GAGCAGGCGGCCTCTGCATCCTTT 480 31021457 ASXL1_004_Myeloid_Panel GCCCTGCTGGGTCAGTCTTAG 481 31021383 ASXL1_005_Myeloid_Panel CACAGCCCACTAAAGAGGAGCCCA 482 31021554 ASXL1_006_Myeloid_Panel CGGGGTTGGACTGGCGCCAGGA 483 31022205 ASXL1_007_Myeloid_Panel GTGGTGATGGTGGTGAGGCCTGTGG 484 31022405 ASXL1_008_Myeloid_Panel GGTGGGGATGATCCGGGGGCATAT 485 31022316 ASXL1_009_Myeloid_Panel TGCCAGGCCTTGCCCCTACTGTC 486 31022664 ASXL1_010_Myeloid_Panel GTACACTTTCCAGGGGTGCTCGGG 487 31022579 ASXL1_011_Myeloid_Panel GGATCCTGTAAATGTGACCCCC 488 31022903 ASXL1_012_Myeloid_Panel GCAAGGCCTGGCATGGCTGGT 489 31022803 ASXL1_013_Myeloid_Panel GGTAGTGAAACAGCCCAAACCAG 490 31023107 ASXL1_014_Myeloid_Panel GCTTGGCCAGTTCCTTTCTCT 491 31023005 ASXL1_015_Myeloid_Panel GGAGACTCTGAAGCACTGAGTCCT 492 31023348 ASXL1_016_Myeloid_Panel CGATGGGATGGGTATCCAATGCA 493 31023225 ASXL1_017_Myeloid_Panel GTTGACAGTAACTGCCATTGCTGT 494 31023445 ASXL1_018_Myeloid_Panel GGTGACCTTCAAAGTCAGAGGCTG 495 31023541 ASXL1_019_Myeloid_Panel GTAGCTTGCCCCTAGAGAAGGT 496 31023730 ASXL1_020_Myeloid_Panel GTGGGGCAGATTGGTTCCAATTGG 497 31023643 ASXL1_021_Myeloid_Panel GCAACTGCATCACAAGTGGGTTAG 498 31023850 ASXL1_022_Myeloid_Panel CCCTCCATCCAGTGACAAATCCCA 499 31024024 ASXL1_023_Myeloid_Panel GCAGTTCTCTTCCTTTAGTTGTG 500 31024088 ASXL1_024_Myeloid_Panel GCGAGCCATGGCTCTGGTCTTTTG 501 31023955 ASXL1_025_Myeloid_Panel CCTCGTTTCTCATCTCCAAATGTG 502 31024203 ASXL1_026_Myeloid_Panel AACCCTTCAGCGCCCCAGGC 503 31024325 ASXL1_027_Myeloid_Panel GTGGGGTACAGACTCCAAGGGAAG 504 31024429 ASXL1_028_Myeloid_Panel GCCGAGAACAGGAAAGCTACTGGG 505 31024533 ASXL1_029_Myeloid_Panel GAAGGGGCTCAGTGAGCCTCTGGA 506 31024643 ASXL1_030_Myeloid_Panel CCTCTAGCTCTCCCACCTTTC 507 31024759 ASXL1_031_Myeloid_Panel GCAGCACGGTGGAAAGCATCTCG 508 31024876 ASXL1_032_Myeloid_Panel GCTCTGTGTATTGTGCCTTGTGGT 509 31024985 ASXL1_033_Myeloid_Panel GAGGTCAATGGATCTCACCAAAGCCA 510 57484392 GNAS_001_Myeloid_Panel GGTGGTAGGAGGGCGAGCTGGCTT 511 36164550 RUNX1_001_Myeloid_Panel GCGGCGGCAGGTAGGTGTGGTAG 512 36164640 RUNX1_002_Myeloid_Panel GGTGACCGGCGTCGGGGAGTAGGT 513 36164725 RUNX1_003_Myeloid_Panel GCGGGGGTCGGAGATGGAGGG 514 36164740 RUNX1_004_Myeloid_Panel GCGGAAGTGAGTAGGAGGTTGCGGA 515 36164821 RUNX1_005_Myeloid_Panel GTCCAGGAGACTAGAGGTGCATG 516 36171551 RUNX1_006_Myeloid_Panel ACGCCCATTTCACCTGGACGTG 517 36171668 RUNX1_007_Myeloid_Panel GAGGCACGAGGGTTGGGCGTG 518 36206645 RUNX1_008_Myeloid_Panel CGGGCTTGGTCTGATCATCTAGT 519 36206751 RUNX1_009_Myeloid_Panel GCGGCGCACAGCCATGAGGGT 520 36206820 RUNX1_010_Myeloid_Panel GGGCTGGTACACCCTCCAGGCT 521 36231754 RUNX1_011_Myeloid_Panel CATCATTGCCAGCCATCACAG 522 36252824 RUNX1_012_Myeloid_Panel GCTGAGCTGAGAAATGCTACCGC 523 36252939 RUNX1_013_Myeloid_Panel GCAGAGGAAGTTGGGGCTGTCGGTGCGCA 524 36259124 RUNX1_014_Myeloid_Panel GGCCAGCACCTCCACCATGCTG 525 36259181 RUNX1_015_Myeloid_Panel GCCAGTGACGTGACTGAGCACA 526 44514751 U2AF1_001_Myeloid_Panel CATGGAATATGTCAGCAGCATGAC 527 44524436 U2AF1_002_Myeloid_Panel GCATGCGTGTGGAGGAGGGGACTG 528 15833892 ZRSR2_001_Myeloid_Panel GGCCAATAGTTGAAAATTACTCAC 529 15833769 ZRSR2_002_Myeloid_Panel AAATTCAGGAAAAGAAACCAGCC 530 15836680 ZRSR2_003_Myeloid_Panel TTTCCTCAATTGTTCCACTGC 531 15838326 ZRSR2_004_Myeloid_Panel GCTTCCAGGTCTTTGGAGCAAGAG 532 39911360 BCOR_001_Myeloid_Panel GTAAAATGAAAAGTGCGCCCAAC 533 39911563 BCOR_002_Myeloid_Panel GTAAGGAGCTGTTAGATCTGGTGG 534 39911472 BCOR_003_Myeloid_Panel CGTTCTCAACAGCATCGTGCAGAG 535 39914615 BCOR_004_Myeloid_Panel CTTATGGTGCTGACCCCACC

536 39914711 BCOR_005_Myeloid_Panel TCGCCCAGTCCAATGCCTTG 537 39932867 BCOR_006_Myeloid_Panel
CATGTGGTCAGCTTTGGAAGCATC 538 39933099 BCOR_007_Myeloid_Panel CAGCAGCGGAGTTCATCATGCCCG 539 39932988
BCOR_008_Myeloid_Panel CAGGGGTTTTCTTCCCCTCTGGGCCTGAG 540 48649480 GATA1_001_Myeloid_Panel
GCTGGAAGCTTCTCAAATGGATG 541 48649716 GATA1_002_Myeloid_Panel GGTGTGGAGGACACCAGAGCAGGA 542 48649600
GATA1_003_Myeloid_Panel GCAGCTCTGCCTCTTTCCGTTTTG 543 53431919 SMC1A_001_Myeloid_Panel
GCACTGCCTGTGGCTTACTTTC 544 53432033 SMC1A_002_Myeloid_Panel GCCTTCAGGTCACTGGCCCCA 545 53432127
SMC1A_003_Myeloid_Panel CCAGTACTGAGCCTGTCCAG 546 53432252 SMC1A_004_Myeloid_Panel
GACAAGGGCATTGCCACAAGCATA 547 53432356 SMC1A_005_Myeloid_Panel CCTCACCTCCAGGTAGTCAAG 548 53432571
SMC1A_006_Myeloid_Panel GCCGCATTGCCTTTGGAGGCCA 549 53432460 SMC1A_007_Myeloid_Panel GCTTTTGGAAGCTGGCTCAGG
550 53432798 SMC1A_008_Myeloid_Panel GGGTCAGGCCAGTGTTCAAGGG 551 53432684 SMC1A_009_Myeloid_Panel
GGCTATTGTGTGACCAACTTGGTC 552 123181254 STAG2_001_Myeloid_Panel GGTGAAACTAATCTAACAGACACA 553 123181181
STAG2_002_Myeloid_Panel GCAAGTTTGCATATTTCGTGGTGT 554 123182853 STAG2_003_Myeloid_Panel
AAGATGTGCCCTTCAGACTGCTT 555 123184027 STAG2_004_Myeloid_Panel CCAGTCGGTTCAAGGTTAGTATTA 556 123184930
STAG2_005_Myeloid_Panel GTGTCTATGACCCTTGACAAAG 557 123185048 STAG2_006_Myeloid_Panel
GCATATTTGCACTAATGTTCAGAT 558 123185136 STAG2_007_Myeloid_Panel GAAATAAGCAGTAACAGGTGCTT 559 123189974
STAG2_008_Myeloid_Panel ACCATGTCAGTCATTAGTGGAATC 560 123220383 STAG2_009_Myeloid_Panel
CCACCAGCTAGCAAAGAATTTCGG 561 123220499 STAG2_010_Myeloid_Panel CCGGCAGCAACAGAGACCTTGAAA 562 133511669
PHF6_001_Myeloid_Panel GCCACTTTAAGTCTCAAGAAATGC 563 133511625 PHF6_002_Myeloid_Panel
GCATTTCATCATCATCATAAAGGG 564 133527622 PHF6_003_Myeloid_Panel GTATGTGACTTTCTAAGGCTGTAT 565 133527501
PHF6_004_Myeloid_Panel CCACGTTTCAGCCACTTTTCAG 566 133527920 PHF6_005_Myeloid_Panel
GGGGAGGAAGAAAATGAAGCACGA 567 133547793 PHF6_006_Myeloid_Panel GCCTGGTGTCACTAGGGCTGC 568 133547896
PHF6_007_Myeloid_Panel ATGCAGGAAAATTAACATTCAGAATCC 569 133549033 PHF6_008_Myeloid_Panel
GACTGCAAAGTGTACATTTCTG 570 133551218 PHF6_009_Myeloid_Panel SEQ scan_target_sequence ID
CGGGGGCGGTACCTGTAGTGTGCAGGAAACTGCCACCTCAGCAGCAGCAGGCCCAGGACGGCGCTGAGGCCCAGCACTAGATGCAGAGCGGT
571 AAAGGG
GCCTTCGCCTGTCCTCATGTATTGGTCTCTCATGGCACTGTACTCTTCTTGTCCAGCTGTATCCAGTATGTCCAACAAACAGGTTTCACCATCTATA
572 CTGGGG
AAATGACTGAGTACAAACTGGTGGTGGTTGGAGCAGGTGGTGTTGGGAAAAGCGCACTGACAATCCAGCTAATCCAGAACCACTTTGTAGATG
573 CCAGTG
CCTTACACACACGCAAAATACTCCTTCAGCGGAGCGAAGAGGTGGCGGATGACTGGCACGCTCCATGACCGGCCCAGCAGTCTCTGCCTCGCC
574 TAGTGG
TTTCTCCCCCAGGGTATTTGGTTTCCCAGTCCACTATACTGACGTCTCCAACATGAGCCGCTTGGCGAGGCAGAGACTGCTGGGCCGGTCATGGA
575 CGCTCC
CTAGTTCAGCAAAGTGAGGACCATTACTACGAGGTCAAACTCCATAAAGCAGGGCAAAGACCAGCATTTTCCTGTCTTCATGAATGAGAAAGAC
576 AAGGTA
ACAGTCTCTCTTCTGCCTCCTAGGCCGTTGGCATCCACTGTGAATGATAAGCTGGAGCTGCAGGAGTGTCTGGAGCATGGCAGGATAGCCAAGG
577 TGGGGG
CTCATCTTCAAACCGTCTCCTGTTTTGTAGTCCAACCCTGTGATGATTGATGCCAAAGAAGTGTCAGCTGCACACAGGGCCCGCTACTTCTGGGC
578 GTGAAA
CTGGCCAAACCAAGGTTGCTGGCTATACCTCGAGAAATCGCGAGATGTCCCTCTTGTCACTAACGCCCATGGCCACCACATTCTCAAAGAGCCA
579 TGGGCC
CTTCCGACCTCTCAGAGGGCACTGGCCGGCTCTTCTTTGAGTTCTACCGCCTCCTGCATGATGCGCGGCCCAAGGAGGGAGATGATCGCCCCTT
580 CCATGG
CCTACCGTAGAGGCCCTTGCGAGCAGGGTTGACGATGGAGAGGTCATTGCAGGGACTGCCCCCAATCACCAGATCGAATGGGCCCCACTCCTGC
581 GGGCCT AATGTAGCGGTCCACCTGAATGCCCAAGTCCTTCAGCACCAGGAGCCCTGCACCAGCCAGCAGACAGCACCGTTAC 582
GGACCGCTACATTGCCTCGGAGGTGTGTGAGGACTCCATCACGGTGGGCATGGTGCGGCACCAGGGGAAGATCATGTACGTCGGGGACGTCCG
583
ACCGCTGGGCCTGCATCTGACCTGTTGTGCTCACTGCTTAGGACCCTCCAAAGGTTTACCCACCTGTCCCAGCTGAGAAGAGGAAGCCCATCCC
584 CTACAG
GGTCGTGGTTATTAGCGAAGAACATCTGGAGCCGGGAGGGCCAGTCCTCTCGCCGCCGCAGCAGCCCGTAGGTACCCTTGTGCCCGCACATGTA
585 GGCGGCGAGAGGACTGGCCCTCCCGGCTCCAGATGTTCTTCGCTAATAACCACGACCAGGAATTTGTGAGTGCTGG 586
CCTTCCAGGTGCTTTTGCGTGGAGTGTGTGGACCTCTTGGTGGGGCCGGGGGCTGCCCAGGCAGCCATTAAGGAAGA 587
CTGTCTAGAACTGCTTTCTGGAGTGTGCGTACCAGTACGACGACGACGGCTACCAGTCCTACTGCACCATCTGCTGTGGGGGCCGTGAGGTGCT
588 GGTGAG
ACCTTGCAGTTTTGGCACATTCCTCCAACGAAGAGGGGGTGTTCCAGGGTAACATTGAGGCTCCCACAGGAGATGCAGATGTCTGGAAAGCAG
589
ACATCTGCATCTCCTGTGGGAGCCTCAATGTTACCCTGGAACACCCCCTCTTCGTTGGAGGAATGTGCCAAAACTGCAAGGTAGGAGCACACCC
590
GCCCCATGCCACACTAGGAGTGCCAGAGTTCCCAGGCAACAAACTTACCCTCAATGTTCCGGCACTTCTGCCGCACCTCGTACACCAGCCGCTC
591 AGGAGG
GAAGCAGGCCAACTACCTCTTGTGCGCTCATCAATAATCTCCTTGACCTTGGGCTTCTCCGCTGTGCTCTTCCGGGGCTTTTTGGCTGGTGGAGG
592 TCCACC
TGCGTAGGCAGCTGCCTCAGGTTCCACCCACATGTCCGTGTACACTTCTTTGTAGGGATTCTTCTCTTCTGGAGGAGGAAAGCAGGTGCCAAGG
593 AGCCCC
CCCCCCAGGGCCCATTCAATCATGGGCTTGTTCTGCACCTCCACGGCCTTGGCAGTGTCACTCTCATCGCTGTCGTGGCACACCGGGAACAGCT
594 AGG
CTTCCAGCCTTCTGGCCCTAAGGGCCTGGAGCCACCAGAAGGTAAATGAGGGCACCCAGCTTTCTGGGACCCCTGCCCGCCAGGCAGATCCAC
595 GAG
ACATGGGCTGCTTGTTGTACGTGGCCTGGTGGAACGCACTGCAAAACGAGCTCAGCGGCATCAGCTTCTCAACACACACCTGGGGGGACAAGC
596 TGCAAG
CCGCTGAGCTCGTTTTGCAGTGCGTTCCACCAGGCCACGTACAACAAGCAGCCCATGTACCGCAAAGCCATCTACGAGGTCCTGCAGGTGAGTC
597 CCTAGA
ACCACTGAGAATTTGCCGTCTCCGAACCACATGACCCAGCGGGTGCCTTCAGCTGCTCGGCTCCGGCCCGTCATCCACCAAGACACAATGCGGC
598
CCTCGTGACCACTGTGTAATGATTTCTGCTCCTTGGGGCTCCAGGACGGCCGGGGCTTTGGCATTGGGGAGCTGGTGTGGGGGAAACTGCGGG

599
GGCATTCTTGTCCCCAGCATCGGACCCCACGGGCTCAGGCGTGGTAGCCACAGTGGGGGATGCGGGGTCAGTGGGCTGCTGCACAGCAGGAGC
600 CC
CCATAAGAGGAATAAGATACCCAATAGCCTTCAAGAAAGCAGCCAAACCCTATTTTTAAATAAAAAATATATGTACTTTAGTAATTTAGATTTATGT
601 ATCAAA
ATGCAGAATATGCCAACTACTATACTAGAGAAGTGATGTTAATCCTTATTCGAGAATTCCAGTCTCCTGATGAGGAAATGAAAAAAATTGTGCTGA
602 TGTAAA
TTAAAACCTGTGTTTGGTTTTGTAGGTCTTGTGGATGAGCAGCAGAAAGTTCGGACCATCAGTGCTTTGGCCATTGCTGCCTTGGCTGAAGCAGC
603 GATTCT
AGGGCAGAGGCTACAACAGCAAAAGCTCTAGCTGTTGTGTTACGGACATACTCATCCATGTTATCTATATCAGGTCTCATGGTAGAGATCATAGTA
604 AACAAA
TTTGCTGTTGTAGCCTCTGCCCTGGGCATTCCTTCTTTATTGCCCTTCTTAAAAGCTGTGTGCAAAAGCAAGAAGTCCTGGCAAGCGAGACACAC
605 GCTATT
ACTTACTTGATCCCCATAAGCATGACGACCTATGATGATAGGTTTTACCCATCCACTCACAAGCCGGGGGATATTTTTGCAGATAATGGCTTCTCTC
606 TCGTAT
CTAGGTTAACAGGCCACTGACCATGAAGAAGGAAGGGATCCAGACTCGGAACCGGAAGATGTCCAACAAGTCCAAGAAGAGCAAGAAAGGGC
607 CA CACAGGCGTTGCAGACAGGGTCCCCGTTGGCGTTTCGGCGCCATAAGGTGGTGGTTGTCGTCTGACAATTTGCACAACA 608
CAGAAGGCCGGGAGTGTGTCAACTGTGGGGCCACAGCCACCCCTCTCTGGCGGCGGGACGGCACCGGCCACTACCTGTGCAATGCCTGTGGCC
609 GAC
TGACATATGGCCATTTCTGTTTTCCTGTAGCAAAACCAGAAATCCTGACTTACGACAGGCTCGTGAATGGCATGCTCCAATGTGTGGCAGCAGGA
610 ATTTTT
ATGGGTACTCACGTTTCCTTTAACCACATAATTAGAATCATTCTTGATGTCTCTGGCTAGACCAAAATCACAAATCTTTGTGATCCGACCATGAGTA
611 GTCTCT AGACTAAGTCCATTCCTGATACCATCACCTCCCATTTGCCAGACAGAACCTCTGGCTACAAAGCTCCAGAATGGAA 612
ACTCTTTCAAAAGTTATTATGGAATACCCTGTATGAAGGGAAGCCAGAATAGTCGTGTGAGTCCTGACTTTACACAAGAAA 613
TATTCCATAATAACTTTTGAAAGAGTGCCACTTGGTGTCTCCATTTACTTCTGGATGAGCTCTCTCAGGCAGTGGGCTTCCATTCTGGAGCTTTGT
614
AAATTGAAACAAGACCAAAAGGCTAATGGAGAAAGACGTAACTTCGGGGTAAGCCAAGAAAGAAATCCAGGTGAAAGCAGTCAACCAAATGT
615 GTGAGT
TCTTGTTTCAATTTCTTGATCTGAAGGAGCCCAGAGAGAGAAGGTTCACTAACTGTGCGTTTTATTCCTCCATTTTGCAAACACTTGGAATACCCT
616 CTCACA
AATGAGCAGGAGGGGAAAAGTGCTAATTACCATGACAAGAACATTGTATTACTTAAAAACAAGGCAGTGCTAATGCCTAATGGTGCTACAGTTTC
617
TCAGAATCTGAAGCTCTGGATTTTCAGGCCCACTGCAGTTATGTGTTGAAAAACTGGTGAAATCTTTAACTGCATTTTCTTGGGCTACAGAACTC
618 CGGAGA
AATGCCATTAACAGTCAGGCTACTAATGAGTTGTCCTGTGAGATCACTCACCCATCGCATACCTCAGGGCAGATCAATTCCGCACAGACCTCTAA
619 GCAGTG
TTAATGGCATTTATGTGAGATGTGGTTTTCTGCACCGCAATGGAAACACAATCTGGATAATATTGAGACAGTGTTTTTTCCAGGAGTTCACCATGT
620 ACTGTA
CAACTACAACAACAAAAATCAGTTTTTGAGATATGCCCATCTCCTGCAGAAAATAACATCCAGGGAACCACAAAGCTAGCGTCTGGTGAAGAAT
621
CATATCTCAAAAACTGATTTTTGTTGTTGTAGTTGTTCTGGTTTCTGAAAGGAACAGGTATTTAGCATTGCAGCTAGTTTACTGGCATTATCAGCAT
622 ACCACT
TTTTCTGCCACTACCACACCACCACCACCATCACAATTGCTTCTTTCTCCCCCTCCTCCTCTTCCACAGGTTCCTCAGCTTCCTTCAGAAGGAAA
623 GAAGAA
GGTAGTGGCAGAAAAGGAATCCTTAGTGAACACTGAGCTTTGCTTGAAGTAAGCACCATTCATTTCATTTTGTTTTAAATACCGTTCAGAGCTGC
624 GGAACC
CCATCTACACATGTATGCAGCCCTTCTCCGATGCTTTCTGAAAGGCCTCAGAATAATTGTGTGAACAGGAATGACATACAGACTGCAGGGACAAT
625 ACAAGA
AGATGGATTAGGACTCTGGGAAGGTGGTGCCTCAGGTTTACCCTCTATTTTCACTTCCCTTAAAAGTGTTGTGTTACTTTGGTTGGGGTAGTGGTC
626 CAGAGT
GAGATTCTGAAGGGTCGAGACAAGGAGCAAACACGAGATCTTGTGCCCCCAACACAGCACTATCTGAAACCAGGATGGATTGAATTGAAGGCC
627 CTAAAA
GCCCTTCAGAATCTCTTGCTCTTTGTTTCTCATCAACTGCTGGCAGTTGTCCTGTAGCTCTCCACTGCTACCAAAAATTGGTGGGTTATGCTTGAC
628 TCAGA
GGGCTCCCAAGGCAAGCTTACACCCAGAAAACAACACAGCTGGAGCACAAGTCACAAATGTACCAAGTTGAAATGAATCAAGGGCAGTCCCA
629 CAAAAA
AAGCTTGCCTTGGGAGCCCCCCAGGCATGTTGGAATTTCCAGTGTATTGTTTGGAGGTCATTTGATTGGAGAGATTGGGTTGATACTGAAGAATT
630 TTAGAT
ACTGAAAAACTTATGTCCCCAGTGTTGAAACAGCACTTGAATCAACAGGCTTCAGAGACTGAGCCATTTTCAAACTCACACCTTTTGCAACATA
631 CAACCA
ACATAAGTTTTTCAGTTTGGGAATCTGCTCTTTGTTGAAAATGAAATCTAGTGCCACACAGTGACTGCACATGAGCTTTTGGTAAATGGTCTGTT
632 GTTTTT
GATCATTCTTTGGCCAGACTAAAGTGGAAGAATGTTTTCATGGTGAAAATCAGTATTCAAAATCAAGCGAGTTCGAGACTCATAATGTCCAAATG
633 ATCGTA
GATCCTTCTCTTTGCTGATCATTGTTGCTTTGGGGGTGAGGAAAAGTCTGGAGTATTTCCTCTTTATTCTTTATTTGTAATTTTTGCTGCTGTTGCTC
634 TGGGAT
TAGTTTCAGAGAATAAAGAACAGACTACACATCCTGAACTTTTTGCAGGAAACAAGACCCAAAACTTGCATCACATGCAATATTTTCCAAATAAT
635 ACAGGT
ATTCTCTGAAACTAGGTGTGTATTGTTTGAACAAGAAACCTGTATTTTGCATGCACTTGATTTCATGGTCTGACTATAAGGGGAATTTCTACGATT
636 CATTTG
ATACATAACCATGCAAATGTTTTTCCTGTGCCTGACCAGGGAGGAAGTCACACTCAGACCCCTCCCCAGAAGGACACTCAAAAGCATGCTGCTC
637 GAACAG
TGGTTATGTATCAAGTACCTTTGCTGAGCAAGTTGCGCAGCTTGTTGACCAGACATATCTTGGTTTCTATTTTTATATCCCTGTAGAACTGAAGCTT
638 TGAAAGCACCT
CAGATGCACAGGCCAATTAAGGTGGAACCTGGATGCAAGCCACATGCCTGTATGCACACAGCACCACCAGAAAAAAAACATGGAAAAAGGTAA

639 GTGAT
ATACAGGCATGTGGCTTGCATCCAGGTTCCACCTTAATTGGCCTGTGCATCTGACTATGGCAAGACTCAGTTTGGGGTTGCTGTGTTTGCTGCTG
640 CTTAGA
AAATCACAGAAGCAAGTAAAAGTTGAAATGTCAGGGCCAGTCACAGTTTTGACTAGACAAACCACTGCTGCAGAACTTGATAGCCACACCCCA
641
ACATTTCAACTTTTACTTGCTTCTGTGATTTGAGAGTAAGAGCCTTATGGTCAAATAACGACTTGGCGTGAAACTGCTTCAGATGCTGCTCCATGC
642 CATTAT
AGATACTCCTATAAAAAATTTATTGGATACACCTGTCAAGACTCAATATGATTTCCCATCTTGCAGATGTGTAGGTAAGTGCCAGAAATGTACTGA
643 AGCAAATTTAT
AATAAATTTTTTATAGGAGTATCTAGTAATTTGGAAGGTGACTCTATAAAATTATTGAGAACAGAAGCAGCTGTTCTTTTGGTTGGTGTCTTTTCTC
644
ATAATAATCTTCTATTATCTCAACAGAGCAAATTATTGAAAAAGATGAAGGTCCTTTTTATACCCATCTAGGAGCAGGTCCTAATGTGGCAGCTATT
645 ATTAAC
GGGTTTCTTTAAGGTTTGGACAGAAGGGTAAAGCTATTAGGATTGAAAGAGTCATCTATACTGGTAAAGAAGGCAAAAGTTCTCAGGGATGTCC
646 GATAAA
CTGGCCACACCTGTGAGGCTGCAGTGATTGTGATTCTCATCCTGGTGTGGGAAGGAATCCCGCTGTCTCTGGCTGACAAACTCTACTCGGAGCT
647 CGCTCA
GGATGAGAATCACAATCACTGCAGCCTCACAGGTGTGGCCAGCTCGCTCCCGCACCAAACACAGTAGCTTCTCTTCACTGCTGCTTCTGCGAAC
648 CAAACA
CAACCAAAGATTGGGCTTTCCTATCAGTGGCCGCAAAGAGGGGAGAGGCCCTGGGCTTCACTTACTCTTCATTCAAGGCACACCGGCGATTGGT
649 CGGTAA
ATAGCAATGAATTTGGTCTTTTGATTTTTCAGGAGAACTTGCGCCTGTCAGGGGCTGGATCCAGAAACCTGTGGTGCCTCCTTCTCTTTTGGTTGT
650 TGTAAG
TAAACAAACCTCTTTTGGGTCATCCCCAAGCAGCTTAAACTTCCTTGGGATCTTGCTTCTGGCAAACTTACATCCATTGTAGTACATGCTCCATGA
651 ACAGGT
AGGAAGAGAAACTGGAGTCTCATTTGCAAAACCTGTCCACTCTTATGGCACCAACATATAAGAAACTTGCACCTGATGCATATAATAATCAGGTA
652
GAGTGCCGTCTGGGTCTGAAGGAAGGCCGTCCATTCTCAGGGGTCACTGCATGTTTGGACTTCTGTGCTCATGCCCACAGAGACTTGCACAACA
653 TGGGCT
AGTGACCCCTGAGAATGGACGGCCTTCCTTCAGACCCAGACGGCACTCTGGTGCTCTGTGTTCATATTCAATCTGAAAAATAAAAGTGTGTGTG
654 TACACC
CCTTTATACAAAGTCTCTGACGTGGATGAGTTTGGGAGTGTGGAAGCTCAGGAGGAGAAAAAACGGAGTGGTGCCATTCAGGTACTGAGTTCT
655 GAGCCA
CCACACTCCCAAACTCATCCACGTCAGAGACTTTGTATAAAGGCAGAACGTGAAGCTGCTCATCCTCAGGTTTTCCTCCAAATTCTCGATTGTCT
656 AGGGAA
TGAAAAGCTTTCCTCCCTGGAGAACAGCTCAAATAAAAATGAAAAGGAAAAGTCAGCCCCATCACGTACAAAACAAACTGAAAACGCAAGCC
657 TGTAAA
ACTTTTCCTTTTCATTTTTATTTGAGCTGTTCTCCAGGGAGGAAAGCTTTTCAGCTGCAGCTTTCTTGGCTTCTAGTTTCCTTTGTCGGCAAGTCT
658 CTTTTC
ACAGAACTTTTGCGACTTTCAGGACCAGTCATGCAGCAGTCCCAGCAGCCCCAGCCTCTACAGAAGCAGCCACCACAGCCCCAGCAGCAGCAG
659
GGCCCAATCCAGTTAGTCCTTATCCAAACTCTTCACACACTTCAGATATCTATGGAAGCACCAGCCCTATGAACTTCTATTCCACCTCATCTCAAG
660 CTAATC
AGTTTGGATAAGGACTAACTGGATTGGGCCGTCTCATGTATGGATTGGTGGATCCAGAAGCAGAATAAGAGTTGACAGACTCTGTCTGAGGGTG
661 GCTGCT
AGTGGACAACTGCTCCCCATATCTGGGTTCCTATTCTCCCCAGTCTCAGCCGATGGATCTGTATAGGTATCCAAGCCAAGACCCTCTGTCTAAGCT
662 TTACCA
GAACCCAGATATGGGGAGCAGTTGTCCACTGATAGGTTTCCATTGCATTGATATGATGGATATTGGGTATTCTGATTCAAAAGCCCAGGGTAAGGC
663 TATGAA
AGACCAAATGTACATCATGTAGGGAAATTGCCTCCTTATCCCACTCATGAGATGGATGGCCACTTCATGGGAGCCACCTCTAGATTACCACCCAAT
664 AAAAAT
TCCCTACATGATGTACATTTGGTCTAATGGTACAACTGCTGAAACCATCTCCCTGCATATTTTGGTTTCCATAACCTAAGTATTTAGATGTAAAACT
665 GGTAAA
AAACATGGACTATAAAAATGGTGAACATCATTCACCTTCTCACATAATCCATAACTACAGTGCAGCTCCGGGCATGTTCAACAGCTCTCTTCATGC
666 TGACAT
ATGCCCTGCATCTCCAAAACAAGGAGAATGACATGCTTTCCCACACAGCTAATGGGTTATCAAAGATGCTTCCAGCTCTTAACCATGATAGAACT
667 AATTAA
CGAGCAGAGCTTTCTGGATCCTGACATTGGGGGAGTGGCCGTGGCTCCAACTCATGGGTCAATTCTCATTGAGTGTGCAAAGCGTGAGCTGCAT
668 TAGGAA
CGCTCGCTGTCTGACCAGACCTCATCGTTGTCCTCTGCACCAGAAGCCACACCCTGGACTAGTGCCAATGGCTGCTTTTCCTGACCATTAGCATC
669 CACAA
AAGCCAAAATGGCTGAAAAAGCCCGTGAGAAAGAGGAAGAGTGTGAAAAGTATGGCCCAGACTATGTGCCTCAGAAATCCCATGGCAAAAAA
670 AAACTT
CAGCCATTTTGGCTTCCCAAAGAGCCAAGCCATGTTTTGGCTCATTCATGCTCTTATGCTGGTAAAAGACGAGGGAGATCCTGGTGGGGTGATTC
671 TGGCAT
ATATATCTGTTGTAAGGCCCTGTGACCCGAGTGAAGGCATATGGAGATGTAGTTACTGTGGAGTCTGTGGTCACGGACATGGTCCTTTCGGCAAG
672 GGCTCT
ACAGAAATGAAATAAGACGGAAAATTTTTTAACAAATTGTTTAAACTATTTTCTTAAAGAGACTTCCTCCACTGCCAGAGATCTTGAATAGCCTG
673 AAGGAA
AGACAACTGTTCAAACTGATGGGACCCACTCCATCGAGATTTCACTGTAGCTAGACCAAAATCACCTATTTTTACTGTGAGGTCTTCATGAAGAA
674 GGAAAA
TGTCAAGGGATTTCCATTTCTCTTTCGATGCCGACATACTTCAGGGCATCAGCCTGGCTGTATCTGAAACAACAGGAAGGAGATGTCCGCTGGAT
675 ACTTAA
CTTTGCAGTTATGATGGTTAACGGTGATCACAGGATAGGTATTTTTGCCAAGAGAGCCATCCAGACTGGCGAAGAGCTGTTTTTTGATTACAGGT
676 CTCTAA ATTTACCGAATGATTTGCAAAACGAATTTTGTTACCCTTGCGGGTTGCATCCACCACAAAATCTAAAAAGAAAAAA 677

AAAAGAATTTTCTCCTGTGTCTTTCTTTTTAGATTATTTCTCAAGATGAAGCTGACAGAAGAGGGAAAGTGTATGATAAATACATGTGCAGCTTTC
678 TTCAGA
TGATGTGATTGTGTTTTATTCTCTAGCATCTATTGCTGGCACCATCTGACGTGGCAGGCTGGGGGATTTTTATCAAAGATCCTGTGCAGAAAAATG
679 AGGTAA
TCCACAAGTAAGACAGAGGTCAGGGTCACACTCTCGGACAGCCAGGTAGCACGGGCACTGCTTGGTGTTGCACTGTGCTTTGCAGCGGCATCC
680 AGGTTT
CCCTGACCTCTGTCTTACTTGTGGAGCCGCTGACCATTGGGACAGTAAAAATGTGTCCTGCAAGAACTGCAGTATTCAGCGGGGCTCCAAAAAC
681 TTGTTT
ATCAACCCTGTGATCATCCACGGCAGCCTTGTGACAGTTCGTGCCCTTGTGTGATAGCACAAAATTTTTGTGAAAAGTTTTGTCAATGTAGTTCA
682 GCAATT
TCCCGCAGAAATTTGGTTTAATTTTCTTTGTGTTTTTGCAGGTTGTGGGCTGCACACTGCAGAAAGATACAGCTGAAAAAGGGTTAGCATCTTTC
683 ATATCT
TTATTTTGCAGCTTTTCATGCAACACCCAACACTTATAAGCGGAAGAACACAGAAACAGCTCTAGACAACAAACCTTGTGGACCACAGTGTTAC
684 ATTATT
TCTATGTTGGGGGTACATTCAGGAGGAAGTGCGCCTGGGAGCTGCTGTTCGGTGAGTTCTTTATATCTGACATTAACCAAGAAAAATTTAAGTAA
685 AAAACA
CCAACATAGATGGACCAAATGCTAAATCTGTTCAGAGAGAGCAAAGCTTACACTCCTTTCATACGCTTTTCTGTAGGCGATGTTTTAAATATGACT
686 ATTGTA
ATGAAACTGTTTTACATAACATTCCTTATATGGGAGATGAAGTTTTAGATCAGGATGGTACTTTCATTGAAGAACTAATAAAAAATTATGATGGGA
687
GACCTTAGAAAAAGGAGGAAAGGAGGAGAGGCAGATAATTTGGATGAATTCCTCAAAGAATTTGAAAATCCAGAGGTTCCTAGAGAGGACCAG
688 ATCGGT
TAATAGCTCTTTACACGCTGTCTTACACCGCTTGTACCAGAAGACCTTAGAAAAAGGAGGAAAGGAGGAGAGGCAGATAATTTGGATGAATTCC
689 CCTAGA
ATATTACCTTCAGTAGTCTGTTATTCCACAAAGGCTGAGCAGGTAAAGAAAACAGTTTTTCTACTCCTCCTGTCTCTTTCCACATCATCAATTTCT
690 TAGTAACAATATCT
TATCATTCCAGTTAAAGAAACAAAAGCCAAGAGGAAGAGGAAGCTAATTGTTGACAGTGTCAAAGAGTTGGATAGCAAGACAATTAGAGCCCA
691 TACTTT
GGTGGGCCTGATAGTCCTGATTCAGTGGATCCCGTTGAACCAATGCCAACCATGACTGATCAAACAACACTTGTTCCAAATGAGGAAGAAGCAT
692 GGTAAGCATATGAA
TGAGTATCTAATGACTTACAAATATCAAATCTTCATTTCTGATTTTGTGAAACACCATTTGGTTCATATGAGTAGGCCTCTGTAATGTTGGTGAGGT
693 TTCTGA
TTTCTCACAAGCATTTGGTTTTAAATTATGGAGTATGTGTCTGTGGAGACGAGAGTAAGTAAAACTACAGGCTTTCTAATGCCTTTCTCAGAGCAT
694 CAGTTT
AGGCCATTTTAAATGGAATAGACAGCATAAACAAAGTGCTAGACCACTTCCGTCGAAAAGGAATAAACCAGCATGTTCAAAATGGCTATCATGGT
695 AACCAG
TCTAAAAATGCTAAATATCAAGCAAAAGCTTTAACCTGTTTCCAGCAGTGACTTCCACGCATGTGTAGAAAGCTGGTTCACATTCAAAGTTATTC
696 GAACAT
TCTTACTCTGTTTATATTTAGGTTATTTTATCACATTGTTGATTCAGATGAAGTCAGCACGAAGATTTTAATGGAGTTTAATAAAATGAATCTTCCTC
697 TAACAA
AGCATGTGTTAGATTATGTGATAAAAAATAACATTATAAAAGAGAAATACACCTTATCACACAATGACTCACATTGGTTTCAGGATAGGCTGTATC
698 CAGAAA
ACAAAATTTCATTTTTAGGATGCTATTCCTATGATCAGCAAACTGAGGTACAATCCCAGATTTGACAAAGCTTTCAAACATGTGTTTGGAAAGACT
699 TCAACC
TTAAATGATTTGTTAGAATTTATCTGTTTAAAGCTAAGAATTAGTATTACAAACCTTCCAAAGTAATACAGTCCATAGTGAAAGCACGGGCCAGCT
700 AAATAA
TTGTTTATAGGTGACCAAGTCAGCCATCGGGGTGCTCTAACTGGGGGTTATTATGACACAAGGAAGTCTCGACTTGAATTGCAAAAAGATGTTAC
701 CTTGAA
AGTTTACGCACTTGTTTTACCTGTATGAGTCCTGGTGTGGGTCTTCAGGTGGTCGGACCGGGAGAACTTTCGCTGACAAGTTTTACACTGGAATC
702 GGTCTA
CCCCAAGGTGAGAAACCATACCAGTGTGACTTCAAGGACTGTGAACGAAGGTTTTCTCGTTCAGACCAGCTCAAAAGACACCAAAGGAGACAT
703 CTGGCA
CGTTTCTCACTGGTCTCAGATGCCGACCGTACAAGAGTCGGGGCTACTCCAGGCACACGTCGCACATCCTGCAGGCAGAGAGTAAGAGGAAGC
704 ACGTAG
AGACCAGTGAGAAACGCCCCTTCATGTGTGCTTACCCAGGCTGCAATAAGAGATATTTTAAGCTGTCCCACTTACAGATGCACAGCAGGAAGCA
705 TCTTGG
ACCTGAATGCCTCTGAAGACACCGTGCGTGTGTATTCTGTATTGGGCTCCGCAGAGGATGGGCGTTGTGTGGTTATCGCTCTCGTACCCTGTGCT
706
TATTTATTCAACTAATAGTCTTTTAATTTTTTTTAATCAAAGGAACAATATGAATTATACTGTGAGATGGGCTCCACATTCCAACTATGTAAAATATG
707 AAGATT
TTACATAGCTGAAAAAAGTCGCTGTTTAGATCCGTACCTGCCAGGATGTAAGACAGGATGTGCACATGAGGTGTCCACAGGGCTCAATCTTTACA
708 TACATA
TTACTATCTTTTGCTTCTTCTGCAGGAATCAGAAGGTCAGGGCTGTCCTTTCTGCCGATGTGAAATTAAAGGTACTGAACCCATCGTGGTAGATCC
709 CCTGTT
AAATAAATGTGATTTGCCTTCTAGAACAGTAGACACAAAACAGGCTCAGGACTTAGCAAGAAGTTATGGAATTCCTTTTATTGAAACATCAGCAA
710 ATAAA
TGTGTTTCTCCCTTCTCAGGATTCCTACAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGC
711 CATGAG
CTGAATATAAACTTGTGGTAGTTGGAGCTGGTGGCGTAGGCAAGAGTGCCTTGACGATACAGCTAATTCAGAATCATTTTGTGGACGAATATGAT
712 TAATAT
GTGATGTTCCATGTAATACTGGACCAACTCAGCCAAAGTGGCAAATTTCTCCCCTCCATACAGGTCATAGTAATCACCAGTGTTCTGAATCTTGAT
713 AAAATA
TTTCTTTCCAGACACTACAACAACAGGAGTGCAAACTTCTCTACAGCCGAAAAGAGGGTCAAAGGCAAGAAAACAAAAACAAAAATAGATATA
714 AT
AAAACACTGTGAAAAGCAAAGCTTACCATGATGATATTTGCATTGATGTAATCTGAAACAGGCTCATTGGGATCACCATCGTGTAGGACAACCCT

715 GACCAC
TGTCGCTTCTTGCCCACCAGATGACCCACCTTTCTCTCTGATGATGTCAATAAGAATATCAATCACAATGAACGTCCCTGTCCGGCCAATTCCAGC
716 AG
TGACTGCGATATTGACGTTCCCAAAACCATCCAGATGGTGCGGTCTCAGAGGTCAGGGATGGTCCAGACAGAAGCACAGTACCGATTTATCTATA
717 ACTACA
ATAAGTAGGAAATAGCAGCCTCACATTGCCCCTGACAACATAGTTGGAATCACTCATGATATCTCGAGCCAATCCAAAGTCACATATCTTCACCAC
718 CCTGGC
TTACCTGACAGTGTGCACGCCCCCAGCAGGTTCACAATATTCTCGTGGCTTCCCAGCTGGGTCATCATCTTGAGTTCTGACATGAGTGCCTCTCT
719 AAAGA
TTTGCAGGGAAGGTACTAGGATCAGGTGCTTTTGGAAAAGTGATGAACGCAACAGCTTATGGAATTAGCAAAACAGGAGTCTCAATCCAGGTTC
720 TA
CTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTAC
721 TAAATT
ACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAG
722 AATGTT
TTTACCTTTGCTTTTACCTTTTTGTACTTGTGACAAATTAGCAGGGTTAAAACGACAATGAAGAGGAGACAAACACCAATTGTTGCATAGAATGA
723 GGGCCT
AATATCACAAGAACAACTGTTGTACCTGGAGAGTTTAAAAGGATCGTCTCACAAGATGTGCCAAGGGAATTGTATGCACAGCACTTGACCAGGA
724 AGAGTA
ATGTTTAGAGTACTGCTCGACACCCACTGTCCAAACACTTTTCTGTTAGCCTTTCTATTCCAGACTCCTTCTGTGATCTCTTCTGTGCAGCTGAAA
725 AGGTGA
TTACTTGGGAGACTTGTCTGAACACTTCTTCCAGGTCCAAGATGGTAATGGGTATCCATCCGAGAAACAGGACGCCTGACTTGCCGATGCTTCTC
726 AAAGAA
AGCTCCAGTCGGGGGGGTGCCCAGGTCAGTGGATCCCCTCTCCACCCTGGCCTACCTGGTCGCCATGGGCGTGCCTGCCAATGGTGATGGGCTTG
727 GTTTTT
CCAGGGACTAGGCGTGGGATGTTTTTGCAGATGATGGGCTCCCGGAAGACAGTCCCCCCCCAGGATGTTCCGGATAGTTCCATTGGGACTTTTCCA
728 AGGACA
GGGAGGCTGTCAGTGGGGAACAAGAAGTGGAGAATGTCAGTCTGAGTCAGGCCCTTCTGTCTTGAACATGAGTTTTTTATGGCGGGAGGTAGA
729 GTAGGA
TCTTTTAACTCAGGTACTGTGTATATACTTACTTCTCCCCCTCCTCTGTTGCTGCAGATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTG
730 GCCCAG
CTCTTTCCTAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGGTACTAAGT
731 TTTCCA
CTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCCAGTAGATTACCACTACTCAGGATAGGAAAAGAGAAGCAAGAGGCAGTA
732 TAAAAA
CCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGA
733 AGGAGA
GCACAGCAGGCCAGTGTGCAGGGTGGCAAGTGGCTCCTGACCTGGAGTCTTCCAGTGTGATGATGGTGAGGATGGGCCTCCGGTTCATGCCGC
734 T
CCTGCTTGCCACAGGTCTCCCCAAGGCGCACTGGCCTCATCTTGGGCCTGTGTTATCTCCTAGGTTGGCTCTGACTGTACCACCATCCACTACAA
735 G
GGGCACCACCACACTATGTCGAAAAGTGTTTCTGTCATCCAAATACTCCACACGCAAATTTCCTTCCACTCGGATAAGATGCTGAGGAGGGGCC
736 CAGAGG
GAGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTCTGGTTTGCAACTGGGGTCTCTGGGAGGA
737 CTCCAG
CACAACCTCCGTCATGTGCTGTGACTGCTTGTAGATGGCCATGGCGCGGACGCGGGTGCCGGGCGGGGGTGTGGAATCAACCCACAGCTGCAC
738 CATCTT GTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTGAGCAGCTG 739
TTCACTTGTGCCCTGACTTTCAACTCTGTCTCCTTCCTCTTCCTACAGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGC
740
GGATACGGCCAGGCATTGAAGTCTCATGGAAGCCAGCCCCTCAGGGCAACTGACCGTGCAAGTCACAGACTTGGCTGTCCCAGAATGCAAGAA
741 GTAGGT
GTCACAGACTTGGCTGTCCCAGAATGCAAGAAGCCCAGACGGAAACCGTAGCTGCCCTGGTAGGTTTTCTGGGAAGGGACAGAAGATGACAGC
742 GCCGGT
GCCGCCGGTGTAGGAGCTGCTGGTGCAGGGGCCACGGGGGGAGCAGCCTCTGGCATTCTGGGAGCTTCATCTGGACCTGGGTCTTCAGTGAAC
743
GGCTGGGGGGCTGAGGACCTGGTCCTCTGACTGCTCTTTTCACCCATCTACAGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCC
744 CTGAAG
CTTGCAGCAGCCAGACTGCCTTCCGGGTCACTGCCATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTC
745 CATTGG
AGGTTTCAGCTGAGATAGCTCGAGAGAATGTCCAAGGTGTAGTCATACCCTCAAAAGATCCAGAACCACTTGAAGAAAATTGCGCTAAAGCCCT
746 ATAATA
AAACCTCTAAAAAATTCTCTGAGAAGGCATTGCTACGAACCAGGGCAGGTATATGGTCCTTAGAATTCACCCTTGGCCATGGATCCTCCTCCAGT
747 AATAAG
AAATGAAAGCCCAAGAAATTGAAAGAACCCCTCCAACAAACTTTAAAAGGACATTAGAAGAGTCCAATTCTGGCCCCCTGATGAAGAAGCATA
748 GTGCTC
TGGCCAGGAGTTGACATCTTCAAATTTTTTTGGTCCATGACAGTGTTTGTTGAATTAGTAGGCACAAGGCCAATTGGAAGGCTATTATTCAAAGA
749 TTAGCG
CCAGAAGAAAATTGGAAATCCTTTACTTCATCAACACAGGAAAACTGTTTGTGTTTGCTGAAATGCATCTGGGAAATGAGGTTTTTCCAAACTTA
750 GGTGCC
AAAGGATTTCCAATTTTCTTCTGGCCCCTAAGTCTGCGTCGCATGGTGAGTTTAACAGAGTTCTTTCGCTGTGAGGTTGTGGGGAGACTTGCAGC
751 CATTT TCCGGGGGGCGGCCGTAGCGCGCCATTTGCACCCGC 752
GTCCCCTGTGAGCGAGTCCCACAGTGAGGAGACGATCCCCAGCGACAGCGGCATTGGGACAGACAACAACAGCACTTCTGACCAAGCGGAGA
753 TTTTGA
GAGGAGGAGGAGGCAGAGGACAAGGAGGATGATGAGGACAAAGATGAGGATGAGGAGGATGAGGAGGACAAGGAGGAAGATGAGGAGGAA
754 TAGAGA

GTCCTCTGCCTCCTCCTCCTCTTTGCGTTTCTTGTCTTCTTCCTCCTCCTTAAGCCTCTGCTCCTCGTCCTGTTTGTCCTTCATTTGTTTCTCTGCTC
755 CAGGGC
ACCAGTGACAATGACCGCCTGCGCAAGCGGGTGGAACAGCTGAGCCGCGAACTGGACACGCTGCGGGGCATCTTCCGCCAGCTGCCAGAGAG
756
CAAGAACAGCAACGAGTACCGGGTGCGGCGCGAGCGCAACAACATCGCGGTGCGCAAGAGCCGCGACAAGGCCAAGCAGCGCAACGTGGAC
757 TGACAA GTGCGAGGGCGGCGGCGGCGGCGGCGGCTGGTAAGGGAAGAGGCCGGCCAGCGCCAGCTGCTTGGCTTCATCCTCCTC
758 GGCCCCACGGGCGGCGGCGGCGGCGGCGACTTTGACTACCCGGGCGCGCCCGCGGGCCCCGGCGGCGCCG 759
TGCCGGCTGTGCTGGAACAGGTCGGCCAGGAACTCGTCGTTGAAGGCGGCCGGGTCGATGTAGGC 760
GCGCGGGGCCCGCGCCCCGGGGAAAGCCGAAGGCGGCGCTGCTGGGCGCGTGCGGGGGGCTCT 761
ATTTTGATTTGCAGGCTGGGTTTGACCAAAGAAGAGTCATTGCAGCAGAACGTGGGCCAGGAGGAGGCTGAAATCAAAAGTGGCTTGTGTGTC
762 GGTCCA
AAGGAATCTGTACAAAAAACAGGAGTCAGAACAAGCAGGGGTTGCTAAGGATGCAAAATCTGTGGCCTCAGATGTTCCCCTCTACAAGGATGG
763 GAGCAG
TGTTCTGACTCCTGTTTTTTGTACAGATTCCTTCTGGCTCTGGTTCGGAGATCTGGCCGAGAGCGTTTCTTAAAATGCCCATCTCGCTGTCGGGTC
764 GATTCT
GTGGCTTCTCGGATCCAGGCTGAGCCAGACAACTTGGCACGTGCCTCTGCATCTCCAGACAGAATTCCTAGCCTGCCTCAGGAAACTGTGGATC
765 TCCTTT
ATGCAGAGGCACGTGCCAAGTTGTCTGGCTCAGCCTGGATCCGAGAAGCCACAGACTCAACTGGGAATTCGGGACCCTCCAGGTCGGGTGCTC
766 TGCTCA
AACCCAAGGATCAGAAGAGGAAATCCTTTGAGCAGGCGGCCTCTGCATCCTTTCCCGAAAAGAAGCCCCGGCTTGAAGATCGTCAGTCCTTTC
767 AAAAGC
TAAAACTATTTTCTAATTCTTTTTTTGCAGATTCAACTTTCACGTATCAAACCACCCTGGGTGGTTAAAGGTCAGCCCACTTACCAGATATGCCCC
768 TCCTGC
CCACTGCCATAGAGAGGCGGCCACCACTGCCATCGGAGGGGGGGGTGGCCCGGGTGGAGGTGGCGGCGGGGCCACCGATGAGGGAGGTGGCA
769
CCTCTCTATGGCAGTGGTGACCTCTCGCCCCTCGGACCTGCAGAGCACGGGCTTTAATGTCTGCGAGGGTCCTGGCGCCAGTCCAACCCCGGCA
770
AGGAGAGAGGACCTGCCTTCTCTGAGAAAGGAGGAAAGCTGCCTACTACAGAGGGCTACAGTTGGACTCACAGATGGGCTAGGAGATGCCTCC
771 CAGCCA
CAGCTTTCCTCCTTTCTCAGAGAAGGCAGGTCCTCTCTCCTAGCTCTGGACATGGCAGTTCCGGCCTGGGTATGCTCCCCATTTAGAGGATAAGG
772 TCTGAC
GGAAAGTGATGATGAGGAGCAAGGACCCACCGTTCCTGCAGACAATGGTCCCATTCTGTCTCTAGTGGGAGATGATACATTAGAGAAAGGAACT
773 TATGAA
GTCCTTGCTCCTCATCATCACTTTCCCAGGAAGTGGTGCCAGACTCACATTCAGTTCTAACATCCGGATGCAACTGAGGCTGCTCCACTAATCTC
774 GTAGGG
CGAATTAGGGCTTGGTGGCTCATGCCCTCCTATGAGGGAAAGTGATACTAGACAAGAAAACTTGAAAACCAAGGCTCTCGTTTCTAACAGTTCT
775 TGATGA
CATGAGCCACCAAGCCCTAATTCGTCATCAAATGCTCTGTTCTGCAGGCAATCAGTCGGTGAGGATTCAGGTGTGGAACTGGGGGTCACATTTAC
776 TCAAGA
ACAGCTGAGGAGGGTCTAGATCCTCTTGACAGCCTTACTTCACTCTGGACTGTGCCATCTCGAGGAGGCAGTGACAGCAATGGCAGTTACTGTC
777 ATCAAC
TGTCAAATCCCCAGGCAATGCAGGAGGGGTGGGAGCAGCTTTCTCCCACTCCTCTCCAACCTGGGGCTCAACAGATGGTATGTGTTCTCTGGAT
778 ATCATT
TAGTGTCAGCCTCACTGCTGTCCTCCGTGAGGTGACCTTCAAAGTCAGAGGCTGTATCCGTGGACTCACCGTGAGGACTCAGTGCTTCAGAGTC
779 CCACCT
GCATGTCACCATTCACCTTGGACAGTGGGGCAGATTGGTTCCAATTGGGTTTCTCATCCTTGTCCACCGAAGATCCCTTTGTCACTGCAGCTTCT
780 CCGTGA
TCCGCCAAAAGATCCCAGATTCCCTACTGCTGGCCAGTACTGAGTACCAGCCAAGAGCCGTGTGCCTGTCCATGCCTGGGTCCTCAGTGGAGGC
781 TGCAGG
TACTGGCCAGCAGTAGGGAATCTGGGATCTTTTGGCGGACCGCACATACTCGAGACACCCAGCTCTGAGGAGCAACCATCCCATCTGTCCTTGT
782 TGGACA
CATGTAAAGATCCCATGCGTAGCGAGCCATGGCTCTGGTCTTTTGTAAGTGGTACTTGTGGGGATTCTGACATGCTGTCATCGTGGGCTGGTGGA
783 CCTGCA
TAAGGGCTTTGAAGGAGCCTCTTCTGCCAGATAGCTGTGAAACAGGCACTGGTCTTGCCAGGATTGAGGCCACCCAGGCTCCTGGAGCACCCC
784 TTGACT
TGAGGCCACCCAGGCTCCTGGAGCACCCCAAAAGAATTGCAAGGCAGTCCCAAGTTTTGACTCCCTCCATCCAGTGACAAATCCCATTACATCC
785 CAAAGA
CAAGACCAGTGCCTGTTTCACAGCTATCTGGCAGAAGAGGCTCCTTCAAAGCCCTTAAAGAACTGGGGCTGCTTCCATCAACCATGCCACTGTT
786 TGCGTA
GATTCCAAAGAGCAGTTCTCTTCCTTTAGTTGTGAAGATCAGAAGGAAGTCCGTGCTATGTCACAGGACAGTAATTCAAATGCTGCTCCAGGAA
787 AGAACA
AACACCTCGTTTCTCATCTCCAAATGTGATCTCCTTTGGTCCAGAGCAGACAGGTCGGGCCCTGGGTGATCAGAGCAATGTTACAGGCCAAGGG
788 GGCTGC
TTGGCTCTGGGAATGTGGCTGCAACCCTTCAGCGCCCCAGGCCTGCGGACCCGATGCCTCTTCCTGCTGAGATCCCTCCAGTTTTTCCCAGTGG
789 TGTCTG
CCAAGCACAAACTCCATGTCTGGTGGGGTACAGACTCCAAGGGAAGACTGGGCTCCAAAGCCACATGCCTTTGTTGGCAGCGTCAAGAATGAC
790 GCAAAT
TCCTCTTAAGGCAAATGCCGAGAACAGGAAAGCTACTGGGCATAGTCCCCTGGAACTGGTGGGTCACTTGGAAGGGATGCCCTTTGTCATGGAC
791 GCCAGG
GAGAGCCAGGGAAGGGGCTCAGTGAGCCTCTGGAGCCTTCTTCTCTCCCCTCCCAACTCAGCATCAAGCAGGCATTTTATGGGAAGCTTTCTAA
792 ATTATT
TTAATTATTCCTCTAGCTCTCCCACCTTTCCCAAAGGCCTTGCTGGAAGTGTGGTGCAGCTGAGCCACAAAGCAAACTTTGGTGCGAGCCACAG
793 CTGACA
GCAAATGTTCACTGACAGCAGCACGGTGGAAAGCATCTCGCTCCAGTGTGCGTGCAGCCTGAAAGCCATGATCATGTGCCAAGGCTGCGGTGC
794 CTCAAA

GTTATATAAAAAGGTAACAGTTGGCTTACTGGAAGTTGACTTTGTCCACCTGGAACTTGGTCTCAAAGATTCCAGAAGTCAGGACACGGCAGCC
795
AGCAGCGCGGAGCCGGTGGAGGCGTTGGTGCAGGGCGGCAGGATGCGCGGCGGCGAGCGCTCGCCGCCCACCATGGAGAACTGGTAGGAGCC
796
CCGGCCGAGGCGCCGTAGTACAGGTGGTAGGAGGGCGAGCTGGCTTGGAACGGGCCTCCCTGCGCTTGCGACGAGCCGGGGTAGG
797 GCGGCGGCAGGTAGGTGTGGTAGCGCGTGGCCGAGCCCATGGCCGACATGCCGATGCCGATGCCCGA 798
TGTGGTAGCGCGTGGCCGAGCCCATGGCCGACATGCCGATGCCGATGCCCGAGGTGACCGGCGTCGGGGAGTAGGTGAAGGCGCCTGGATAGT
799
CGCCTGGATAGTGCATGCGGGGGTCGGAGATGGAGGGCAGCGCGGGGAACTGGCGCGGGTCGCTGAACGCTGTCAGGTCGGGTGCCGCTGCA
800
CACCCAGCAACGCCCATTTCACCTGGACGTGCCAGCGGCATGACAACCCTCTCTGCAGAACTTTCCAGTCGACTCTCAAGTAAGCCACTTGAAA
801 TGGAAG
TTTACATATAATTGACCTTTCTGATTCTCTTCAGATACAAGGCAGATCCAACCATCCCCACCGTGGTCCTACGATCAGTCCTACCAATACCTGGGAT
802 CCAGCA
CCAGTTGTGGGTGGTGGCCCAGGTGCAGGAGAGGCGGGCAGTGGGCTCCATCTGGTACTTACCCTGCATCTGACTCTGAGGCTGAGGGTTAAA
803
TTCAGGGAGGCACGAGGGTTGGGCGTGGGGGCTGGGTGGTGTGGGCTGACCCTCATGGCTGTGCGCCGCAGCTGCTCCAGTTCACTGAGCCGC
804
CCCATCCCCTCCCCTCCCTGCTCCCCACAATAGGACATCGGCAGAAACTAGATGATCAGACCAAGCCCGGGAGCTTGTCCTTTTCCGAGCGGCTC
805
ACAGGGAAAAGCTTCACTCTGACCATCACTGTCTTCACAAACCCACCGCAAGTCGCCACCTACCACAGAGCCATCAAAATCACAGTGGATGGG
806 CACTTG
TTTCAAGCATAGTTTTGACAGATAACGTACCTCTTCCACTTCGACCGACAAACCTGAGGTCATTAAATCTTGCAACCTGGTTCTTCATGGCTGCG
807 AGTTTT
AAGTGTATGTATAACATCCCTGATGTCTGCATTTGTCCTTTGACTGGTGTTTAGGTGGTGGCCCTAGGGGATGTTCCAGATGGCACTCTGGTCACT
808 TACTCG CTCTCCGGGCCAGTACCTTGAAAGCGATGGGCAGGGTCTTGTTGCAGCGCCAGTGCGTAGGCAGCACGGA 809
TAGGCAGCACGGAGCAGAGGAAGTTGGGGCTGTCGGTGCGCACCAGCTCGCCCGGGTGGTC 810
AAAAGGCTGTGATTGACTTGAATAACCGTTGGTTTAATGGACAGCCGATCCACGCCGAGCTGTCACCCGTGACGGACTTCAGAGAAGCCTGCTC
811 GGAGTG
TCGGTTTATTGTGCAACCGAGAGCACCTGTCTCCATGACGACATGCTCCAATTTTGAAATAAAATGAACAGTTGACTCTGTAAGGGAAAATGAG
812 CAAACA
ATGACTATGACCCTGACGCAAGCCTGGAGTACAGCGAGGAAGAAACCTACCAACAGTTCCTAGACTTCTATGAGGATGTGTTGCCCGAGTTCAA
813 AGGTGG
CATCCCTCCTGCACTGCTCCATTCCAAACGTCGTAAACATGCTCTTAATAAGAAGGGTAGGACTGGATGTTGGGAAATTATGTTTACGTGAACATC
814 TCACTA
TGTGACAAATCAGGAAGACATCCACAAGCAGAATACTTACGACTGGTACTGAACATATACATTGCCCCTCAGGTGAGGTTCCAAATTGCAGCTG
815 CATAAA
AAAGGGAAGAAGAATGCCAAGCAGCCCTTTCTCTGTTTAACGGACGATGGTATGCAGGACGACAGCTGCAGTGTGAATTCTGCCCCGTGACCC
816 GACAAAGTGATGATTTT
GCTCACCAGTAGTTGTCTGAGGCCAGATCACTGGGGTGGAGCCACTCTACAGAGGAGCCCAGCAGAGTCTGAATTTCGTTCGTGAATTCCACCA
817 TTGAAG
AATTTCCACGTTTGGAAAATTGCAGCGAAATATGCGGGAGGACATTTTCAATTTCTTAAGGACATCCGAAAGCAGTAGCCAGTTTCGTGGCCTAC
818 TTTCCA
GCATATTTCGCTGCAATTTTCCAAACGTGGAAATTGTCACCATTGCAGAGGCAGAATTTTATCGGCAGGTTTCTGCAAGTCTCTTGTTCTCTTGCT
819 CTGAAA
TCATACCTGTTAAGAACTTTTCCATAAGTTCACTGTGGGTCATTTTCATGATGGTTCTACCTGAGTACGTAGCCAAGGTGGGGTCAGCACCATAAC
820 AGTGAT
AAAGGAGACAACTGCTTTATAAGCAAGTGTGGCTTGCATGAGCATAATTCTATTGCGCCTCTCTTCCTAGGCCTCTGCACGATGCTGTTGAGAAC
821 TTCTCT
CATTGGCATTGGGGGCGGGTGATGCGGAGGCTGGGCGGCCTGCACTCGACACTGACCCTGAAACGTTAGTGATGACAGCATCGGTGCCGCCCAT
822 GTGGTA
TTCAGATCTATAGATAGCACAACCATTTCCTGGAGGAGATAGTGTTTCTTTCGGAATCTCACTTCCGGAGAGCACTAAGCCACTTCCAGCCCTGC
823 CTTTTT
ATCTATAGATCTGAAATCATCAGCACTGCTCCCTCATCCTGGGTGGTGCCCGGGCCAAGTCCTAACGAAGAGAACAATGGCAAAAGCATGTCGC
824 ATACCA
CCCCTTCTGTCCTCGCAGGTTAATCCCCAGAGGCTCCATGGAGTTCCCTGGCCTGGGGTCCCTGGGGACCTCAGAGCCCCTCCCCCAGTTTGTG
825 AGAAT
AGGCCTACAGACACTCCCCAGGTAACTCCATTGAGTGGCTGTCTTGGCATTGGCTGAGTGCTGTTGGGGTTGCCATGGAGATCCTTGGCTAGGTC
826 GAAATG
CTGTAGGCCTCAGCGTCCCTGTAGTAGGCCAGTGCCGCAGCTGCAGCGGTGGCTGTGCTCGGGGCAGTGGAGGAAGCTGCTGCATCCAAGCCC
827 GATTCT
AACAGGGCTGAAGGCCAGGCCCCACCTGCAGATTCAGGGCTAGATGTCGTGTCTTGGTCTGTTCTAGGTCACTCTGGGAGTACTTGAGCCGCAT
828 CCTGAC
ACTGCACCTGACGCAGCTCTGCCTCTTTCCGTTTTGCCTTCATCTGCTCCTGAAGGGAACAAGAAAGAAGGGCTAGGTGGTAAGGTGGTGGCTC
829 AAAACA
ACCTAGGCTTAGGACTCCCACTGCTAAAAACAGCACTGCCTGTGGCTTACTTTCAGCTCCTCTGTCAAGCGCTCCTTCTTCTCTTTCAACTTGTC
830 GCCTTG
GGCCTTCAGGTCACTGGCCCCACCAGAGATCACTCCTGACTTCTGGAATAGGGTTCCATCCAGTGCCACTGTCTACACACAGCAGGGGGAAGAG
831 GAATCT
GAGAAGCTGAACAAATGAATCTCCAGTACTGAGCCTGTCCAGCTCCAGCCTGGGCAAGGGAATCCACACCTTGTGGCGCTGGTGGCCTCCAAA
832 GTCACA
CCAGCTCCCGGAGTTTCTCATCTGTAGGCTTCACCTGTGGGGAGAAGCTCAGTCAGTGGCAGAACACAAACAGGGAGTACTAGAGGAGGGGCC
833 ACAAG
AACTCCGGGAGCTGAAGGGGGCCAAGCTAGTGATTGATGTGATTCGCTATGAGCCACCTCATATCAAAAAGGCCCTGCAGTATGCTTGTGGCAAT
834 ATGCCC

TAATGGCATCCATGTTCTTGCCCAAAACCTTGGTTACAGCAATCTGATACTTCTTTTGTGTGGGCTGGCATAGGTCAATGAGGCGGCCGTACTGAC
835 TATGAA
TGGATGCCATTATTGTGGACTCGGAGAAGACAGGCCGGGACTGTATTCAGTATATCAAGGAGCAGCGTGGGGAGCCTGAGACCTTCTTGCCTCT
836 GGGATT
AATATGGATAATACACAAAGACAATATGAAGCAGAACGGAATAAAATGATTGGAAAACGAGCCAATGAGAGGCTAGAACTCCTGCTACAAAAGC
837 TATTTA
CCAATCATTTTATTCCGTTCTGCTTCATATTGTCTTTGTGTATTATCCATATTAATGCTAAGATTTAGTGCCACATTCACCAAAGCTGTCATCAACTTC
838 AAGTAT
AGCTTCAGGAAAATCAAGATGAAATAGAAAATATGATGAATGCAATATTTAAAGGAGTGTTTGTACATAGATACCGGTAAGTTGTGACAGTTTTT
839 TACTCA
CCCATTCAGTGATGCGATAGCTGAAATTCGAGCTATTTGCATTGAAGAGATTGGCATTTGGATGAAGATGTATAGTGATGCCTTTCTTAATGACAG
840 TATGCATGATAAGGT
TTTTAATGCATTGTCTCATCTTTTTTTTTTTTTTTTTTAGCAAGGTGAAGTAAGACTCAAATGTCTTACTGCTCTACAAGGGCTTTATTATAACAAA
841 TTTTTA
ACTTTTTACCAGTCGGTTCAAGGTTAGTATTACTTAAGAATTTACAAATAACTTGTCATTTGCAAACACTTTTCTCTTGCTTTCCTTTTAAAAATAT
842 AGAATT
TAAAAATATTTTAATTTTTTTGTCCTTAGGATAGAATTGTGTCTATGACCCTTGACAAAGAATATGATGTTGCAGTACAAGCAATAAAATTACTCAC
843 TTTGTT
ATATATAGATTTACTTTTTGTAGAGAAATTCTCCAGCTGCTACTGCTACTGGCCGGTGAGCTGAATAAACCAGATGATAGACATTTTCACAATCTTC
844 TCCTAA
GATTTCTTTTCAAGGTATGTTTACTTGGAAAAGTTCATGACCTTTCAGATGTCACTCCGAAGAGAGGATGTGTGGCTTCCACTGATGTCTTACCGA
845 GATGAC
TTACTGAGTGAAAGCTGCATGCCCTCAACCACTTTCCGTTTTCCTGTAGATGGTTTTGATTTTTTACTCCGTACTGTTGACCCCCGGCTGCTGATTC
846 TCATCA
AAAAAAGGGCCTACAAGACAGCGCAAATGTGGCTTTTGTAAGTCAAATAGAGACAAGGAATGTGGACAGTTACTAATATCTGAAAACCAGAAG
847 AGTATA
CAGATATTAGTAACTGTCCACATTCCTTGTCTCTATTTGACTTACAAAAGCCACATTTGCGCTGTCTTGTAGGCCCTTTTTTCTGTTCAACTGAGCT
848 TAGAAT
ATAAAGCTCAAATACGAGAGAAACCTTCACAAGGAATTTACATGTAATTATTTAACTTCTCTTTAAGTTTTTTTTTTAACAATAATACTTTCTTTGG
849 TTCAAA
TTTATCATGCAATGCACAGTGGTAGTGGTATGTCCTGTGACATGTTTTCACATCACAACCAATTGTTGCTCCAGGACAATGGCACAAAGAACACA
850 TTATTA ATTTCTTCATTTTTTATAGGGTCTATTGCCGAAAACACAAGAAAACTGCACATAACTCCGAAGGTACATCATTTAG 851
AATACCGATAGCATATTTTCATGATTTTTTTTAAGTTCGTTTTTTCTTTTACATTTGCAGAGAGATAGGTCTCCACACAGAAGCAGCCCTAGTGACA
852 CATGTA
TTGGGCTTAAAAGAACCATGCTTACCATGCACTTATAATGGGCAGCTGCCTTCTTGGCATTAAATATATGCAGTTTTCCTCGTGCTTCATTTTCTTC
853 ATTTAG
GACCATTCTTTTTCCTCGTTTAATCTCCTGAAGTACAGTTTTAATATCAAAGTCTCCAAATTCTGCTCTTGATGTTGTTGTGAGCTGGACTGTGCCA
854 A
TGTTTTCTTACTTGTAAATTCCTCGTGACATATTTTCAATGTATTTAGCTTTGTCTTGTACTCCACAGTGGTAATGGTAAGTCTTAACACAGGCTTT
855 CAGGCT feature_ feature_ SEQ start_ stop_ probe_ failure_ mip_sequence ID position position strand flags
TCAGACTTCGGCCCACCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGTCCACCGCCAGTCTCCTGCCTGG 856
43814931 43815035 - 0
GTGTGGAGGGTAAGGGGGCAGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGATGGCAAATACACAGAGGAA 857
115256486 115256577 + 0
GTAGCCCGCTGACCTGATCCTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAACAGGTTCTTGCTGGTGTG 858
115258743 115258748 − 0
ACTGGGAAACCAAATACCCTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTACCTCAGTTTGCCCCCATGTC 859
25457148 25457289 + 0
GCTGAAGGAGTATTTTGCGTGTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCACCCTGCCCTCTCTGCCT 860
25457144 25457294 − 0
CCCGGGTTGTGCTGGCATCTGGCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCTCTTTTCTCCTCTTCAT 861
25458573 25458698 − 0
GCAGGGAGAAGGAAGGGCAGGATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTTATCCAGGTTTCTGTTGTT 862
25459792 25459882 − 0
GCTCCTGGGCCTGGGGGGCTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTGTTTCATGCTCCTCCTTGG 863
25461992 25462092 − 0
GCGCATCATGCAGGAGGCGGTAGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGTAGAAGCCATTAGTGAG 864
25463166 25463483 + 0
GCGTTAGTGACAAGAGGGACATCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCCCCAGCTGATGGCTTTCT 865
25463166 25463483 − 0
GCTGTCCAGGGACAGAGGCAGACANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTGGAGGGGACAGGATGGTA 866
25463503 25463605 + 0
TTGGAGCCATCTCCCTGGCACCCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCTCACACACCTCCGAGGC 867
25464533 25464580 + 0
GTCCATGCTGTGGGGCGCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTGAAGGACTTGGGCATTCAGGT 868
25464429 25464508 − 0
GTGAGGGGTGCAGGCCCAAGAGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTGGGTGGGAGCTTGGGAC 869
25466760 25466845 − 0
CTTCCTTAATGGCTGCCTGGGCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCCAGCACTCACAAATTCCT 870
25467088 25467139 + 0
GCCTGGGGCGCGGTCTCGAGCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGGGTACCTACGGGCTGCTGC 871
25467018 25467212 − 0
CCCCTGGAACTGCTACATGTGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTCTCCTCTGCTCACTGGGTCT 872
25467018 25467212 − 0
GCTGTTGTGGCCTCCAGTGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTGGTTTCTGACCCTTCCCGCTG 873

25467407 25467525 − 0
GGTGAGTACCACCGAAGGGCCTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCTGGGTGGGTGTGCTCCT 874
25468119 25468204 + 0
TGCCGTTGAGGCCGGCCCTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATCCCCTCCCTCTGCTTTCCAG 875
25468119 25468204 − 0
CCGCGCCTGCTCCTCGGATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTCCTAAGTGCCTCTGCTACTCT 876
25468879 25468940 + 0
CACATGTCCGTGTACACTTCTTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCTGGTGCCACCCTCTCCA 877
25469025 25469183 + 0
TTCCCCCACCCTCCTTACAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGGCTTTTTGGCTGGTGGAGGTGG 878
25469025 25469183 + 0
GTGACACGCCAGGGTTGGGGTTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTAGGGCCAGAAGGCTGGAAG 879
25469487 25469650 + 0
GGCTGCCAAGGCCTCCACAGAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGATTGAATGGGCCCTGGGGGG 880
25469487 25469650 − 0
CACCCACCCCATGCCTTGCAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGACCTCGTAGATGGCTTTGCGGT 881
25469917 25470030 + 0
GCACTAGGAGGCCTGGAAGTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGTGTGTGTTGAGAAGCTGATG 882
25469917 25470030 − 0
TTCCCCCACACCAGCTCCCCAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTACTGCCAAACCCCACAACTT 883
25470458 25470621 + 0
GTGTCTTGGTGGATGACGGGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATGGGGGGATCAGGGTGGCAGGG 884
25470458 25470621 − 0
CGGGCCCCTGGTTTTCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCTGGCTCGTCATCGCCTGCTTTGGT 885
25470974 25471055 + 0
AGGTAATTGGTGGATTTACCTTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTAGTTGGCATATTCTGCAT 886
198266442 198266624 + 0
CTGGATATGTTTCATGGTTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGGTATCTTATTCCTCTTATGG 887
198266442 198266624 − 0
GTGTTAAAGCCTTTATGGAAGGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTAGGTAATGTTGGGGCATAG 888
198266810 198266849 − 0
GAAAGGACAGTCATGAGTTGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGGCAATAAAGAAGGAATGCCC 889
198267481 198267491 + 0
CTTATGGGCTGTGCCATCTTGCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCGTAACACAACAGCTAGAGCT 890
198267342 198267373 − 0
GGTGCCATTTGGTGATTTCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAAAATCACATTATTGCCAACATG 891
209113112 209113210 + 0
TGCAGGAGAAGTCATCCCCCTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCTGAAAACTGGTGGTTGCCT 892
128200060 128200163 − 0
GGTGCCGGCTCTTCTGGCGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATTGTGCAGCTTGTAGTAGAGGC 893
128200661 128200789 + 0
CACTCATCAAGCCCAAGCGAAGACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTCTCTCCCTGTTCCCCTG 894
128202700 128202851 − 0
GTCCAGGAACTGAGCAGAGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTTGCTGAGGTTTTCCAGCACTC 895
55589745 55589869 + 0
GTGAATACACTATTAGGTTGGAGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCAGGACTGTCAAGCAGAGA 896
55599285 55599349 − 0
GCCCACTGCCTGAGAGAGCTCATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCAACCATGTTGAGGGCAAC 897
106155099 106155185 + 0
GTAGAGGGTATTCCAAGTGTTTGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAATGGAGACACCAAGTGGC 898
106155144 106155319 + 0
GTTCTGTCTGGCAAATGGGAGGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGCTTCCCTTCATACAGGG 899
106155144 106155319 − 0
TCTGTAGCCCAAGAAAATGCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTCTGGGCTCCTTCAGATCAAG 900
106155044 106158550 + 0
CGACTATTCTGGCTTCCCTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTCTTTCTCCATTAGCCTTTTGG 901
106155044 106158550 − 0
TGGAACACACACATGGTGAACTCCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCAGAGCTTCAGATTCTG 902
106155646 106155733 + 0
CATTTGGTTGACTGCTTTCACCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACTTTTCCCCTCCTGCTCAT 903
106155044 106158550 − 0
GTGAGTGAGGCCTGTGATGCTGATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGAAAACCACATCTCACATA 904
106155044 106158550 + 0
GCACCATTAGGCATTAGCACTGCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACTCATTAGTAGCCTGACTG 905
106155044 106158550 − 0
CCAGCAGCAATTTGCAAGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTACCTGTTCCTTTCAGAAACCAGAA 906
106156091 106156165 + 0
GCAGCTGGCTTTGGAGGCAGCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTTATTTTCTGCAGGAGATGGG 907
106155044 106158550 − 0
CACCACCACTACCCCAACCAAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTCAGTGTTCACTAAGGATTCC 908
106155044 106158550 + 0
TGAACAGAATTCTTCACCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCAATTGTGATGGTGGTGGTGGTGT 909
106156165 106156274 − 0
CCAATGTCAGAACACCTCAAGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCACCTTCCCAGAGTCCTAAT 910
106155044 106158550 + 0

GCTTTTTCCTTCTGAAGGAAGCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAGGGCTGCATACATGTGT 911
106155044 106158550 − 0
CGTAATGAGGCATCACTGCCATCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGATGAGAAACAAAGAGCAA 912
106155044 106158550 + 0
CCACAATGGAACAGTCATTGTCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCGTGTTTGCTCCTTGTCTCG 913
106155044 106158550 − 0
CCCTCACACCAGGTGCACTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGGAAATTCCAACATGCCTGGG 914
106155044 106158550 + 0
GGGATTCCGCTTGGTGAAAACGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTGTGTTGTTTTCTGGGTGT 915
106155044 106158550 − 0
TCCCAGAGTTCACATCTCCCTCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAACAAAGAGCAGATTCCCAA 916
106155044 106158550 + 0
GGAACTGGAGATGTTGGTCCACTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTGCTGTTTCAACACTGGGG 917
106155044 106158550 − 0
GAAATTCCCCTTATAGTCAGACCATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATGATCAGCAAAGAGAAG 918
106157293 106157510 + 0
GGTTGTGTTTGTGCTGCCTGTTTATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTAGTCTGGCCAAAGAAT 919
106157294 106157418 − 0
GCTTTCAAGAACAGGAGCAGAAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTGTTCAAACAATACACACC 920
106155044 106158550 + 0
GACATTATGAGTCTCGAACTCGCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGATGTGTAGTCTGTTCTTT 921
106155044 106158550 − 0
CAGCAAACACAGCAACCCCAAACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTGCTCAGCAAAGGTACTTG 922
106155044 106158550 + 0
GTGAAGAAGATCTTGCTTTGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGCACAGGAAAAACATTTGCA 923
106157742 106157861 − 0
AATGTGCAGCAAAAGAGCATCATTGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACTGAGTCTTGCCATAGT 924
106158077 106158150 + 0
GCAGCATGCTTTTGAGTGTCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTTTTCTGGTGGTGCTGTGTGC 925
106155044 106158550 − 0
CTTCTTCAGAAAAGACACCAACCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGACCATAAGGCTCTTACTCTC 926
106158273 106158480 + 0
CACAGCTTGCAGGTGGATTCTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTCAAAACTGTGACTGGCCCTG 927
106155044 106158550 − 0
CTTCAGATATGGGATTTTCCTTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGTCACCTTCCAAATTACT 928
106158273 106158480 + 0
GCTGGGGTGTGGCTATCAAGTTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGTCTTGACAGGTGTATCC 929
106158273 106158480 − 0
GCAAAGGCACAGGGCAGATTAACGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTAGTATAATTGAGGTCTAAA 930
106162468 106162605 + 0
GCCTTTGGTCTTAAATCTTGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTGTATGTGTGTGTGTTTCTGT 931
106163988 106164088 + 0
CCAATCGCCGGTGTGCCTTGAATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTGTTTGGTGCGGGAGCGAG 932
106164823 106164875 + 0
CCCCCCACCCCAACCAAAACAAAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCGGGATTCCTTCCCACACCA 933
106164725 106164940 − 0
GCTCCGAGTAGAGTTTGTCAGCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCACGCTGAACTCTCTTCCTTT 934
106164725 106164940 − 0
TTTGCCAGAAGCAAGATCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGCACAGCCTATATAATGCTATCC 935
106180773 106180933 + 0
TTCTGGATCCAGCCCCTGACAGGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGCGATTATACATCAGGAAG 936
106180773 106180933 − 0
GGCAGCAATTGTAACAACTTACTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGAATTATTCACTTTATAC 937
106182914 106183008 + 0
GAGGACAGCTTAGCAGCTGTTGAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAATATGAACACAGAGCACCA 938
106190761 106190911 + 0
GAAAACTCACTAGTATTTAGACCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGCACAGAAGTCCAAACATGC 939
106190761 106190911 − 0
GTCAAGACTTGCCGACAAAGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGATGAGCAGCTTCACGTTCTG 940
106193714 106194080 + 0
GTAAGACATTACAGCCTCAACTACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTTTCTCCTCCTGAGCTT 941
106193714 106194080 − 0
GCATTTGTAGATAAATGTGTTGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAGCCAAGAAAGCTGCAGC 942
106193714 106194080 + 0
GCCGAAAAGAACTCAGTACCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTTTTGTACGTGATGGGGCTG 943
106193918 106193967 − 0
CCCCAGCAGCAGCAGCCACANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTCTGTTCTCTCTTACCCTGTCC 944
106196203 106196292 + 0
CCATGAACCCTTACCCTGGGCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCACCAATCCATACATGAGAC 945
106196203 106197683 + 0
GCTGGGGCTGTGGTGGCTGCTTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGATATCTGAAGTGTGTGAAG 946
106196203 106197683 − 0
GCCAAGGTTTGGAAATAGCCAGAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAATGCAATGGAAACCTATC 947
106196203 106197683 + 0
CCTGCAGCTTGAGATGAGGTGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGCTGAGACTGGGGAGAATAG 948

106196203 106197683 − 0
GGTGAACATCATTCACCTTCTCACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTTTCAGCAGTTGTACCATT 949
106196203 106197683 + 0
GTGTATGGATGGGTGGTAGACTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGTGGGATAAGGAGGCAATT 950
106196203 106197683 − 10
GCTTTCCCACACAGCTAATGGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCACCCAATCTGAGCAATCC 951
106196203 106197683 + 0
GTGATGCTAATGGTCAGGAAAAGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATGTTCAACAGCTCTCTTC 952
106196203 106197683 + 0
TCACCCCACCAGGATCTCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAACGATGAGGTCTGGTCAGACAG 953
106196203 106197683 + 0
GCAGTTCTATCATGGTTAAGAGCTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCAGGATCCAGAAAGCTC 954
106197125 106197218 − 0
CAGAGCCCACTTACCTGCGTTTCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACATGGCTTGGCTCTTTGGG 955
106196203 106197683 + 0
GCAGCTCACGCTTTGCACACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTCCTCTTTCTCACGGGCTTTTT 956
106196203 106197683 − 0
GAAGTTTCATGTGGCTCAGCAGGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACAAAAGGGGGTGATATCAT 957
106196203 106197683 − 0
CCACAACACTTCATAGACATCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGACAGCCAGATATCAACTGTT 958
170837531 170837568 − 0
CAGTAGATCTCATTTTCCTATCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCATCCACAAAATGGATCC 959
140453092 140453191 + 0
CACAACAAAGCCTGCTGAAGATAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGGGGGAGGAGGTAGCAGA 960
148504736 148504801 + 10
GGGCTTTTTCTACTGGATTGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTCACTGACACCAGTGTGTCT 961
148506160 148506251 − 0
GTAAGCACAGCCCAGTGAATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCTACCTTTTGCATAGCAGTTTGG 962
148506400 148506485 + 0
GCTGGGAGGCAGTGAGTTCCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTCAGGCTTGATCACCTTTATCC 963
148507415 148507487 − 0
GGCACTGATAACCTGTATTCAGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTCACCCTCCTTTTTTGA 964
148508716 148508816 − 0
GGAGGTTCTTCACTCATCACCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTACTGTCCCAATGGTCAGCGGC 965
148511048 148511235 + 0
GTAGTTAGCTATTTAGTGATGCAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGGCTGTCCGAGAGTGTGA 966
148511048 148511235 − 0
GCATGAGAACTAAATAGGTCTTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTCTAACCATGTTTACAACT 967
148511999 148512138 − 0
GCTTTGTTTTCATTTGTTTTAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTCTCTGTTGGATTTGTAGCT 968
148512570 148512669 − 0
GCAGAGGGTACTTGAGAGGACTTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTATTAGATTCTTTGTTTCAT 969
148516685 148516783 − 0
GTTTCTAAAAGGTTTCCATGTGTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAGATTTAGCATTTGGTCCA 970
148523544 148523730 + 0
CGTTTTCATTTTCTATCTTTGTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACTTCCTCCTGAATGTACCC 971
148523544 148523730 − 0
GAGCCATATGCTTCTTCTCTTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTTTTCTTTTAGGTGGAAG 972
148526828 148526931 − 0
TTGTTCTGTTGGAATAGTTCCTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTACACCGCTTGTACCAGAA 973
117864785 117864951 − 0
GAGGACCAGCAACAGCAGCATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAATTTTTCTTTTTTTTTTTTT 974
117864785 117864951 − 0
GAATAATCACTAAGTTGGGCTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAGTAAAAATTCTGCAAACT 975
117866482 117866595 + 0
GGATCTGGCACCGCCCACCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAGGAAAATGATCTTATTTTTTAT 976
117866604 117866713 − 0
CCTTTAGATTTATACAGCATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTTTTTTTTTTTTTTTACAGTG 977 117868403
117868530 − 0
AGACTAGAAGGTTTGATTTATCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGGACAAAAAAGACAGTAA 978
5069950 5070055 − 0
CAGGATCACAGCTAGGTGTCAGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGCAAGTATGATGAGCAAGC 979
5073739 5073781 + 0
CTTTCTACACATGCGTGGAAGTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTCATTTCTGACAACTTAC 980
112350168 112350333 + 0
GCTGGTTTATTCCTTTTCGACGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTAAGCTATTCTTATTCCCTCT 981
112350168 112350333 − 0
GTTAGATGTCAGGGATACAGCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCTGAGTACCAATAAAGATTTG 982
112350747 112350893 + 0
AGTAACCTCTCCAGGAAGATTCATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTGTATAGTGCCTGGGCACT 983
112350747 112350893 − 0
CAGCTGGCCCGTGCTTTCACTANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGTGTTGTGATCTCTCTGTTG 984
112352828 112352984 + 0
GAGTCTTTCCAAACACATGTTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCGCCCAGCCAGATTATATGTT 985
112352828 112352984 − 0

GCAAAGCTCAATGAAAACCTGCGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACAGACCTATTACATATGTT 986
112356153 112356245 + 0
GCCTCGGCCCTAACAATGTGGGCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAAAATAAATGTGAAGAAA 987
32413516 32413615 + 0
GCTGTGTTCCCTTGGGCTAGGGTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCAAATAGAATATGTGTCTT 988
32414197 32414308 − 0
GTCTTGAGGGAGAGTGAGCACTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGTAAGCACACATGAAGGGG 989
32417797 32417956 + 0
GCAAACATGGTTCAAGAGCTCCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCTTGTACGGTCGGCATCTG 990
32417797 32417956 − 0
AGGCTCAGTGTGGCTCACAGTCGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGGGCCTGTCTGTGTGCTC 991
32421491 32421591 + 0
GAGCCCTGTGGACACCTCATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGTTAACATTTATAATTGCAGT 992
119148874 119149011 + 0
GTTGGAATGTGGAGCCCATCTCACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTACCGAATTTTCCAAGGTTA 993
119148874 119149011 − 0
GAGGCAAGGAGCAGAGGGAGCTCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGTATTTTCAGATGCATCTG 994
119149218 119149335 + 0
CACAGATCTGTTTTCTGCAAAATCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTACCTATGGTCCTAGTAGG 995
25378562 25378647 − 0
GACTGGGGAGGGCTTTCTTTGTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGCACTGTAATAATCCAGAC 996
25380275 25380285 − 0
GCATATTACTGGTGCAGGACCATTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATAAGGCCTGCTGAAAATGA 997
25398211 25398286 − 0
GTCCATTGGAAAGGGAGGCAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCATTCTTCTCTTTTAATTGCCC 998
112888139 112888229 − 0
TCCGCTCAGTAATAGTCACTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCACGTAATAATATTGACTTTTC 999
112910747 112910847 + 0
GGTCACATAAGTCCTGGACTGCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGCTAGAAATGTATGGTCAG 1000
112915440 112915540 − 10
GGACAACAGAATCATTCATGGGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATAAACTAAAAACAGAAAC 1001
112926228 112926328 − 0
GCGCAGGATTGAAGAAGAGCAGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGATGTTTCCTTCGTAGGTGT 1002
112926848 112926919 + 0
GGCCAGGTCTCTGTGAACACACTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCACAAAATAGCCGTATAAAA 1003
28592612 28592705 + 0
AAGGAGCATTAAAAATGTAAAACTCAAGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTCGTGGAAGTGGG 1004
28602314 28602426 + 0
GTGGAAGGACAGCAACAAAGATGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCACGTACTCACCATTTGTC 1005
28608022 28608130 − 0
GCTTCAGAGATGAAATGATGAGTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATTCCATTCTTACCAAACT 1006
28608200 28608360 + 0
TCTGCAGCATTTCTTTTCCATTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAAGCCAGCTACAGATGGT 1007
28608200 28608360 − 0
GCAACAAAAGAGTGTCACTCAGCGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGAGGAAAGAATAATGAATT 1008
28608437 28608546 + 0
CTGCTCGACACCCACTGTCCAAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTGGGGAATTCCTGATGGTGG 1009
28609629 28609815 + 0
GCTGTCATCAGATTGGAAGTTAGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCCTTTTATGGCTTCACTC 1010
28609629 28609815 + 0
CGTGTGAAATAAGCTCACTGGCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGAGGCATCAATGTCCTTA 1011
28610070 28610185 + 0
GCAGATGATGGGCTCCCGGAAGACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGAGGATGGCTAGGCGAGG 1012
90631835 90631946 + 0
GAGATAATAGTGGTCCCACTGCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGTGATGGGCTTGGTCCAG 1013
90631835 90631946 + 0
GACAGAAGCAGGGAGGAGAGATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGGGAGGGAGAGATGGGGGT 1014
7572925 7573012 + 0
GCTGGGAAGGAGCCAGGGGGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAAACAATTGTAACTTGAACCA 1015
7573973 7574036 − 0
GTCTAACACTCAAAATGCCGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTCACTTTTATCACCTTTCCTTGC 1016
7576850 7576934 − 0
ACCAGGCTCCATCTACTCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTCTCTTCCTCTGTGCGCCGGTCT 1017
7577014 7577158 + 0
CCAAGGGTGCAGTTATGCCTCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTTTGAGGTGCGTGTTTGTG 1018
7577014 7577158 − 0
GTAGTGGATGGTGGTACAGTCAGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGAGGCAAGCAGAGGCTGGG 1019
7577495 7577613 + 0
GCGGCATGAACCGGAGGCCCATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAAAAAAAAAAAAAGGCCTCC 1020
7577495 7577613 − 0
CCTGGGGACCCTGGGCAACCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAACCAGACCTCAGGCGGCTCATA 1021
7578168 7578295 + 0
GTGAGCAGTAGGGGGGCTTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGTGGAAGGAAATTTGCGTGTG 1022
7578115 7578211 − 0
GTTGAGGGCAGGGGAGTACTGTAGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATGGTGGGGGCAGCGCCT 1023

7578364 7578560 + 0
GGGCTGGAGAGACGACAGGGCTGGTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATGGCCATCTACAAGCA 1024
7578364 7578560 − 0
TTCCACACCCCCGCCCGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGCCGTCTTCCAGTTGCTTTATCTG 1025
7578364 7578560 − 0
TTTCTGGGAAGGGACAGAAGATGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAAACAAAAGAAATGCAGGG 1026
7579308 7579600 + 0
GTAGGAGCTGCTGGTGCAGGGGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCAGGGCAACTGACCGTGCAA 1027
7579308 7579600 + 0
GCATCAAATCATCCATTGCTTGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGAGGGGGCTGGTGCAGGG 1028
7579443 7579523 + 0
ACCCAGGTCCAGATGAAGCTCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGGGACCTGGAGGGCTGGGG 1029
7579308 7579600 − 0
AAGGGCAGGCCCACCACCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCATGCTGGATCCCCACTTTTCCT 1030
7579812 7579915 − 0
GCCTTCCAATTGGCCTTGTGCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCCTTCTCAGAGAATTTTTTAG 1031
58740352 58740920 + 0
AAAAAATTTATCCCAGAACTCAACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTCTCGAGCTATCTCAGCTG 1032
58740352 58740920 − 0
AGCCTGCAAGTCTCCCCACAACCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGAAGATGTCAACTCCTGGCC 1033
58740352 58740920 + 0
CAATTTTCTTCAAGTGGTTCTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCAATTTCTTGGGCTTTCATT 1034
58740352 58740920 − 0
GATGTTGAACTTTTTTTAAGGGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATGCGACGCAGACTTAGGGG 1035
58740352 58740920 + 0
CGTCTATGCTTCTTCATCAGGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTTTTCCTGTGTTGATGAAGT 1036
58740352 58740920 − 0
AGCTCGCGGCCGTCCAGCACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGTCCCCGGCGGCTGTGGTGTGAG 1037
74732956 74732961 + 0
TTTCTGCTCCCTGGACAACCCGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTCCCTAAAGGAAATCACGCT 1038
42531868 42531969 + 0
GGCCTGCCTCCAGGGCTGGACTGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGAAGACAAGAAACGCAAA 1039
13054525 13054730 + 0
CTTGCCCCCTGCCAGCCCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATCTTTGTCCTCATCATCCTCCTT 1040
13054525 13054730 − 0
GCAACTGCGCGTGAGGCGCGCGGCTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAGGTGCTGGAGCTG 1041
33792300 33792469 − 0
TGACCGCCTGCGCAAGCGGGTGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGGCCAAGAAGTCGGTGGA 1042
33792244 33793326 − 0
GCGGGGCTCCTGCTTGATCACCAGCGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCGGGTGCGGGTGCGG 1043
33792674 33792865 + 0
TCATGCCCGGGGGAGCGCACGGGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGCCAAGGCGGCCGTG 1044 33792970
33793010 − 0
GCTGATGTCGATGGACGTCTCGTGCTCGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTGGCCTTCTCCTGC 1045
33793025 33793090 + 0
GCAGGTGGCTGCTCATCGGGGGCCGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGTGGGGGGGGAGGCT 1046
33793243 33793300 + 0
GCCACCCGACAGCGAGATGGGCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGCCTGAAACTGATGGCTGTG 1047
31021087 31021727 + 0
TCCCCATCTGCCAGGCACATCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAGATCTCCGAACCAGAGCCAG 1048
31021087 31021727 + 0
CCTGGGACACACAAGCCACTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTGCATCCTTAGCAACCCCTGCT 1049
31021087 31021727 − 0
GAGCAGGCGGCCTCTGCATCCTTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCGAATTCCCAGTTGAGTCT 1050
31021087 31021727 + 0
GCCCTGCTGGGTCAGTCTTAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAGGCTAGGAATTCTGTCTGGAG 1051
31021087 31021727 − 0
CACAGCCCACTAAAGAGGAGCCCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCAGGAAACTGTGGATCAGG 1052
31021087 31021727 + 0
CGGGGTTGGACTGGCGCCAGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTAGGTCAGATCACCCAGTCAGT 1053
31022233 31025152 + 0
GTGGTGATGGTGGTGAGGCCTGTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGGGGCGAGAGGTCA 1054
31022435 31022452 + 0
GGTGGGGATGATCCGGGGGCATATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCGATGGCAGTGGTGGCCG 1055
31022322 31022412 − 0
TGCCAGGCCTTGCCCCTACTGTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGAACTGCCATGTCCAGAGCT 1056
31022233 31025152 + 0
GTACACTTTCCAGGGGTGCTCGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGTAGCCCTCTGTAGTAGG 1057
31022233 31025152 − 0
GGATCCTGTAAATGTGACCCCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTGAGTCTGGCACCACTTCCTG 1058
31022233 31025152 + 0
GCAAGGCCTGGCATGGCTGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCATTGTCTGCAGGAACGGTGG 1059
31022233 31025152 − 0
GGTAGTGAAACAGCCCAAACCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCAGAACAGAGCATTTGATGA 1060
31022233 31025152 + 0

GCTTGGCCAGTTCCTTTCTCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTATCACTTTCCCTCATAGGAGGG 1061
31022233 31025152 − 0
GGAGACTCTGAAGCACTGAGTCCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGCATTGCCTGGGGATTTG 1062
31022233 31025152 + 0
CGATGGGATGGGTATCCAATGCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGATCTAGACCCTCCTCAGC 1063
31022233 31025152 − 0
GTTGACAGTAACTGCCATTGCTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTTGTCACTGCAGCTTCTC 1064
31022233 31025152 − 0
GGTGACCTTCAAAGTCAGAGGCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATCTGTCCTTGTAACCAGAC 1065
31022233 31025152 − 0
GTAGCTTGCCCCTAGAGAAGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGGTGTCTCGAGTATGTGCGG 1066
31022233 31025152 + 0
GTGGGGCAGATTGGTTCCAATTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGCTCTTGGCTGGTACTCAG 1067
31022233 31025152 − 0
GCAACTGCATCACAAGTGGGTTAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCCACTGTTTTTTCCAAGAC 1068
31022233 31025152 − 0
CCCTCCATCCAGTGACAAATCCCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGAAGCAGCCCCAGTTCTT 1069
31022233 31025152 + 10
GCAGTTCTCTTCCTTTAGTTGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGCACTGGTCTTGCCAGGAT 1070
31022233 31025152 + 0
GCGAGCCATGGCTCTGGTCTTTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGGGTGGCCTCAATCCTGG 1071
31022233 31025152 − 0
CCTCGTTTCTCATCTCCAAATGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTAGGAAACTGGAAGAAATG 1072
31022233 31025152 + 0
AACCCTTCAGCGCCCCAGGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCCCAGGAGATCTTACTACCTCGAG 1073
31022233 31025152 + 0
GTGGGGTACAGACTCCAAGGGAAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGGCCAAGGGAAGAAGCTTT 1074
31022233 31025152 + 0
GCCGAGAACAGGAAAGCTACTGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTCCCAGTGGGAAGTTGGGA 1075
31022233 31025152 + 0
GAAGGGGCTCAGTGAGCCTCTGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGAAGACTTTTGTGGGGGG 1076
31022233 31025152 + 0
CCTCTAGCTCTCCCACCTTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTGCCCTTCTGGAAATTACCCC 1077
31022233 31025152 + 0
GCAGCACGGTGGAAAGCATCTCGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCAACTGAGTTCCACCAGCT 1078
31022233 31025152 + 0
GCTCTGTGTATTGTGCCTTGTGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCACAGTGCATCACTTTCCTT 1079
31022233 31025152 + 0
GAGGTCAATGGATCTCACCAAAGCCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAAGAAACCATGATCTCT 1080
57484402 57484481 − 0
GGTGGTAGGAGGGCGAGCTGGCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGTTCGGGAGGCTGGGGTTG 1081
36164474 36164925 + 0
GCGGCGGCAGGTAGGTGTGGTAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCATGGAGAACTGGTAGGAG 1082
36164474 36164925 + 0
GGTGACCGGCGTCGGGGAGTAGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTGCGACGAGCCGGGGTAGG 1083
36164474 36164925 + 0
GCGGGGGTCGGAGATGGAGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGGGTAGGGCGGCGGCAGGTAGG 1084
36164474 36164925 + 0
GCGGAAGTGAGTAGGAGGTTGCGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTCGGGGAGTAGGTGAAGG 1085
36164474 36164925 + 0
GTCCAGGAGACTAGAGGTGCATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCATTGCCTCTCCTTCTGTG 1086
36171591 36171765 − 0
ACGCCCATTTCACCTGGACGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCATTTTTTAAATCCCACCCCAC 1087
36171591 36171765 − 0
GAGGCACGAGGGTTGGGCGTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGGAAGGTGTGTGCACATGGGGG 1088
36206704 36206900 + 0
CGGGCTTGGTCTGATCATCTAGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGGTTAAAGGCAGTGGAGTGG 1089
36206704 36206900 + 0
GCGGCGCACAGCCATGAGGGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCTTCCCTCCCTCCTTCCCTCCC 1090
36206704 36206900 − 0
GGGCTGGTACACCCTCCAGGCTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTTGTTCTCTATCGTGTCCCC 1091
36231767 36231880 − 0
CATCATTGCCAGCCATCACAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGGTTTGTTGCCATGAAACGTG 1092
36252844 36253026 + 0
GCTGAGCTGAGAAATGCTACCGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATCACTACACAAATGCCCTAA 1093
36252844 36253026 − 0
GCAGAGGAAGTTGGGGCTGTCGGTGCGCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTGTCCTCCCACCACC 1094
36259157 36259187 + 0
GGCCAGCACCTCCACCATGCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTCTTGTTGCAGCGCCAGTGCG 1095
36259192 36259400 + 0
GCCAGTGACGTGACTGAGCACANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTCGCCGTGAGGAAGATGCGG 1096
44514777 44514876 − 0
CATGGAATATGTCAGCAGCATGACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAAACAAACCTGGCTAAACG 1097
44524444 44524480 + 0
GCATGCGTGTGGAGGAGGGGACTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAATGGAGCAGTGCAGGAGGG 1098

15833798 15834016 + 0
GGCCAATAGTTGAAAATTACTCACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTTGCGTCAGGGTCATAGT 1099
15833798 15834016 − 0
AAATTCAGGAAAAGAAACCAGCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAACAGAAACAGAACAACAAAC 1100
15836703 15836772 − 0
TTTCCTCAATTGTTCCACTGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCATATCATTTGATTTTTGGTTT 1101
15838328 15838442 + 0
GCTTCCAGGTCTTTGGAGCAAGAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTACATGGTGGGTCCAGCTT 1102
39911360 39911656 + 0
GTAAAATGAAAAGTGCGCCCAACNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTCTGCCTCTGCAATGGTGAC 1103
39911360 39911656 + 0
GTAAGGAGCTGTTAGATCTGGTGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAATTGAAAATGTCCTCCC 1104
39911360 39911656 − 0
CGTTCTCAACAGCATCGTGCAGAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAGACCATTTCTTGAACTTTG 1105
39914617 39914770 + 0
CTTATGGTGCTGACCCCACCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGCCCAGCTTTGCCTGTTGCTTTT 1106
39914617 39914770 − 0
TCGCCCAGTCCAATGCCTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTCCTGCTGGTTTTGGTGCCATCTG 1107
39931589 39934460 + 0
CATGTGGTCAGCTTTGGAAGCATCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAGGGAGCAGTGCTGATGAT 1108
39931589 39934460 + 0
CAGCAGCGGAGTTCATCATGCCCGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTCCAGGAAATGGTTGTGCT 1109
39931589 39934460 − 0
CAGGGGTTTTCTTCCCCTCTGGGCCTGAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTCTGTGTCTGAGGA 1110
48649515 48649604 + 0
GCTGGAAGCTTCTCAAATGGATGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGCCTACTACAGGGACGCTG 1111
48649516 48649738 + 0
GGTGTGGAGGACACCAGAGCAGGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGAGTTACCTGGGGAGTGT 1112
48649516 48649738 − 0
GCAGCTCTGCCTCTTTCCGTTTTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTGTGGATGGCCTTTGGAG 1113
53431940 53432902 + 0
GCACTGCCTGTGGCTTACTTTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATCTGCAGTCCATGGGCCTGAG 1114
53431940 53432902 + 0
GCCTTCAGGTCACTGGCCCCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCTAGGTGGTAAGGTGGTGGCTG 1115
53431940 53432902 + 0
CCAGTACTGAGCCTGTCCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTTCTCATCCCAGCGCCGTGCCTT 1116
53431940 53432902 + 0
GACAAGGGCATTGCCACAAGCATANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGGGGAAGAGAGAAGAGGGG 1117
53431940 53432902 + 0
CCTCACCTCCAGGTAGTCAAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNATCAATCACTAGCTTGGCCCCCT 1118
53431940 53432902 + 0
GCCGCATTGCCTTTGGAGGCCANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCAGGTGAAGCCTACAGATGAGA 1119
53431940 53432902 − 0
GCTTTTGGAAGCTGGCTCAGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCCTGTCTTCTCCGAGTCCACAA 1120
53431940 53432902 + 0
GGGTCAGGCCAGTGTTCAAGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNACCAAGGTTTTGGGCAAGAACA 1121
53431940 53432902 − 0
GGCTATTGTGTGACCAACTTGGTCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGGCACTAAATCTTAGCATT 1122
123181202 123181359 + 0
GGTGAAACTAATCTAACAGACACANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCCTCTCATTGGCTCGTTTT 1123
123181202 123181359 − 0
GCAAGTTTGCATATTTCGTGGTGTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAATGATGTGTTTTTTTAC 1124
123182853 123182930 + 0
AAGATGTGCCCTTCAGACTGCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTATGCATCGTTTTTCCTTCC 1125
123184036 123184161 + 0
CCAGTCGGTTCAAGGTTAGTATTANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAGTTGAAAATACATAGAG 1126
123184969 123185250 + 0
GTGTCTATGACCCTTGACAAAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAGAGCTTAATTCCAAACTGGA 1127
123184969 123185250 + 0
GCATATTTGCACTAATGTTCAGATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTTTTCTCTTGCTTTCCTTT 1128
123184969 123185250 + 0
GAAATAAGCAGTAACAGGTGCTTNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGCCTTAGAAAATGAGTAACAG 1129
123189975 123190088 − 0
ACCATGTCAGTCATTAGTGGAATCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTATCAAAGCTAACAGTTTC 1130
123220395 123220624 + 0
CCACCAGCTAGCAAAGAATTTCGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAAGAGAATAAATTATATCC 1131
123220395 123220624 − 0
CCGGCAGCAACAGAGACCTTGAAANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTCAAGCTCAGTTGAACAG 1132
133511647 133511790 + 0
GCCACTTTAAGTCTCAAGAAATGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCGCTGCCACCTTCTGGTTTT 1133
133511647 133511790 − 0
GCATTTCATCATCATCATAAAGGGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNCTACCACTGTGCATTGCATG 1134
133527529 133527670 + 0
GTATGTGACTTTCTAAGGCTGTATNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGGTTTCTCTCGTATTTGAGC 1135
133527529 133527670 − 0

CCACGTTTCAGCCACTTTTCAGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTTAGTTTGCTTACTAATTTTTG 1136 133527932 133527989 + 0
GGGGAGGAAGAAAATGAAGCACGANNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGAAATGTTAAGTAAGCTTGA 1137 133547847 133548010 + 0
GCCTGGTGTCACTAGGGCTGCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNAAACAAACAACAAAAAAACAAAA 1138 133547847 133548010 − 0
ATGCAGGAAAATTAACATTCAGAATCCNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNTGTTGCATAACAAATATAAAAACTACA 1139 133549044 133549153 − 0
GACTGCAAAGTGTACATTTCTGNNNNCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNGTTTAGGGAAATAGACAACTGT 1140 133551219 133551319 − 0

REFERENCE LIST

[0137] 1. Diepen S Van, Katz J N, Albert N M, Henry T D, Jacobs A K, Kapur N K, Kilic A, Menon V, Ohman E M, Sweitzer N K, Thiele H, Washam J B, Cohen M G. Contemporary Management of Cardiogenic Shock: A Scientific Statement from the American Heart Association. *Circulation.* [0138] 2. Helgestad O K L, Josiassen J, Hassager C, Jensen L O, Holmvang L, Sørensen A, Frydland M, Lassen A T, Udesen N L J, Schmidt H, Ravn H B, Møller J E. Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: a Danish cohort study. *Eur J Heart Fail* 2019; 21; (11):1370-1378. [0139] 3. Jentzer J C, Lawler P R, Diepen S Van, Henry T D, Menon V, Baran D A, Džavík V, Barsness G W, Holmes D R, Kashani K B. Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. Circ Cardiovasc Qual Outcomes 2020; 13; (12):1033-1045. [0140] 4. Andrié R P, Becher U M, Frommold R, Tiyerili V, Schrickel J W, Nickenig G, Schwab J O. Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction. *Crit Care* 2012; 16; (4). [0141] 5. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P V., Mar B G, Lindsley R C, Mermel C H, Burtt N, Chavez A, Higgins J M, Moltchanov V, Kuo F C, Kluk M J, Henderson B, Kinnunen L, Koistinen H A, Ladenvall C, Getz G, Correa A, Banahan B F, Gabriel S, Kathiresan S, Stringham H M, McCarthy M I, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson J G, Neuberg D, Altshuler D, Ebert B L. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med* 2014; 371; (26):2488-2498. [0142] 6. Acuna-Hidalgo R, Sengul H, Steehouwer M, Vorst M van de, Vermeulen S H, Kiemeney L A L M, Veltman J A, Gilissen C, Hoischen A. Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. *Am J Hum Genet* 2017; 101; (1):50-64. [0143] 7. Young A L, Challen G A, Birmann B M, Druley T E. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. *Nat Commun* 2016; 7:12484. [0144] 8. Genovese G, Kähler A K, Handsaker R E, Lindberg J, Rose S A, Bakhoum S F, Chambert K, Mick E, Neale B M, Fromer M, Purcell S M, Svantesson O, Landen M, Hoglund M, Lehmann S, Gabriel S B, Moran J L, Lander E S, Sullivan P F, Sklar P, Grönberg H, Hultman C M, McCarroll S A. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med* 2014; 371; (26):2477-2487. [0145] 9. Dorsheimer L, Assmus B, Rasper T, Ortmann C A, Ecke A, Abou-El-Ardat K, Schmid T, Brune B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher A M, Rieger M A. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. *JAMA Cardiol* 2019; 4; (1):25-33. [0146] 10. Jaiswal S, Natarajan P, Silver A J, Gibson C J, Bick A G, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova G K, Neuberg D, Libby P, Kathiresan S, Ebert B L. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med* 2017; 377; (2):111-121. [0147] 11. Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. *Nature Reviews Cardiology.* [0148] 12. Yu B, Roberts M B, Raffield L M, Zekavat S M, Nguyen NQH, Biggs M L, Brown M R, Griffin G, Desai P, Correa A, Morrison A C, Shah A M, Niroula A, Uddin M M, Honigberg M C, Ebert B L, Psaty B M, Whitsel E A, Manson JAE, Kooperberg C, Bick A G, Ballantyne C M, Reiner A P, Natarajan P, Eaton C B. Supplemental association of clonal hematopoiesis with incident heart failure. *J Am Coll Cardiol* 2021; 78; (1):42-52. [0149] 13. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and cardiovascular disease. *Circ Res* 2018; 123; (3):335-341. [0150] 14. Baran D A, Grines C L, Bailey S, Burkhoff D, Hall S A, Henry T D, Hollenberg S M, Kapur N K, O'Neill W, Ornato J P, Stelling K, Thiele H, Diepen S, Naidu S S. SCAI clinical expert consensus statement on the classification of cardiogenic shock. *Catheter Cardiovasc Interv* 2019; 94; (1):29-37. [0151] 15. Medeiros J J F, Capo-Chichi J-M, Shlush L I, Dick J E, Arruda A, Minden M D, Abelson S. SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes derived data 2. *bioRxiv* 2021:2021.06.03.446993. [0152] 16. Pascual-Figal D A, Bayes-Genis A, Diez-Diez M, Hernández-Vicente Á, Vázquez-Andrés D, la Barrera J de, Vazquez E, Quintas A, Zuriaga M A, Asensio-López M C, Dopazo A, Sánchez-Cabo F, Fuster J J. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. *J Am Coll Cardiol* 2021; 77; (14):1747-1759. [0153] 17. Watson C J, Papula A L, Poon GYP, Wong W H, Young A L, Druley T E, Fisher D S, Blundell J R. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. *Science* (80-) 2020; 367; (6485):1449-1454. [0154] 18. Abdel-Wahab O, Adli M, LaFave L M, Gao J, Hricik T, Shih A H, Pandey S, Patel J P, Chung Y R, Koche R, Perna F, Zhao X, Taylor J E, Park C Y, Carroll M, Melnick A, Nimer S D, Jaffe J D, Aifantis I, Bernstein B E, Levine R L. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. *Cancer Cell* 2012; 22; (2):180-193. [0155] 19. Assmus B, Cremer S, Kirschbaum K, Culmann D, Kiefer K, Dorsheimer L, Rasper T, Abou-El-Ardat K, Herrmann E, Berkowitsch A, Hoffmann J, Seeger F, Mas-Peiro S, Rieger M A, Dimmeler S, Zeiher A M. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. *Eur Heart J* 2021; 42; (3):257-265. [0156] 20. Geppert A, Dorninger A, Delle-Karth G, Zorn G, Heinz G, Huber K. Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. *Crit Care Med* 2006; 34; (8):2035-2042. [0157] 21. Heeschen C, Dimmeler S, Hamm C W, Brand M J van den, Boersma E, Zeiher A M, Simoons M L. Soluble CD40 ligand in acute coronary syndromes. *N Engl J Med* 2003; 348; (12):1104-1111. [0158] 22. Shami A, Edsfeldt A, Bengtsson E, Nilsson J, Shore A C, Natali A, Khan F, Lutgens E, Gonçalves I. Soluble CD40 levels in plasma are associated with cardiovascular disease and in carotid plaques with a vulnerable phenotype. *J Stroke* 2021; 23; (3):367-376. [0159] 23. Milner J D, Orekov T, Ward J M, Cheng L, Torres-Velez F, Junttila I, Sun G, Buller M, Morris S C, Finkelman F D, Paul W E. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. *Blood* 2010; 116; (14):2476-2483. [0160] 24. Qin Y, Zhang C. The regulatory role of IFN-γ on the proliferation and differentiation of hematopoietic stem and progenitor cells. *Stem cell Rev reports* 2017; 13; (6):705-712. [0161] 25. Baldridge M T, King K Y, Boles N C, Weksberg D C, Goodell M A. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. *Nature* 2010; 465; (7299):793-797. [0162] 26. Agarwal P, Li H, Choi K, Hueneman K, He J, Welner R S, Starczynowski D T, Bhatia R. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling. *Cell Rep* 2021; 36; (2):109386. [0163] 27. Abegunde S O, Buckstein R, Wells R A, Rauh M J. An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis. *Exp Hematol* 2018; 59:60-65. [0164] 28. Broek I Vande, Asosingh K, Vanderkerken K, Straetmans N, Camp B Van, Riet I Van. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. *Br J Cancer* 2003; 88; (6):855-862. [0165] 29. Bick A G, Pirruccello J P, Griffin G K, Gupta N, Gabriel S, Saleheen D, Libby P, Kathiresan S, Natarajan P. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. *Circulation* 2020; 141; (2):124-131. [0166] s1. Mehra M R, Canter C E, Hannan M M, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016; 35(1):1-23. doi:10.1016/j.healun.2015.10.023 [0167] s2. Organ Transplant|US Organ Donation System|UNOS. Accessed Jan. 27, 2022. https://unos.org/transplant/ [0168] s3. Khush K K, Cherikh W S, Chambers D C, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart

transplantation report—2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1056-1066. doi:10.1016/J.HEALUN.2019.08.004 [0169] s4. Costanzo M R, Force T, Rosa M, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29(8):914-956. doi:10.1016/j.healun.2010.05.034 [0170] s5. Kittleson M M, Kobashigawa J A. Long-term care of the heart transplant recipient. Curr Opin Organ Transplant. 2014; 19(5):515-524. doi:10.1097/MOT.0000000000000117 [0171] s6. Giarraputo A, Barison I, Fedrigo M, et al. A changing paradigm in heart transplantation: An integrative approach for invasive and non-invasive allograft rejection monitoring. Biomolecules. 2021; 11(2):1-17. doi:10.3390/biom11020201 [0172] s7. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498. doi:10.1056/NEJMoa1408617 [0173] s8. Jaiswal S, Natarajan P, Silver A J, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377(2):111-121. doi:10.1056/NEJMoa1701719 [0174] s9. Bhattacharya R, Zekavat S M, Haessler J, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2020; 53(3):788-797. doi:10.1161/strokeaha.121.037388 [0175] s10. Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 2019; 4(1):25-33. doi:10.1001/jamacardio.2018.3965 [0176] s11. Bolton K L, Koh Y, Foote M B, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun. 2021; 12(1):5975. doi:10.1038/s41467-021-26138-6 [0177] s12. Genovese G, Kähler A K, Handsaker R E, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-2487. doi:10.1056/NEJMoa1409405 [0178] s13. Dawoud A A Z, Gilbert R D, Tapper W J, Cross N C P. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia. 2022; 36(2):507-515. doi:10.1038/s41375-021-01382-3 [0179] s14. Pascual-Figal D A, Bayes-Genis A, Diez-Diez M, et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2021; 77(14):1747-1759. doi:10.1016/j.jacc.2021.02.028 [0180] s15. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018; 123(3):335-341. doi:10.1161/CIRCRESAHA.118.313225 [0181] s16. Medeiros J J F, Capo-Chichi J-M, Shlush L I, et al. SmMIP-tools: a computational toolset for processing and analysis of single-molecule molecular inversion probes-derived data. Bioinformatics. 2022; 38(8):2088-2095. doi:10.1093/bioinformatics/btac081 [0182] s17. Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020; 17(3):137-144. doi:10.1038/s41569-019-0247-5 [0183] s18. Sano S, Oshima K, Wang Y, et al. TET2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol. 2018; 71(8):875-886. doi:10.1016/j.jacc.2017.12.037 [0184] 19. Sano S, Wang Y, Yura Y, et al. JAK2-V617F-Mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic Transl Sci. 2019; 4(6):684-697. doi: 10.1016/j.jacbts.2019.05.013 [0185] s20. Sano S, Wang Y, Ogawa H, et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight. 2021; 6 (13): e146076. doi: 10.1172/jci.insight.146076 [0186] s21. Yura Y, Miura-Yura E, Katanasaka Y, et al. The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene Ppm1d Promotes Inflammation and Non-Ischemic Heart Failure in Mice. Circ Res. 2021; 129(6):684-698. doi: 10.1161/CIRCRESAHA.121.319314 [0187] s22. Fuster J J, MacLauchlan S, Zuriaga M A, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017; 355(6327): 842-847. doi: 10.1126/science.aag1381 [0188] s23. Nikolova A P, Kobashigawa J A. Cardiac Allograft Vasculopathy: The enduring enemy of cardiac transplantation. Transplantation. 2019; 103(7): 1338-1348. doi: 10.1097/TP.0000000000002704 [0189] s24. Chih S, Chong A Y, Mielniczuk L M, Bhatt D L, Beanlands R S B. Allograft vasculopathy: the achilles' heel of heart transplantation. J Am Coll Cardiol. 2016; 68 (1):80-91. doi:10.1016/J.JACC.2016.04.033 [0190] s25. Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020; 34(3):e13794. doi:10.1111/CTR.13794 [0191] s26. Fahmy N M, Yamani M H, Starling R C, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation. 2003; 75(1):72-78. doi:10.1097/00007890-200301150-00013 [0192] s27. Tarazón E, Corbacho-Alonso N, G. Barderas M, et al. Plasma CD5L and non-invasive diagnosis of acute heart rejection. J Heart Lung Transplant. 2020; 39(3):257-266. doi:10.1016/J.HEALUN.2019.11.004 [0193] s28. Jones I K A, Orloff S, Burg J M, et al. Blocking the IL-1 receptor reduces cardiac transplant ischemia and reperfusion injury and mitigates CMV-accelerated chronic rejection. Am J Transplant. 2021; 21(1):44-59. doi:10.1111/ajt.16149 [0194] s29. Alyaydin E, Welp H, Reinecke H, Tuleta I. Predisposing factors for late mortality in heart transplant patients. Cardiol J. 2021; 28(5):746-757. doi:10.5603/CJ.A2020.0011 [0195] s30. Newell L F, Dunlap J, Gatter K, et al. Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. Am J Transplant. 2021; 21(12):3894-3906.

Claims

1. A method of predicting the risk of a disease condition of a solid organ in a patient, the method comprising: a) receiving a sample from the patient containing hematopoietic stem cells; b) sequencing the sample to detect a degree of clonal hematopoiesis; c) comparing the degree of clonal hematopoiesis in the patient to a control degree; and d) determining the patient is at an elevated risk of the disease condition if the degree of clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner.
2. The method of claim 1, wherein the degree of clonal hematopoiesis is measured using a variant allele frequency of mutations determined to be associated with clonal hematopoiesis.
3. The method of claim 2, wherein the variant allele frequency (VAF) is ≥2%.
4. The method of claim 3 wherein the VAF is ≥5%.
5. The method of claim 1, wherein the following genes are sequenced in the sample: TET2, DNMT3A, and ASXL1, and optionally one or more of, but preferably all of, BCOR, BRAF, CALR, CBL, CEBPA, EZH2, FLT3A, GATA1, GATA2, GNAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NRAS, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TP53, U2AF1, WT1, and ZRSR2.
6. The method of claim 1, wherein the sequencing is performed using single-molecule molecular inversion probes (smMIPs).
7. The method of claim 2, wherein the mutations associated with clonal hematopoiesis are detectable by the probes listed in Table A.
8. The method of claim 2, wherein the mutations associated with clonal hematopoiesis are detected using a library comprising at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.
9. (canceled)
10. (canceled)
11. (canceled)
12. The method of claim 1, wherein the solid organ is a heart.
13. The method of claim 12, wherein the disease condition is cardiogenic shock.
14. The method of claim 13, wherein an elevated risk of cardiogenic shock is associated with an elevated risk of death.
15. The method of claim 13, further comprising treating or preventatively treating the patient for cardiogenic shock.
16. The method of claim 12, wherein the disease condition is an adverse outcome after orthotopic heart transplant (OHT).
17. The method of claim 16, wherein the adverse outcome is an elevated risk of mortality and/or elevated risk of cardiac allograft vasculopathy.
18. The method of claim 17, further comprising treating or preventatively treating the patient for cardiac allograft vasculopathy.
19. The method of claim 12, wherein the disease condition is hypertrophic cardiomyopathy.
20. The method of claim 19, further comprising treating or preventatively treating the patient for hypertrophic cardiomyopathy.
21. The method of claim 1, wherein the solid organ is a lung.

22. The method of claim 21, wherein the disease condition is an adverse outcome, including death, after lung transplant.
23. The method of claim 22, further comprising treating or preventatively treating the patient for the adverse outcome after lung transplant.
24. A kit comprising a library of probes library comprising at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% of the probes listed in Table A.
25. (canceled)
26. (canceled)
27. (canceled)
28. A method of predicting the benefit of immunotherapy in a patient with melanoma, the method comprising: a) receiving a sample from the patient containing hematopoietic stem cells; b) sequencing the sample to detect a degree of clonal hematopoiesis in TET2; c) comparing the degree of TET2 clonal hematopoiesis in the patient to a control degree; and d) determining the patient would benefit from immunotherapy if the degree of TET2 clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner.
29. The method of claim 28, further comprising treating the patient with immunotherapy.
30. A method of predicting metastatic risk in a patient with a non-hematological cancer, the method comprising: a) receiving a sample from the patient containing hematopoietic stem cells; b) sequencing the sample to detect a degree of clonal hematopoiesis in TET2; c) comparing the degree of TET2 clonal hematopoiesis in the patient to a control degree; and d) determining the patient is at a lower risk of metastasis if the degree of TET2 clonal hematopoiesis in the patient is higher than the control degree in a statistically significant manner.
31. The method of claim 30, further comprising treating the patient with a treatment and monitoring regimen reflective of a low risk of metastasis.